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Abstract 
Neuroblastoma is a paediatric cancer derived from the sympathoadrenal cell lineage that commonly 
presents as a high-risk metastatic disease with a poor prognosis.  
Currently, differentiation therapy with retinoic acid is an effective therapeutic option used in the 
clinic, however not all tumours respond. New therapeutic agents that can control not only tumour 
growth but also metastasis are urgently needed and drugs that promote differentiation are 
particularly appropriate for neuroblastoma treatment. 
Preclinical models are required to aid the development of novel therapeutics for this challenging 
childhood malignancy, however current systems are complex and inherently costly. Here we employ 
a 3Rs-compliant cost-effective preclinical chick embryo model to act as a tool for neuroblastoma 
therapeutic research.  
Neuroblastoma cell lines were engrafted on the chorioallantoic membrane (CAM) of chick embryos 
and allowed to form tumours over a 7 day period. If cells were preconditioned in hypoxia they 
metastasised into the chick embryo. First, we validated the chick embryo model using retinoic acid 
and then investigated the potential of CDK inhibitors on neuroblastoma cell differentiation, tumour 
progression and metastasis.  With retinoic acid and the CDK inhibitors we observed a reduction of 
tumour cell proliferation and an increase in differentiation markers. The CDK inhibitors were 
particularly effective in inhibiting metastasis with a single injection reducing the number of embryos 
with metastasis by 60%. In addition, the expression of a panel of genes with known roles in 
metastasis, which increased upon hypoxia-preconditioning, was largely reduced by RO-3306 (CDK1 
inhibitor). These results demonstrate that CDK inhibitors are a promising alternative to currently 
existing therapies. We have also begun to establish the chick embryo model as an alternative to the 
mouse xenograft model for short term analysis of cell differentiation, proliferation, apoptosis and 
metastasis in response to drug therapy. 
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1.1. Neuroblastoma: an introduction 
Neuroblastoma is a paediatric cancer derived from the neural crest cells destined to form the 
sympathetic nervous system.  These neural crest cells give rise to the sympathetic neural ganglia and 
the adrenal medulla (Park et al., 2013). The neuroblastoma tumour forms in the adrenal glands or 
the sympathetic ganglia and disseminates to other parts of the body including bone, bone marrow, 
liver and skin (Maris et al., 2007). Neuroblastoma is a peculiar disease characterised by various 
biological and histological heterogeneity ranging from spontaneous regression without treatment to 
advanced resistant and metastatic disease  (Weinstein, 2003; Maris et al., 2007). 
1.1.1. Epidemiology, genetic predisposition and aetiology 
Neuroblastoma is a rare tumour, nevertheless it is the most commonly occurring extra-cranial solid 
tumour in children within 2 years of age (Heck et al., 2009; Cheung and Dyer, 2013) and the third 
most common paediatric malignancy, following leukaemia and brain tumours. It has an incidence of 
10.2 per million birth (Schwab et al., 2003; Maris et al., 2007). Most cases (90%) are diagnosed in 
children before 5 years of age; and rarely in older children up to about 14 years old; or even 
occasionally in adults up to 19 years of age (Izbicki, Mazur and Izbicka, 2003; Maris, 2010; 
Schleiermacher, Janoueix-Lerosey and Delattre, 2014). Despite the fact that, neuroblastoma has the 
highest rate of spontaneous regression of all human cancers (Brodeur, 2003) the metastatic form of 
the disease has survival probabilities of less than 40% and it thus accounts for approximately 15% of 
childhood oncology deaths (DeBerardinis et al., 2008; Maris, 2010). Neuroblastoma can be of either 
familial (1-2%) or sporadic in origin (98%) (Friedman et al., 2005). Familial neuroblastoma is usually 
diagnosed at an earlier age, often within the child’s first year of life and multiple primary tumours at 
diagnosis is much more common in those with a genetic predisposition than in patients with 
sporadic disease (Mullassery and Losty, 2016). Hereditary neuroblastoma is often associated with 
mutations in the anaplastic lymphoma kinase (ALK) gene and in the paired-like homeobox 2B 
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(PHOX2B) gene, together they account for approximately 90% of hereditary neuroblastoma (Mossé 
et al., 2008; Deyell and Attiyeh, 2011).  
In contrast to most adult malignancies, very few causative factors have been identified in paediatric 
malignancies and this applies to neuroblastoma. The embryonal origin of tumour cells and young age 
at onset suggest pre- and perinatal environmental effects may be of significance. Several factors has 
been investigated  including gestational weight and age, prenatal hormone exposure, alcohol 
consumption, maternal smoking, however no consistently associated factor has been identified in 
large studies (Bluhm et al., 2008; McLaughlin et al., 2009).  
1.1.2 The neural crest  
The neural crest (NC) is a multipotent embryonic cell population that arises from the embryonic 
ectoderm cell layer at the neural plate border (Figure1.1 a) and in turn give rise to a number of 
diverse cell lineages including melanocytes, craniofacial cartilage and bone, smooth muscle, 
peripheral and enteric neurons and glia (Patel et al., 2012). A network of migration pathways and 
microenvironmental cues act together to control and maintain the mobility, directionality and 
specificity of cellular movement in migratory neural crest cells (NCCs) and disruption of which may 
predispose multipotent neural crest precursors to malignant transformation (Cheung and Dyer, 
2013). 
1.1.2.1. Development of sympathetic nervous system  
During embryo development, at the third and fourth weeks of gestation in human, the ectoderm 
differentiates into the neural ectoderm (neural plate) and the non-neural ectoderm, the two regions 
interact at the neural plate border (Gammill and Bronner-Fraser, 2003). Inductive changes within the 
neural plate border produced by the ectoderm, the neuroepithelium and the underlying mesoderm 
induce the expression of a series of transcription factors, such as those encoded by the Snai1/2, Slug, 
Twist, Foxd3 and Sox10 genes, that define the formation of the neural crest territory and control 
subsequent NC development (Mayor and Theveneau, 2013). 
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Prior to migration, neural crest cells (NCCs) undergo complete or partial epithelial-to-mesenchymal 
transition (EMT), which confer enhanced migratory ability (Mayor and Theveneau, 2013; Shyamala 
et al., 2015).  
NC specifier genes such as Snai1/2, Slug and Twist form a transcriptional network to promote EMT  
through degrading the basement membrane and downregulating  the cell-adhesion molecules such 
as N-CAM, N-cadherin, cadherin-6B and integrins,  resulting in NCCs delamination enabling migration 
(Friedl, 2010; Mayor and Theveneau, 2013). whilst other NCCs specifiers  such as Sox10 and Foxd3 
are responsible for cell survival, migration and maintaining multipotency (Kim et al., 2003; Stewart et 
al., 2006). Compared to non-migratory NCCs, early migratory NCCs possess high level of MYCN 
protein that in turn facilitates migration. Expression of MYCN reduces in differentiating sympathetic 
neurons and therefore is found to be absent in adult tissues (Zimmerman et al., 1986; Dzieran et al., 
2018). 
After delamination, NCCs migrate from different positions along the anterior-posterior axis 
developing into various tissues. Thus NCCs can be categorised into cranial NC, cardiac NC, vagal NC 
trunk NC and sacral NCC based on their axial position of origin together with the cell and tissues they 
contribute to during terminal differentiation (Gilbert, 2000).  
Cranial NCCs form the craniofacial mesenchyme that differentiates into various cranial ganglia and 
craniofacial cartilages and bones as well as smooth muscles, connective tissue and melanocytes 
(Friedl, 2010). The majority of cranial NCCs population enter the pharyngeal pouches and arches 
where they contribute to the thymus, bones of the middle ear and jaw and the odontoblasts of the 
tooth primordia whist some enter the frontonasal region  to give rise to the frontal and nasal bones 
(Gilbert, 2000). Cardiac NCCs give rise to regions of the heart such as the musculo-connective tissue 
of the large arteries, and part of the septum, which divides the pulmonary circulation from the aorta 
as well as participate in the formation of semilunar valves  (Gilbert, 2000; De Lange et al., 2004). The 
vagal NCCs from the enteric nervous system, which innervates the gastrointestinal digestive tract 
(Gilbert, 2000). Trunk NCCs give rise to two populations. Cells destined to become 
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melanocytes migrates dorsolaterally into the ectoderm towards the ventral midline. Whilst cells 
destined to form dorsal root ganglia, sympathetic ganglia and adrenal medulla migrate 
ventrolaterally through the anterior portion of each sclerotome (Gilbert, 2000). Sacral NCC, which is 
a component of trunk NCCs contributes together with the vagal NCCs to form of enteric nerves 
system and the parasympathetic ganglia.  
Several migration and microenvironmental cues act together to control and maintain the mobility, 
directionality and specificity of cellular movement in migratory NCCs  (Gammill and Roffers-Agarwal, 
2010; Theveneau and Mayor, 2012), and disruption of which may predispose multipotent neural 
crest precursors to malignant transformation (Cheung and Dyer, 2013). In trunk NCCs (Figure1.1 b), 
sympathetic precursor NCCs expressing chemokine receptor type 4 (CXCR4) are repelled from the 
intersomitic spaces by semaphorins  and drawn to the dorsal aorta and the region surrounding the 
gut by the chemotactic CXCR4 ligand, stromal cell-derived factor 1 (SDF-1) (Kasemeier-Kulesa et al., 
2006; Kulesa and Gammill, 2010). Ephrins are expressed in the posterior section of each sclerotome, 
bind to NCC surface Eph receptors, initiate migration-promoting and -inhibitory effects, depending 
on the class of ephrins encountered (Krull et al., 1997; McLennan and Krull, 2002), thus controlling 
the specificity of cellular movements (Kasemeier-Kulesa et al., 2006). 
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Figure1.1 Neurulation and the development of sympathoadrenal lineage of neural crest. a The 
neural crest is first induced at the region of the neural plate border (green). After neural tube 
closure, the neural crest delaminates from the region between the dorsal neural tube and overlying 
ectoderm and migrates out towards the periphery. b Neural crest cells giving rise to the adrenal 
gland and sympathetic ganglia migrate  to the region of the dorsal aorta and undergo 
differentiation. Bone morphogenetic protein (BMP), initiates differentiation of the sympathoadrenal 
precursor and multiple transcription factors are involved in this process. At this stage cells 
committed to becoming sympathetic ganglia acquire the catecholaminergic enzymes, dopamine-ß 
hydroxylase (DBH) and tyrosine hydroxylase (TH). a  adapted from  (Gammill and Bronner-Fraser, 
2003) and b adapted from (Cheung and Dyer, 2013).  
a b 
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Post-migratory NCCs  aggregate at the dorsal aorta to form primary sympathetic ganglia prior to 
divergence into sympathetic ganglion neurons and adrenal chromaffin cells (Huber, 2006). In 
response to bone morphogenetic proteins (BMPs) secreted by dorsal aorta, NCCs destined to 
become sympathetic neurons undergo neuronal and catecholaminergic differentiation (Mohlin, 
Wigerup and Påhlman, 2011).   
The dorsal aorta–derived BMPs signalling results in upregulation expression of various transcription 
factors that are essential for neuronal differentiation. Initially BMPs induce achaete-scute homolog 1 
(ASCL1) expression (Schneider et al., 1999). ASCL1 (MASH-1 in rodents, hASH-1 in humans, and 
CASH-1 in chicks) is the first marker of neuronal specification, however, high level of  hASH-1 are 
seen in neuroblastoma tumours and cell lines (Söderholm et al., 1999). BMPs induce the expression 
of PHOX2B, essential for the ASCL1 maintenance (Pattyn et al., 1999) while, ASCL1 promotes the 
expression of PHOX2A. Together, ASCL1, PHOX2A and PHOX2B drive the expression of enzymes 
necessary for catecholamine synthesis, including tyrosine hydroxylase (TH) and dopamine ß-
hydroxylase (DBH) (Ernsberger et al., 2000). PHOX2B also initiates terminal sympathoadrenal 
differentiation.  ASCL1 promotes further development of early precursors that are already 
committed to a neuronal fate, allowing the transition into a mature sympathetic neuron or 
chromaffin cell. Loss-of-function studies demonstrate that mice lacking PHOX2B fail to properly 
develop autonomic ganglia (Pattyn et al., 1999). Furthermore, the PHOX2B gene is found to be 
mutated in some of familial neuroblastomas. 
An inactivating mutation of PHOX2B is known to predispose an individual to developing 
neuroblastoma through dedifferentiation and increasing proliferation of sympathoadrenal cells 
resulting in malignant transformation (Bourdeaut et al., 2005; Raabe et al., 2008; Reiff et al., 2010). 
In one study, consistent with PHOX2B role as an important neurodevelopmental gene, inducing 
overexpression of wild-type PHOX2B in neuroblastoma cell lines inhibited cell proliferation and 
synergized with all-trans retinoic acid to promote differentiation (Raabe et al., 2008). Mutated 
PHOX2B has also been occasionally detected in sporadic neuroblastoma (Van Limpt et al., 2004) 
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while overexpression of both mutated PHOX2A and PHOX2B is frequently detected in both  
neuroblastoma cell lines and primary tumours (Longo et al., 2008). The expression of Heart And 
Neural Crest Derivatives expressed transcript 2 (HAND2), is dependent on PHOX2B, yet precedes 
PHOX2A, and in addition, is expressed independently of ASCL1. HAND2 is essential for both the 
proliferation of sympathetic neuron precursors and their noradrenergic differentiation. HAND2-
knockout embryos showed reduced number of sympathetic neurons as well as reduced TH and DBH 
expression in those neurons that developed (Schmidt et al., 2009). HAND2 is routinely detected in 
neuroblastomas, regardless of stage, suggesting that in these tumours, sympathetic differentiation is 
blocked at a relatively early stage in development (Gestblom et al., 1999). GATA2 and GATA3, zinc 
finger transcription factors, are expressed after ASCL1, PHOX2B, HAND2 and PHOX2A, but before the 
expression of the noradrenergic enzymes TH and DBH  (Tsarovina, 2004), and are both critical for the 
generation and differentiation of sympathetic neurons. In the absence of embryonic GATA3, a lack of 
TH and DBH in the sympathetic ganglia of embryos was observed (Lim et al., 2000). GATA3-null 
embryos also showed reduced  ASCL1, PHOX2B and HAND2 in the chromaffin cells, implying that 
feedback from GATA3 is required to maintain expression of supposed upstream transcription factors 
(Moriguchi, 2006).  
Although the five transcription factors mentioned above are expressed in an ordered manner (ASCL1 
before PHOX2B and HAND; PHOX2B before PHOX2A, HAND and GATA2/3), they are cross-linking and 
operate as a network that eventually results in sympathetic or adrenal cell formation. From the 
primary sympathetic ganglia, the prospective chromaffin cells then migrate toward the adrenal 
gland, and the cells destined to become sympathetic neurons travel dorsally to the position of the 
secondary sympathetic ganglia.  Once they reach their desired destination, a change in gene 
expression will commence accordingly to induce differentiation further (Simoes-Costa and Bronner, 
2015).   
Further downstream, neurotrophins (NT), including nerve growth factor (NGF), brain-derived 
neurotrophic factor (BDNF), neurotrophin4/5 (NT-4/5), and neurotrophin-3 (NT-3), are heavily 
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involved in the formation of the neural phenotype via binding to their respective receptors family of 
tyrosine kinases (TrK) (Nakagawara, 2001, 2004). TrkC is the first to be expressed, TrkB is transiently 
expressed around the time or the primary sympathetic ganglia and TrkB needs to be down regulated 
and upregulation of TrkA is required for differentiation to proceed (Banfield et al., 2001). Under 
normal levels of expression, each of these promotes and supports survival and differentiation of the 
sympathetic neurons (Banfield et al., 2001). However, if TrkB downregulation is impaired during 
development, this may contribute to the genesis of neuroblastoma (Straub, Sholler and Nishi, 2007). 
The expression of full length TrkB with its ligand BDNF, is linked with poor outcome and 
undifferentiated tumours strongly associated with MYCN-amplification (Nakagawara and Ohira, 
2004). However, full length TrkA expression is associated with neuroblastoma tumours destined to 
undergo spontaneous regression or increased differential state of tumours (Straub, Sholler and 
Nishi, 2007). Taken together, this suggests the role of TrkA in maintaining the differentiation process 
in sympathetic neurons and are classified as positive markers of neuroblastoma tumours. 
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1.1.3. Molecular biology 
Numerous studies in molecular biology have been conducted to identify and to better understand 
the genetic events involved in development and progression of neuroblastoma. Neuroblastoma 
tumours demonstrate significant clinical heterogeneity; this perhaps reflects the absence of a single 
genetic alteration common to all tumours (Pugh et al., 2013). 
1.1.3.1. DNA ploidy  
Ploidy is defined as the number of sets of chromosomes in each cell. Virtually, all cancers 
demonstrate aneuploidy, an abnormal number of chromosomes (Rajagopalan and Lengauer, 2004). 
Diploid is the normal occurrence of two copies of each chromosome: one maternal and one 
paternal, hence 46 chromosomes in total. The majority of neuroblastoma tumours have either near-
diploidy (37-57 chromosomes) or hyper-diploidy (58-80 chromosomes) (Sakurai, Maseki and Sakurai, 
1987). Malignant tumours with DNA aneuploidy are thought to form as a result of genomic stability 
defects resulting in chromosomal rearrangement with unbalanced translocations. Near-diploidy 
cases tend to confer a worse prognosis compared to hyper-diploid tumours. Thus, DNA ploidy is one 
of the genetic variables used in the International Neuroblastoma Risk Group (INRG) Classification 
System (Cohn et al., 2009). 
1.1.3.2. Segmental chromosome aberrations  
Acquired somatic mutations and associated DNA copy number aberrations, are frequently found in 
high risk neuroblastomas (Pugh et al., 2013). 25-35% of neuroblastoma tumours have a loss/deletion 
of chromosome 1p (Thorner, 2014) whereas >70% of cases have 1-3 additional copies of 17q (17q 
gain). Both chromosome 1p deletion and 17q gain are associated with unfavourable prognostic 
features such as MYCN amplification and an older age of diagnosis (Ambros et al., 2009). Also, a 
deletion in 11q chromosomal region has been found in 15% of high risk neuroblastomas, and rarely 
coincides with MYCN amplification, therefore it is a powerful prognostic marker in  non-MYCN 
amplified tumours and been included as a prognostic criterion in INRG system (Attiyeh et al., 2005).  
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1.1.3.3. MYCN gene amplification 
The most widely researched gene associated with neuroblastoma is MYCN. Approximately 35% of 
neuroblastoma cases are characterized by amplification of MYCN and it is firmly associated with 
advanced disease and poor prognosis regardless of the stage of disease or age at diagnosis (Cohn et 
al., 2009). In children aged less than 18 months with metastasis and MYCN amplification, the overall 
5 years survival rate is 34% however in the same cohort lacking MYCN amplification it was found to 
be 82% (Cohn et al., 2009). 
The MYCN gene is found in chromosome 2p24, and remains a single copy at this location even in 
MYCN amplified cells. Amplification (increased number of copies) of this gene can be present at an 
alternate locus either as extra-chromosomal chromatin bodies (double minutes) or 
intrachromosomally as homogeneously staining region (HSR). HSR are generally located on different 
chromosomes, not at the resident site, 2p24, of MYCN (Moreau et al., 2006).  
MYCN encodes for the N-myc protein, which together with C-myc and L-myc form the myc family of 
basic helix-loop-helix (bHLH) proteins which function as transcription factors (TF). The myc family 
play a fundamental role in the control of the normal (and oncogenic) proliferation, growth, 
metabolism, differentiation and apoptosis of cells. N-myc oncoprotein possesses a leucine zipper 
motif that is important for forming a heterodimer complex with myc-associated factor X (MAX) 
causing transcriptional activation of target genes (Kamijo and Nakagawara, 2012; Gherardi et al., 
2013). MYCN can act as a transcriptional enhancer by forming a heterodimer with the MAX protein; 
this dimer binds to E-box sequences (CANNTG) in the promoter regions of target genes. MYCN-MAX 
complex executes their function through recruiting histone acetyltransferase enzymes (HATs) 
(McMahon, Wood and Cole, 2000). MAD dimerises with MAX, MAD-MAX heterodimers recruit 
histone deacetylates (HDACs) to repress transcription of MYCN target genes. The MAD-MAX complex 
also reduces the amount of MAX available for MYCN binding, as well as competing with the MYCN- 
MAX complexes for the same promoter E-boxes. Thus  MAD-MAX acts as a transcriptional repressor 
while MYCN appears to function as an activator (Grandori et al., 2000; Nikiforov et al., 2003). In 
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addition, MYCN can also repress transcription by forming a heterodimer with myc-interacting zinc 
finger protein 1 (MIZ1) and thus inhibiting transcription of its target genes (Eilers and Eisenman, 
2008). 
Amplification of the MYCN gene typically leads to overexpression and increased transcriptional 
activation /inhibition of over 200 genes resulting in tumour survival and progression. It upregulates 
genes involved mainly in proliferation, angiogenesis and drug resistance and downregulates number 
of genes involved in differentiation and apoptosis (Huang and Weiss, 2013). 
MYCN overexpression alone was not efficient to induce tumorigenesis in genetically engineered 
murine models (Chesler and Weiss, 2011). However, MYCN overexpression associated ALK mutation 
induced spontaneous development of neuroblastoma tumours in mice. The second modification, 
induced ALK mutation, is thought to block apoptosis and maintain MYCN stability resulting in 
neuroblastoma growth. Of note, the resulted tumours in mice mirrored the histology, chromosomal 
aberrations and localisation of those formed in human  (Heukamp et al., 2012; Marshall et al., 2014).  
Downregulation of MYCN is required for terminal differentiation of neuronal precursors so the 
control of MYCN protein is tightly controlled in a cell-cycle–specific manner. Knockdown of MYCN 
expression in murine models of neuroblastoma demonstrated an increase of cellular differentiation 
and a reduction in cell proliferation (Chesler and Weiss, 2011). Therefore, MYCN inhibition is an 
attractive therapeutic approach for MYCN amplified tumours (see section 1.1.3.3.1).  
1.1.3.3.1. Therapeutic mechanisms targeting MYCN activity 
Because the MYCN structure is highly conserved making direct inhibition difficult, much attention is 
being directed to target molecules that interfere and modulate the activity of MYCN. Indeed four 
approaches have been identified to target MYCN activity. The first mechanism is by targeting DNA-
binding functions of MYCN through inhibiting MYC: MAX protein interactions using a dominant 
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negative MYC mutant (Omomyc).  Omomyc protein binds to all MYC family members and prevents 
dimerization with MAX (Soucek et al., 2008; Prochownik and Vogt, 2010).  
Targeting transcription of MYCN is the second mechanism. This involves inhibiting bromodomain and 
extra terminal (BET) family adaptor proteins (BRD2, BRD3, BRD4) that localize to MYC promoters 
(Mujtaba, Zeng and Zhou, 2007), with for example BET inhibitor JQ1 (Puissant et al., 2013). BET 
proteins contain acetyl-lysine recognition motifs, or bromodomains, that bind acetylated lysine 
residues in histone tails usually correlated with euchromatin state and transcriptional activation 
(Mujtaba, Zeng and Zhou, 2007). JQ1 supresses the transcriptional activity of MYCN and hence 
downregulates MYC/MYCN transcriptional program (Puissant et al., 2013).  
The third mechanism is targeting the oncogenic stabilization of MYCN. In proliferating cells, MYCN is 
initially phosphorylated at serine 62 by Cyclin dependant kinase 1/Cyclin B. The S62-phosphorylated 
protein is stabilized and competent to enter the nucleus. Nuclear MYCN binds to its partner MAX 
and stimulates the transcription of target genes important in cell cycle, proliferation, differentiation 
and apoptosis (Gustafson and Weiss, 2010). This priming phosphorylation at S62 allows the binding 
of GSK3β, as well as Pin1 and PP2A in a complex also containing Axin. Active GSK3β phosphorylates 
MYCN at threonine 58, producing doubly phosphorylated, stabilized and transcriptionally active 
MYCN. In a Pin1-mediated process, PP2A dephosphorylates the S62 phosphate, enabling binding of 
and E3 ubiquitin ligases (F-box and WD repeat domain-containing 7 (FBXW7)) (Barone et al., 2013). 
FBXW7 subsequently drives poly-ubiquitination and proteasomal degradation of MYCN. Aurora A 
kinase can bind to and stabilize polyubiquitinated/phosphorylated MYCN, potentially leaving it 
competent to bind to MAX and activate transcription (Huang and Weiss, 2013).  mTORC1 also 
directly phosphorylates and inhibits PP2A, enabling the accumulation of doubly phosphorylated, and 
consequently drive oncogenic stabilisation of MYCN contributing to the general proliferation-
promoting downstream effects of the PI3K /MYCN pathway  (Cheng et al., 2007).Thus inhibition of 
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CDK1, Aurora A kinase or mTORC1 confer MYC protein stabilisation and maintenance leading to 
potential degradation of MYCN (Gustafson and Weiss, 2010).  
Targeting the expression or function of MYCN is the fourth mechanism. Regulation of the expression 
of MYC proteins or modification of MYC function have long been known and are currently used to 
treat neuroblastoma patient. For example, retinoic acid downregulates MYCN expression and 
inhibits its transcriptional oncogenic activity. Downregulation of MYCN expression induces cell-cycle 
arrest and stimulates neuronal differentiation (Thiele, Reynolds and Israel, 1985). MYCN expression 
also can be modulated through regulating the let-7 family of microRNAs, which negatively regulate 
MYCN expression (Molenaar, Domingo-Fernández, et al., 2012). 
1.1.3.4. ALK gene aberrations 
Anaplastic lymphoma kinase (ALK) gene encodes a receptor tyrosine kinase protein that plays an 
important role in the CNS and PNS development. ALK protein has an anti-apoptotic role when bound 
to its ligase (pleiotrophin) (Bowden, Stoica and Wellstein, 2002) as well as a role in cellular 
differentiation and axon guidance (Palmer et al., 2009). Overexpression of ALK  has implications in 
the development of human cancers such as non-small cell lung cancer, anaplastic large cell 
lymphoma, neuroblastoma and several other anaplastic tumours (Berry et al., 2012)  
Activating germline mutations of ALK have been  detected in the majority of familial neuroblastomas 
and point mutations have been found in approximately 7-10% of sporadic neuroblastoma cases 
(Huang and Weiss, 2013).  Constitutive ALK signalling is thought to contribute to oncogenic 
transformation via controlling cell cycle progression, and cell survival and  migration (Carpenter and 
Mossé, 2012). 
The ALK gene is found in chromosome 2p23. The most potent ALK mutation detected is a recurrent 
cytosine-to-adenine change in exon 23 that results in a phenylalanine-to-leucine substitution at 
codon 1174 (F1174L) within the kinase domain (Yan et al., 2011). ALKF1174L mutation occurs in a high 
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proportion of MYCN-amplified neuroblastoma cases. Amplification of the ALK gene almost 
exclusively occurs in MYCN-amplified neuroblastoma primary tumours, and within this group it 
represents 15% of the cases (George et al., 2008). Interestingly, ALK and MYCN (whose gene is 
located at 2p24) are physically linked on chromosome 2p and that may explain why amplification of 
ALK frequently occurs with MYCN amplification (De Brouwer et al., 2010). This combined occurrence 
seems to be associated with a particularly poor outcome suggesting a positive correlation between 
both aberrations as supported by recent animal studies. When mice overexpressing ALKF1174L are 
crossed with MYCN transgenic mice, they breed a progeny with aggressive, invasive and  bulky 
neuroblastoma tumours coupled with poor survival rate (Berry et al., 2012). A similar study on 
zebrafish revealed that the co-occurrence of the two aberrations of ALKF1174L and MYCN accelerated 
neuroblastoma tumour onset and increased the frequency of tumours compared to  MYCN alone 
(Zhu et al., 2012). It should be noted that, ALK cooperates with MYCN to drive malignancy, as 
activation of ALK results in MYCN overexpression. ALK stabilizes the activity of the MYCN protein via 
activating PI3K/AKT/mTOR and MAPK pathways, as well as blocks apoptosis allowing escape route 
for MYCN-amplified cells of being able to apoptose (Berry et al., 2012; Schönherr et al., 2012; Zhu et 
al., 2012). Thus targeting both of MYCN and ALK overexpression may provide a novel therapeutic 
approach for neuroblastoma patients.  
1.1.4. Hallmarks of cancer and Neuroblastoma  
As discussed in the previous section, there are a number of genetic aberrations responsible for the 
development and heterogeneity of neuroblastoma tumours. Alongside the genetic aberrations, the 
transition to malignant form requires the gaining of biological capabilities. In 2011, Hanahan and 
Weinberg have described 8  essential alterations (hallmarks) in cell biology in addition to two 
enabling characteristics that collectively dictate malignant growth (Hanahan and Weinberg, 2011). 
These capabilities/ hallmarks are mostly shared in all types of human cancers and here will be 
discussed in the context of neuroblastoma (Figure 1.2).  
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1.1.4.1. Self-sufficiency in growth signals 
Self-sufficiency in growth signals is considered a defining property of stem cells. Self-renewal is 
important in normal tissue repair, embryogenesis and homeostasis (Horne and Copland, 2017). Cell 
proliferation in normal cells is strictly coordinated to maintain the function with normal architecture 
(Hanahan and Weinberg, 2011). Cell growth signals are largely conveyed through growth factors that 
bind specific cell-surface receptors on the cell membrane to transmit signals to the intracellular 
signalling pathways. Signals transduce to the nucleus leading to an activation of the nuclear 
regulatory factors that regulate DNA transcription and eventually cell cycle entry and growth (Borah 
et al., 2015; Horne and Copland, 2017). Similar to normal cells, cancer cells also use the same 
MYCN, ALK, CDK4/6 
PI3K/mTOR, TrkA/B, 
Aurora kinase A 
GLUT1, 
MYCN 
Caspase-8, 
Survivin, 
TP53, Bcl-2, 
Bim-1, HDAC 
Chromothripsis 
VEGF, HIF-1α, 
HIF-2α 
MMPs, 
EMT/Twist1, 
CXR4/ CXCR7 
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TERT, ATRX 
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granulocytes, B7-
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p14ARF 
Figure1.2 hallmarks of cancer and enabling characteristic acquired by cancer cells during the 
process of tumorigenesis, described by Hanahan and Weinberg (2011). Red boxes illustrate the 
multiple genes and genetic events contribute to the development of neuroblastoma.  
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mechanism process to maintain their proliferation however they deregulate any of the 
aforementioned steps thereby endowing cells with sustained proliferation signalling pathways 
(Robbins et al., 2005). Overexpressed or mutated proto-oncogenes, such as ALK and MYCN, enhance 
the unrestrained proliferation of cells via multiple mechanisms in neuroblastoma tumorigenesis. 
In neuroblastoma, the growth is also controlled by several cytokines and growth factors that interact 
and bind the cell surface receptors,  including receptor tyrosine kinases (Borriello et al., 2016). ALK  
is a receptor tyrosine kinase that is normally expressed in the small intestine, testis and in 
developing embryonal and neonatal brain (Carpenter and Mossé, 2012). Activating ALK mutations 
disrupt the auto-inhibitory function, activate ligand-independent function and enhance kinases 
activation (Holla et al., 2017), resulting in activation of plethora of stream signalling pathways which 
facilitate the cellular process required for tumourgesis including cell proliferation, growth and 
survival (Carpenter and Mossé, 2012). Oncogenic ALK mutations present in the majority of 
hereditary neuroblastoma and 7 to 10% in the sporadic type of neuroblastoma. Therefore, ALK 
provides an attractive target for neuroblastoma therapy and is currently in phase one and two 
clinical trials (Chen et al., 2008; Carpenter and Mossé, 2012).    
MYCN is known to promote cell proliferation and cell cycle progression. During embryogenesis, this 
function is critical to ensure a complete development of the neurons and brain (Knoepfler, 2002). 
MYCN amplification leads to an oncogenic activity such as playing a vital role in the inhibition of 
cellular differentiation through negatively regulation of tropomyosin related kinase A (TrkA) 
expression (Iraci et al., 2011).As a consequent, cells become arrested in the proliferative stage and 
are unable to terminally differentiate into post-mitotic sympathetic neurons (Brodeur et al., 2009).   
Cyclin-dependent kinase 4 (CDK4) is found to be amplified in neuroblastoma (Gogolin et al., 2013). 
CDK4 is a direct transcriptional target of MYCN (Westermann et al., 2008). CDK4 forms a complex 
with cyclin D2 which hyper-phosphorylates retinoblastoma protein thereby allowing E2F1 to initiate 
the transcription of a cascade of genes involved in cell cycle progression leading to uncontrolled 
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proliferation (Westermann et al., 2008; Gogolin et al., 2013). Similar to CDK4, an elevated activity of 
the mitotic kinase CDK1 is detected in MYCN amplified neuroblastoma cell lines. CDK1 forms a 
complex with either cyclin A or B1 and thus the complexes mediate MYCN behaviour during mitosis 
through direct phosphorylation on serine 54 (Sjostrom et al., 2005).Thus inhibiting CDK4 and CDK1 
may offer an attractive target to treat neuroblastoma patients. 
1.1.4.2. Insensitivity to anti-growth signals 
In normal tissue, cell division is tightly controlled via antiproliferative mechanisms including evading 
the mitogenic signals, inhibition of cell adhesion molecules or tumour suppressor genes to prevent 
inappropriate cell growth and maintain tissue homeostasis (Ozaki and Nakagawara, 2011). 
Neoplastic tissues however must overcome these mechanisms to maintain cell proliferation. Tumour 
suppressor genes are vital component of cellular antiproliferative mechanisms through their activity 
in responding to DNA damage, oncogene activation, and uncontrolled cell cycle progression. TP53 is 
a tumour suppressor gene found to be mutated or has otherwise lost its function in most primary 
and relapsed cancers (Olivier, Hollstein and Hainaut, 2010; Ozaki and Nakagawara, 2011). Plethora of 
cellular stimuli triggers the activity of TP53 including DNA damage, oncogene activation and anoxia. 
The typical response of TP53 to DNA damage is by calling temporary halt for the cell cycle 
progression (quiescence) to allow time for DNA repair to take place. If the DNA damage is 
irreversible, TP53 may induce a permanent cell cycle arrest (senescence) or cell death (apoptosis) 
(Robbins et al., 2005; Hanahan and Weinberg, 2011).  
In neuroblastoma, upon diagnosis, inactivating mutations of TP53 are unlikely to be detected (<2%) 
in the primary tumours (Chen et al., 2010). Most TP53 mutations in neuroblastoma tumours 
reported in relapsed or progressive tumours (Tweddle et al., 2003)and these are now very common. 
Some alternative mechanisms of TP53 inactivation on neuroblastoma tumours have been suggested 
including an increase activation of mouse double minute 2 (MDM2), inactivation of p14ARF gene or 
cytoplasm sequestration. MDM2 is known as an oncoprotein that stabilises or sequesters TP53 thus 
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limiting its activity and p14ARFprotected TP53 from MDM2 mediated-degradation (Tweddle et al., 
2003; Van Maerken et al., 2009).  
The Retinoblastoma (RB) gene, the archetypal tumour suppressor gene, inhibits the cell cycle 
progression at the  G1/S checkpoint (Hanahan and Weinberg, 2011). In the inherited form of 
retinoblastoma, affected children possess a germline mutation of the RB gene, a subsequent somatic 
mutation leads to bilateral inactivation (Knudson, 1971).  
1.1.4.3. Evasion of apoptosis 
In addition to unrestrained proliferation, tumour cells must evade apoptosis. Apoptosis is a 
mechanism used by normal cells during development and in the event of them becoming damaged. 
Apoptosis is characterised by a number of biochemical changes including DNA cleavage into 
fragments, membrane surface modification - externalization of phosphatidylserine and cleavage of 
intracellular substrates by Caspases (Coleman, 2010), as well as morphological changes including cell 
shrinkage, chromatin condensation and fragmentation, cell membrane blebbing with loss of 
adhesion to neighbouring cells or extracellular matrix (Kroemer et al., 2009; Koff, Ramachandiran 
and Bernal-Mizrachi, 2015). Two pathways initiate apoptosis, intrinsic “mitochondrial pathway” or 
extrinsic “death receptor pathway”(Parrish, Freel and Kornbluth, 2013), both ultimately result in the 
activation of a proteolytic cascade of caspases leading to cell death (Elmore, 2007).  
In neuroblastoma various genetic aberrations take place to secure tumour cells from apoptosis (Evan 
and Vousden, 2001; Hanahan and Weinberg, 2011). 
The intrinsic pathway of apoptosis is initiated via multiple internal stimuli such as stress or GF 
deprivation. Proapoptotic members of the Bcl-2 family, BAX and BAK, undergo structural 
modification to become active. They then migrate to the mitochondria and homodimerise and 
expose the internal crypt through introducing pores on the outer surface of the mitochondria. This 
increases inner membrane permeability leading to the release of Cytochrome C (Tait and Green, 
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2013). Bcl-2 family of proteins is found to be highly expressed in neuroblastoma cell lines and 
tumours (Dole et al., 1995; Abel et al., 2005).  
The extrinsic pathway, however, is initiated through death receptor binding-ligand. Death receptors 
are characterised by specific protein motifs that contain DD (death domain) and DED (death effector 
domain). Activation of a death receptor leads to the activation of Caspase 8 downstream signalling 
pathways (Koff, Ramachandiran and Bernal-Mizrachi, 2015). Caspase 8 plays a pivotal role in the 
extrinsic pathway of apoptosis. Hyper-methylation of a regulatory region (e.g. CpG island) in Caspase 
8 gene has been described to elicit the loss of its function in neuroblastoma tumours (Teitz et al., 
2000; CASCIANO, 2004).  
Unexpectedly, MYCN has been described to activate TP53 (Chen et al., 2010). This may explain why 
MYCN amplified primary neuroblastoma tumours are more responsive to the chemical therapy, as 
TP53-mediated apoptosis signalling pathways are functional. However, the chemotherapy tends to 
induce mutations in TP53, resulting in loss of apoptotic function and consequently leading to relapse 
and chemo-resistance (Huang and Weiss, 2013).  
1.1.4.4. Limitless replicative potential 
Normal cells can only divided a limited number of times, known as the Hayflick number.  After this 
point, cells can no longer divide and become senescent (Hayflick, 1997). At the end of the 
chromosomes there is a DNA sequence, termed the telomere, which shortens each time the cell 
divides. Short telomeres are recognised by the cell’s DNA repair machinery e.g. TP53 and RB which 
induce cell cycle arrest and senescence. Senescence defines as an irreparable entrance into a non-
proliferative but viable state. In circumstances where p53 or RB are inactivated e.g. tumour cells, the 
cells employ the non-homologous end joining (telomere fusion) mechanism in an attempt to rescue 
the cell, thus eliminating active apoptosis pathways (Hanahan and Weinberg, 2011).  
Stem cells and germline cells both express telomerase; a specialised reverse transcriptase enzyme 
able to lengthens the telomere, and this is virtually absent from somatic cells. However, cancer cells 
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manage to escape from senescence via upregulation of telomerase during the period of genomic 
instability (Robbins et al., 2005; Hanahan and Weinberg, 2011). The vast majority (~90%) of human 
cancer cells upregulate the expression of telomerase to propagate immortalisation trait (Sherr and 
McCormick, 2002; Passos, Saretzki and Von Zglinicki, 2007). 
In neuroblastoma, telomerase is found to be upregulated and associated with advanced cases and 
poor prognosis (Hiyama et al., 1995). Lack of telomerase activity has been linked to the stage 4S of 
neuroblastoma, explaining the spontaneous regression of the tumour (Hiyama et al., 1995). Genome 
sequencing studies indicated that 25% of neuroblastoma patients possess rearrangement of TERT 
(encodes the protein component of telomerase) promotor, resulting in enhancer hijacking and 
activation. Of note, TERT is also a direct transcriptional target of MYCN (Peifer et al., 2015).  
Alternative lengthening (ALT) is a telomerase independent telomere maintenance mechanism found 
in ~10% of human cancers (Cesare and Reddel, 2010). ATRX is an RNA helicase involved in chromatin 
remodelling and telomere maintenance as well as it supresses ALT (Napier et al., 2015). Loss of ATRX 
function mutation occur in  approximately 10% of sporadic neuroblastoma cases, indicating its role 
in eliminating the limitless replicative potential (Molenaar, Koster, Zwijnenburg, et al., 2012). 
1.1.4.5. Inducing angiogenesis 
Despite the growth advantages gained through the previously mentioned hallmarks, tumours cannot 
extend beyond 1-2mm in diameter unless they are vascularised to allow delivery of O2 and nutrients 
and evacuate waste products (Collet et al., 2014). Neoangiogensis refers to the process in which 
there is a growth of new blood vessels from pre-existing vessel. This event is controlled by the 
balance between pro-angiogenic factors e.g. vascular endothelial growth factor (VEGF) and 
inhibitory factors e.g. thrombospondin-1 (TSP-1) (Muz and Azab, 2015). During tumour progression, 
cancer cells require access to blood vessels for growth and metastasis therefore they activate an 
angiogenic switch. The angiogenic switch is activated through increasing the production of  the pro-
angiogenic factors such as VEGF, fibroblast growth factor (FGF), angiogenin, transforming growth 
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factor (TGF)-α, TGF-β, tumour necrosis factor (TNF)-α, platelet-derived endothelial growth factor 
(PDGF), granulocyte colony-stimulating factor, placental growth factor, interleukin-8, hepatocyte 
growth factor, and epidermal growth factor, and concomittent loss of angiogenic inhibitors by 
tumour and stromal cells, leading to neoangiogenesis (Bergers and Benjamin, 2003; Wicki and 
Christofori, 2008; Baeriswyl and Christofori, 2009). However, tumour vasculature is abnormal; blood 
vessels are leaky, dilated and arbitrarily arranged  (Robbins et al., 2005; Hanahan and Weinberg, 
2011). 
Angiogenesis is prominent feature on neuroblastoma tumours (Chlenski, Liu and Cohn, 2003). 
Unfavourable neuroblastoma including MYCN amplification is usually associated with high 
vascularity and microvascular proliferation. High expression of VEGF or PDGFA is tightly correlated 
with the aggressive and metastatic neuroblastoma tumours (Meitar et al., 1996). Unfavourable 
histology Schwannian stroma-poor neuroblastoma tumours demonstrate significant angiogenesis. 
Whilst in Schwannian stroma-rich tumours, stoma cells express an angiogenic inhibitor, identified as 
secreted protein acidic and rich in cysteine (SPARC). SPARC expression is found to be inversely 
correlated with the degree of malignant progression in neuroblastoma tumours (Chlenski et al., 
2002).  
1.1.4.6. Tissue invasion and metastasis 
The most deadly aspect of cancer is its ability to spread, or metastasize. The invasion-metastasis 
cascade is a complex process involving a series of sequential steps to allow spread of a primary 
tumour. These steps involve of local invasion, intravasation into the circulatory system, survival of 
the shear stress and the protective immune cells in the bloodstream, extravasation from the vessels 
and finally growth of micrometastases into macroscopic neoplasia  (McGowan, Kirstein and 
Chambers, 2009; Talmadge and Fidler, 2010; Reymond, D’Água and Ridley, 2013). 
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Matrix metalloproteinases (MMP) family play an important role in the regulation of tumour cell 
adhesion and migration. A correlation between overexpression of MMP2 and MMP9 has been 
detected in advanced neuroblastoma  (Sugiura et al., 1998). 
EMT is required during normal neural crest development, and also is considered an important 
mechanism for both the initiation of tumour invasion and subsequent metastasis (Klymkowsky and 
Savagner, 2009). The EMT program is orchestrated and coordinated by a number of transcription 
factors (TFs) notably Snail, Slug and Twist; they promote EMT in part by suppressing the expression 
of E-cadherin thus facilitating invasion (Micalizzi, Farabaugh and Ford, 2010; Craene and Berx, 2013; 
Lamouille, Xu and Derynck, 2014). An association between overexpression of TWIST-1 has been 
shown in a subset of neuroblastoma metastatic tumours (Valsesia-Wittmann et al., 2004).  
1.1.4.7. Deregulating cellular energetics 
Cancer cells undergo fundamental metabolic changes maintaining energy production (ATP) to 
support their unchecked proliferation (DeBerardinis et al., 2008). They increase their glucose uptake 
through upregulating glucose transporters such as GLUT 1 and GLUT 3  (Hsu and Sabatini, 2008; 
Kristin H Kain et al., 2014),  and switch their glucose metabolism form oxidative phosphorylation to 
glycolysis; this is termed the Warburg effect. Warburg effect has been demonstrated in 
neuroblastoma by the use of positron emission tomography scan to visualise the avid uptake of 
fluorine-18 fluorodeoxyglucose  (Kushner et al., 2001). Studies showed that MYCN is associated with 
regulation of tumour metabolism through activation of genes involved in glycolysis, glutamine 
metabolism, fatty acids metabolism and mitochondrial function (Qing et al., 2010; Zirath et al., 2013; 
Ren et al., 2015). Amplification of MYCN supports the Warburg effect in neuroblastoma tumours by 
activating the transcription of several glycolytic genes such as GLUT 1  (Aminzadeh et al., 2015).  
1.1.4.8. Avoiding immune destruction 
The immune system tightly interacts with cancer cells over the entire process of disease 
development and metastasis progression. This interaction between immunity and cancer can both 
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inhibit and enhance tumour growth. Most tumours, including neuroblastoma, arise in 
immunocompetent hosts (Vajdic and Van Leeuwen, 2009). Malignant cells therefore require a 
strategy to escape eradication by the host immune system (Vinay et al., 2015). They escape the 
immune destruction machinery through disabling the inflammatory cells that have been sent to 
eradicate them. An evasive mechanism that can be used by cancer cells to evade the immune 
destruction is by recruiting the inflammatory cells that previously immunosuppressed such as 
myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) to suppress the actions of 
cytotoxic lymphocytes (Ostrand-Rosenberg and Sinha, 2009; Mougiakakos et al., 2010). 
In neuroblastoma, tumour cells were found to downregulate human leucocyte antigen (HLA) class 1 
and adhesion molecules thus avoiding cell recognition and destruction by the infiltrating CD8+ 
cytotoxic T lymphocytes (CTLs) and neutral killer (NK) cells (Bottino et al., 2014). In addition, MYCN 
amplification down regulates HLA 1 expression  (Bernards, Dessain and Weinberg, 1986). Tumour-
associated macrophages (see section 1.1.4.10) are also recruited to suppress lymphocyte activity 
(Liu et al., 2012).  
1.1.4.9. An Enabling Characteristic: Genome Instability and Mutation 
Acquisition of the eight hallmarks, discussed above, depends largely on several alterations in the 
genomes of neoplastic cells. In addition, two enabling characteristics have been described. The first 
enabling characteristic for tumorigenesis is an increased tendency of alterations in genome during 
the tumour cell cycle (Hanahan and Weinberg, 2011). In contrast to normal cell, tumour cells 
acquired increased susceptibility of genomic instability (Shen, 2011). Unchecked and uncontrolled 
proliferation of tumour cells produces mutant clones that are genetically heterogeneous. In the 
presence of favourable genomic characteristics, these clones will survive and propagate, increasing 
tumour progression (Greaves and Maley, 2012).  
Tumour cells are less genetically stable than normal cells (due to loss of a fully functioning DNA 
repair system) (Greaves and Maley, 2012) and one extreme example of this is Chromothripsis. 
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Chromothripsis is a phenomenon by which up to thousands of clustered chromosomal 
rearrangements occur in a single event and a single chromosome leading to structural aberrations.  
In a study conducted on high risk neuroblastoma tumours, the researchers reported that 
chromothripsis occurred in approximately 18% of these tumours, resulting in structural aberrations 
in genes involved in neuroblastoma pathogenesis (Molenaar, Koster, Zwijnenburg, et al., 2012).    
1.1.4.10. An Enabling Characteristic: Tumour-Promoting Inflammation 
The second enabling Characteristic of tumorigenesis is tumour-promoting inflammation (Hanahan 
and Weinberg, 2011). It is firmly established that tumour cells are highly infiltrated by both adaptive 
and innate immune system components (Pistoia et al., 2013). Although various types of immune 
cells are involved in supporting tumour growth, the main culprits are known as Tumour Associated 
Macrophages (TAMs).  The presence of TAMs in neuroblastoma correlates with advanced stage, with 
the largest infiltration observed in children with metastatic disease (Asgharzadeh et al., 2012). TAMs 
enhance growth of neuroblastoma tumour through increasing activation of a signal transducer and 
activator of transcription 3 (STAT3), enhancing tumour cell proliferation (Hadjidaniel et al., 2017). 
Furthermore, analysis of 249 primary human neuroblastoma tumour samples revealed a significant 
positive correlation between that MYC up-regulation and TAM infiltration markers, CCL2 and CD14 
(Hadjidaniel et al., 2017).  
1.1.5. Histological classification 
As mentioned previously, tumour cells retain progenitor and stem cell markers. In general, the more 
differentiated tumours are less aggressive whereas tumours with more stem cell-like features are 
more aggressive. In respect to differentiation status, the international neuroblastoma pathology 
committee classification (INPC) indicated four forms of peripheral neuroblastic tumours (PNTs) that 
originates from sympathetic progenitor cells (Shimada, 2003). The most differentiated form of PNTs, 
Ganglioneuroma (GN), consists of mature ganglion cells that forms clusters and are surrounded by 
dense Schwannian stroma. GN often presents in older children and is less common than 
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neuroblastoma  (Lonergan et al., 2003). Ganglioneuroblastoma composes of a mixture of 
undifferentiated neuroblasts and mature or maturing ganglion cells. According to the development 
of neuroblastic and Schwannian stroma, GNB splits into two subdivision: nodular and intermixed. 
The nodular GNB is a more malignant form from the intermixed  although it still less common than 
neuroblastoma (Lonergan et al., 2003). Neuroblastoma, the fourth subgroup of PNTs, represents the 
most undifferentiated and aggressive form of PNTs. A distinguishing feature in NB tumours is the 
presence of pseudorosettes (small round cells arranged in nests) surrounded by neuropil 
(eosinophilic neuritic material) (Lonergan et al., 2003). Depending on the development of 
Schwannian stroma, NB may be divided into undifferentiated, poorly differentiated and 
differentiating neuroblasts (Figure1.3)  (Shimada et al., 1999).  
As discussed above, INPC classification displays the grade of maturation ranging from highly 
differentiated form surrounded by dense Shwannian stroma to those with mostly undifferentiated 
neuroblasts. The differentiated neuroblasts, generally, consist of large round cells with abundant 
cytoplasm that contains cytoplasmic Nissl bodies, and a prominent nucleus. However, less-
differentiated neuroblasts have small round cells that contain scant cytoplasm and nuclei with dense 
hyperchromatic nuclei that shows mitotic activity. Tumours therefore were divided into 
unfavourable and favourable subgroups depending on their histological key features. Unfavourable 
histology confers the worst prognosis in patients (Shimada et al., 1999; Peuchmaur et al., 2003). 
INPC system is a modified form of Shimada classification (Shimada et al., 1999), a system that links 
the age of patient to the histological features of the tumour such as the degree of cellular 
differentiation and the presence or absence of Schwannian stoma (Figure1.4 ), as well as the 
mitosis-karyorrhexis index (MKI) (Ikeda et al., 2002; Peuchmaur et al., 2003).  
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Figure1.3 International Classification System for Neuroblastoma Prognosis and Diagnosis. 
Flowchart for prognostic evaluation demonstrates the histological subtypes of peripheral 
neuroblastic tumours based on the abundance of Schwannian stroma and the presence/absence of 
neuroblastic tumour nodules. There are two groups for the final evaluation of PNTs: they are 
favourable histology (FH) and unfavourable histology (UH). Favourable tumours demonstrate 
increased Schwannian stroma development. In addition, this classification illustrates those younger 
patients with low mitosis-karyorrhexis confer better prognosis (not shown). Adapted from 
(Shimada, 2003). 
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1.1.6. Diagnosis  
A combination of laboratory tests, histopathological studies and scanning can be carried out to 
confirm neuroblastoma diagnosis. 90% of NB tumours secrete catecholamine metabolites, 
homovanillic acid (HVA) and vanillylmandelic acid (VMA), in urine (Lonergan et al., 2003). The 
relative amount of secreted catecholamine metabolites can determine the grade of cellular 
differentiation of neuroblastoma tumours therefore low HVA/VA is associated with poorly 
differentiated tumours associated poor prognosis (Strenger et al., 2007). Hence, the ratio of these 
two markers can be then used to detect tumour relapse and progression (Mullassery and Losty, 
2016). In addition, elevated dopamine level is also linked to the existence of neuroblastoma 
(Strenger et al., 2007). Furthermore, a biopsy sample is important for the diagnosis of 
neuroblastoma.  These tissue samples of tumour are used to investigate the histology and molecular 
and genetic changes, for example, identification of gene amplification or other chromosomal 
aberrations and mutations (Pugh et al., 2013).   
In addition to laboratory testing and histopathological studies, a wide range of imaging and scanning 
is used in the diagnosis of neuroblastoma. Patients presenting with abdominal mass may undergo an 
Figure1.4 Neuroblastoma pathological classification. Diagram displaying the three grades of 
neuroblastoma differentiation observed and the two levels of stromal development. Taken from 
http://bmi.osu.edu/cialab/mia_nb.php . 
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initial investigation using ultrasonography (Matthay et al., 2016).This can then followed by cross-
sectional scanning using magnetic resonance imaging (MRI) or computed- tomography (CT). These 
will allow the size of the primary tumour to be estimated and also determining the extent of 
metastasis  if found (Kembhavi et al., 2015). Metastasis is usually determined by bone marrow 
aspirates from which many of the primary cells used in research are derived. To determine the 
primary tumour and the location of metastases, scintigraphy imaging could be performed.  A tool 
like Meta-iodobenzylguanidine (MIBG) scanning also used to evaluate the involvement of bone and 
bone marrow (Shusterman et al., 2011). Finally, tumour cells predominantly rely on the aerobic 
glycolysis to maintain their energy therefore 18F-Fluorodeoxyglucose positron emission scanning is a 
good tool used to measure dependency levels of glucose (Sharp et al., 2009). 
1.1.7. Screening 
Neuroblastoma screening programmes was performed in Japan, North America and Europe using 
the elevated catecholamine levels as method of diagnosis in order to identify patients at a young age 
since these patients had a much better prognosis (Schilling et al., 2002; Woods et al., 2002). This 
programme was successful in identifying the previously undiagnosed cases of neuroblastoma 
however the mortality rate did not improve (Tsubono and Hisamichi, 2004). This was because most 
of the discovered cases had favourable clinical and biological features such as 4S stage and many 
underwent spontaneous regression would normally never have presented at hospital. Ultimately, 
the screening program did not reduce the mortality rate or the incidence of advanced cases, 
subsequently it was abandoned.  
1.1.8. Neuroblastoma presentation 
Localised primary tumours are presented in approximately 40% of neuroblastoma patients at 
diagnosis. The primary tumours may develop in several different sites as they reflect the diverse 
range of NCC derived sympathetic adrenal structures. This therefore suggests that the primary 
tumours may develop anywhere along the sympathetic chain or in the adrenal gland (Matthay et al., 
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2016).The commonest site of the primary tumours is the abdominal cavity followed by thorax. The 
abdominal cavity primary tumours represent 70% of neuroblastoma incidences (Maris, 2010).  
Approximately 50% of neuroblastoma cases presented with metastasis. The liver is the most 
common site for distant metastasis followed by the lymph nodes, bone and skin. The lungs and the 
brain are rarely involved (Taggart et al., 2011). 
1.1.9. Disease staging and prognosis 
Neuroblastoma has been staged according to the International Neuroblastoma Staging System 
(INSS) since early 1990’s (Table1.1). International Neuroblastoma Risk Group (INRG) has developed a 
staging system referred to as INRGSS by adding the risk stratification in order to assist in the 
appropriate management of patients. For that, INRG produced a standard worldwide system, 
through assessing several clinical trials around the world, which included both risk-based staging 
system (Table1.2) and pre-treatment classification schema (Table1.3) (Cohn et al., 2009). Here, the 
staging system includes the presence of Imaging-defined Risk factors (IDFs) such as whether the 
tumour is localised or has metastasised at the time of diagnosis (Brisse et al., 2011).  
Risk stratification is achieved by including important prognostic features such as the age of patient at 
diagnosis, stage, MYCN status and DNA index in addition to International Neuroblastoma Pathology 
Classification (INPC) (Table1.3).  As noted by INRG classification, low risk and localised tumours that 
develop in younger patients with no MYCN amplification have an excellent survival rate with or 
without minimal treatment. In high risk patients, however, unfavourable outcomes are expected 
especially when associated with MYCN amplification. Ultimately, this pre-treatment classification 
schema allows delivery of more adequate treatment (Cohn et al., 2009). 
 
 
31 
 
Table1.1 The International Neuroblastoma Staging System. 
Stage  Definition  
1  Localised tumour with complete gross excision, with or without microscopic residual 
disease; representative ipsilateral lymph nodes negative for tumour microscopically.  
2A  Localised tumour with incomplete gross excision; representative ipsilateral non-
adherent lymph nodes negative for tumour microscopically*. 
2B  Localised tumour with or without complete gross excision, with ipsilateral non-
adherent lymph nodes positive for tumour. Enlarged contralateral lymph nodes must 
be negative microscopically.  
3  Unresectable unilateral tumour infiltrating across the midline, with or without regional 
lymph node involvement;  
Or localised unilateral tumour with contralateral regional lymph node involvement;  
Or midline tumour with bilateral extension by infiltration (unresectable) or by lymph 
node involvement**.  
4  Any primary tumour with dissemination to distant lymph nodes, bone, bone marrow, 
liver, skin, and/or other organs, except as defined for stage 4S. 
4S  Localised primary tumour (as defined for stage 1, 2A or 2B), with dissemination limited 
to skin, liver, and/or bone marrow ***. (limited to infants < 18 months of age)  
* lymph nodes attached to and removed with the primary tumour may be positive  
** The midline is defined as the vertebral column. Tumours originating on one side and crossing the midline 
must infiltrate to or beyond the opposite side of the vertebral column.  
** Marrow involvement in stage 4S should be minimal, ie, < 10% of total nucleated cells identified as 
malignant on bone marrow biopsy or aspirate. More extensive marrow involvement would be considered to 
be stage 4. The mIBG scan (if performed) should be negative in the marrow. (Brodeur et al., 1993).  
 
Table1.2 International Neuroblastoma Risk Group staging system (INRGSS) - based on image defined 
risk factors L1 and L2 refer to localized disease whereas M and MS refer to those with metastatic 
spread (Cohn et al., 2009). 
Stage Definition 
L1  Imaging-defined Risk factors absent: Localised tumour confined to one body 
compartment and not involving vital structures, as defined by the list of image-
defined risk factors 
L2  Local regional tumour with presence of one or more image-defined risk factors  
M  Distant metastatic disease (except stage MS)  
MS  Metastatic disease in children <18 months, with metastases confined to the skin, 
liver and/or bone marrow.  
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Table1.3 The International Neuroblastoma Risk Group Consensus Pretreatment Classification- a 
system designed to provide overall risk stratification based on a wide variety of patient derived and 
disease based features. GN, ganglioneuroma; GNB, ganglioneuroblastoma; NA, non-amplified; Amp, 
amplified. Modified from Cohn et al. (2009). 
INRG 
stage  
Age 
(months)  
Histologic 
category  
Grade of tumour 
differentiation  
MYCN  11q 
aberration  
DNA 
content  
Pre-treatment 
risk group  
L1/L2 GN maturing: 
GNB intermixed 
 
 
 
Very low  
L1 Any, expect GN 
maturing or GNB 
intermixed 
 NA 
 
 
 
Very low 
 
 
 
Amp 
 
 
High 
L2  < 18  Any, expect GN 
maturing or GNB 
intermixed 
 NA No Low 
 
   Yes Intermediate 
 ≥ 18 GNB nodular; 
neuroblastoma  
Differentiating NA  No Low  
  Poorly 
differentiated 
or 
undifferentiated 
 Yes  Intermediate  
  Amp 
 
 High  
M  < 18   NA Hyper-
diploid  
Low  
 < 12 NA Diploid  Intermediate  
 12 to < 
18 
 NA  Diploid  Intermediate  
 < 18 Amp  High  
 ≥ 18 High  
MS   
< 18  
NA  No  Very low  
   Yes High  
 Amp High  
 
1.1.10. Spontaneous regression 
Neuroblastoma has a ‘special’ stage of aggressive disseminated growth involving liver, skin, bone 
marrow in addition to the primary tumour, this stage is termed 4S. The 4S tumours occur in children 
less than 18 months of age (Brodeur, 2018)  and represent approximately 7–10% of all 
neuroblastoma cases. Strikingly, 4S tumours can sometimes spontaneously regress (differentiate) 
with little or no treatment (Schleiermacher et al., 2003).The possibility of spontaneous regression 
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affords a good prognosis for patients however it’s difficult to establish precisely what proportion of 
tumours undergo this phenomenon.  
The mechanisms by which these tumours undergo spontaneous regression have been suggested by 
Brodeur and Bagatell, and include loss of telomerase activity, lack of neurotrophin, humoral or 
cellular immunity, and alterations in epigenetic regulation with the possibility of other mechanisms 
may also involve (Brodeur and Bagatell, 2014). It is likely that a better understanding of the 
mechanisms of spontaneous regression will help to identify targeted therapeutic approaches for 
neuroblastoma tumours.  
1.1.11. Management of neuroblastoma 
Management of patients with neuroblastoma is always dependant on the staging schema. The 
treatment of a localised tumour ranges from watchful waiting to surgical resection however for a 
metastatic tumour the treatment would require concentrated multimodal treatments.  
The current approach to treat high risk neuroblastoma includes three main steps. The first step of 
treatment involves intensive induction of chemotherapy to reduce the tumour size and metastasis 
followed by surgical resection to remove the primary tumour. This step is followed by a 
consolidation step that includes myloablative chemotherapy with autologous haematopoietic stem 
cell transplant AHSCT and the final step of treatment termed “maintenance therapy” including 
immunotherapy and differentiation therapy (retinoic acid treatment) targeting the residual disease 
(Mullassery et al., 2009). GD2 is a disialoganglioside found on the surface of all neuroblastoma cells, 
whilst little is found in normal tissues, therefore the relatively tumour specific occurrence of GD2 
makes it an efficient target for immunotherapy with monoclonal antibodies. Humanized anti-GD2 
monoclonal antibodies (anti-GD2 mAb) have therefore been administrated to patients to target GD2 
leading to immune-mediated cell death (Castel, Segura and Berlanga, 2013; Federico et al., 2017).  
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1.1.11.1. Retinoic acid  
Retinoic Acid (RA) is a bioactive metabolite of vitamin A and has critical effects in the development 
of the nervous system in the embryo in addition to its role in the physiology of adults (Mark, 
Ghyselinck and Chambon, 2006). RA is produced normally in the body from vitamin A through two 
oxidizing steps to retinal and then to RA (Figure1.5). In addition, RA can metabolised  by cytochrome 
enzymes (CYP26 enzymes) to hydroxylated metabolite such as 4-hydroxy-RA and 4-oxo-RA 
(Perlmann, 2002). At the cellular level, RA regulates the expression of target genes involved in 
cell growth, differentiation, apoptosis and homeostasis. Moreover, in keeping with other 
functions, RA has been used as an anti-proliferative drug to treat certain cancers (Niles, 2000). 
RA enters to the nucleus by binding the protein cellular RA–binding protein2 (CRABP2) where it is 
recognised by two protein families, the RA receptors (RARs) family comprising 3 isotypes, RARα, 
RARβ, and RAR γ, and the retinoid X receptors (RXRs) family also including 3 isotypes, RXRα, RXRβ, 
and RXR γ. RARs and RXRs form heterodimers and act as RA-modulated transcription factors  
(Perlmann, 2002). 
RA has 3 different isomers: All-trans RA (ALTR), 9-cis RA, and 13-cis RA, at some point, all three can 
bind to effectors but with different affinities.  ALTR binds to RARs/RXRs heterodimer and then the 
complex binds to RA respond elements RAREs that often exist in gene promoters; therefore acting as 
ligand regulated transcription factors  (Gyöngyösi et al., 2013) (Figure1.6). 
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Activation of the canonical pathway  (genomic pathway) will mainly inhibit cell growth, trigger cell 
differentiation, and potentially apoptosis (Tang and Gudas, 2011). 
Two types of DNA binding sequence (RAREs) are found in RA-regulated genes, they are DR-2 and DR-
5. In the absent of ligand (RA), the transcription of the target genes is blocked. RAR/RXR heterodimer 
binds receptors of target genes and then nuclear receptor corepressors (NCoRs) recruits and 
tethered histone deacetylase (HDAC) and repressive factors such as Polycomb repressive complex 2 
(PRC2) to the RAR/RXR dimer. Consequently, the chromatin is compacted so that the DNA becomes 
inaccessible for transcription.  In the presence of ligand (RA), NCoR-binding dissociates from 
RAR/RXR dimer and allows interaction with co-activators of the nuclear receptor co-activator 
(NCoAs). These NCoAs can activate transcription by recruiting histone acetyltransferases (HATs) and 
Trithorax (A group of three proteins involved in gene expression maintenance such as histone 
modification, chromatin remodelling and DNA- binding). As a result of this, the chromatin  is opened  
over the target gene promoter region and active transcription takes place (Niederreither and Dollé, 
2008; Cunningham and Duester, 2015). 
 
Figure1.5 The scheme of RA generation and signalling in the cell. RA is produced 
intracellularly through two oxidizing steps, firstly retinol is enzymatically converted to retinal 
by alcohol dehydrogenase (ADH) and then retinal is oxidized to RA by aldehyde dehydrogenase 
(ALDH), RA is bound to CRABPs and translocated to the nucleus onto RAR/RXR heterodimers. 
RAR/RXR heterodimers bind to RAREs in target genes. SDR is short-chain dehydrogenases that 
can convert Retinal to Retinol.  Adapted from (Gyöngyösi et al., 2013). 
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RA can be bound to other cellular proteins such as fatty acid binding protein 5 (FABP5) to activate 
other nuclear receptor such as peroxisome proliferator-activated receptor β/δ (PPARβ/δ).  The 
relationship between FABP5 and PPARs is seen to be similar to that between CRABP2 and RARs.  Like 
RARs, PPARs belong to nuclear superfamily that regulates expression of target genes are mainly 
involved in proliferation. RA is higher affinity to RARs compared to PPARs, and the binding affinity 
between RA and FABP5 is far lower compared to RA with CRABP2. In addition, certain organs and 
tissues are found to highly express PPARs as the proliferation and cell maintenance is an important 
aspect in their health, for example, in the brain, skeletal muscles, skin and adipose tissues. 
Moreover, keratinocytes and adipocytes have a high level of compared to CRABP2, resulting in 
proliferative effect following PPAR activation rather than RAR.  Interestingly, RXRs can form a 
heterodimer with PPARs to bind receptor elements RAREs to regulate subset of genes involved in 
energy balance (Al Tanoury, Piskunov and Rochette-Egly, 2013).  
In addition to the canonical pathways (nuclear-transcriptional pathways) of RA, discussed above, RA 
is involved in non-canonical pathways (extra-nuclear and non-transcriptional pathways). Some RARs 
present in the membrane lipid rafts, and upon binding to RA, they activate kinase cascades. In 
 
Figure1.6 Mechanisms of retinoic acid signalling. In the absent of ligand (RA), the receptors 
target genes are repressed through recruiting histone deacetylase (HDAC) and repressive factors 
such as Polycomb repressive  complex 2 (PRC2) that both are tethered through nuclear receptor 
corepressors (CoRs),  and consequently  the  chromatin compacted so that the DNA become in 
inaccessible for transcription. In the presence of RA, NCoR-binding is destabilized in the ligand 
binding domain to allow interaction with co-activators of the nuclear receptor co-activator 
(NCoAs). These NCoAs can activate the RAR/RXR dimers by recruiting histone acetyltransferases 
(HATs) and Trithorax which lead to chromatin decondensation over the target gene promoter 
region. Adapted from (Cunningham and Duester, 2015) 
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response to RA, RARs in the lipid raft of various epithelial and fibroblast cells interact with Gαq to 
activate p38 MAPK through the activation of Ro-GTPases (Figure1.7). Alternatively, in neuron cells,  
in response to RA, RARs activates PI3K/ AKT pathway which in turn activates the ERKs pathway 
(Figure1.7) (Al Tanoury, Piskunov and Rochette-Egly, 2013). Activation of kinase pathways provides 
strong proliferative affects in both normal and cancerous cells; therefore this pathway may give the 
opportunity to the cancer cells to become resistance to RA treatment (Connolly, Nguyen and 
Sukumar, 2013).   
 
 
 
 
 
 
 
 
 
1.1.11.1.1. The biological effects of Retinoic acid on cancer  
RA has been investigated extensively for its potential in the chemoprevention and treatment of 
cancer, predominately due to its activity in arresting the cellular proliferation and inducing 
differentiation. Therefore, RA is a part of standard therapy for many cancers including high-risk 
neuroblastoma (Matthay et al., 2009). 
 
Figure1. 7 The extra-nuclear and non-transcriptional pathways of RA. Subpopulation of RARα 
is present in membrane lipid rafts and initiates cascades of kinase activations upon RA binding. 
In various epithelial and fibroblast cells, in response to RA, RARα localized in lipid rafts 
interacts with Gαq proteins and activates Rho-GTPases and p38MAPK. However, in neuronal 
cells, in response to RA, RARα activates Erks through the activation of the PI3K/Akt pathway. 
Strikingly, in neuronal cells, RA has been also shown to activate Erks via RARγ in association 
with the Src kinase. Modified from (Al Tanoury, Piskunov and Rochette-Egly, 2013). 
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In 1982, Seeger showed that RA induced differentiation of human neuroblastoma cells growing in 
monolayer (Seeger, Siegel and Sidell, 1982).  Similarly, some have used retinoic treatment  to treat 
other cancer cells such as  acute promyelocytic leukaemia (APL) and found that RA induced those 
cells to differentiate into granulocytes (Tallman et al., 1997). RA therapy has since been shown to be 
successful in the clinic.   
RA regulates the transcription of genes that play an important role in both tumour regression and 
tumour progression. As mentioned before,  RA down-regulates MYCN expression,  and hence 
inhibits tumour progression and increases event-free survival in some advanced stage 
neuroblastoma patients (Reynolds et al., 2003; Matthay et al., 2009). In this, RA has been 
investigated and found to be involved in the regulation of stem cell differentiation, this was through 
inducing the expression of differentiation markers which is Tuj-1 and reducing  the expression of 
neural stem cell markers such as CD133, Msi-1, nestin, and Sox2 (Ying et al., 2011). In addition, RA 
has also been found to inhibit expression of growth factors such as EGFR and VEGF and cell 
proliferation-associated markers such as cyclin D1 and human telomerase reverse transcriptase 
(hTERT) (Alizadeh et al., 2014).  
In keeping with RA’s role in differentiation,  a group of researchers , in China, showed that RA 
treatment  induces cell-cycle arrest in human carcinoma cells (Zhang et al., 2014) and seen to cause  
cell cycle arrest and apoptosis of prostate cancer cells (Chen et al., 2012). 
Hsu et al. found RA-mediated G1 arrest is associated with induction of p27kip1 and inhibition of 
cyclin-dependent kinase 3 (CDK3) in human lung squamous carcinoma cells (Hsu et al., 2000). 
Siddikuzzaman and Grace reported that encapsulated RA has the ability to inhibit lung cancer 
metastasis in mouse model (Siddikuzzaman and Grace, 2012). Recent  research indicated that RA can 
suppress hepatoma cell growth and cause apoptosis (Wei et al., 2014). 
Taken together, these studies and trials elucidate the fact that RA is indeed a potential compound to 
suppress cell growth, enhance differentiation, and apoptosis in a variety of malignancies. It’s also 
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possible that RA can work as a helper that cooperates with other treatments and attacks cancer 
cells.  
1.1.11.2. Cyclin-dependent kinases  
Protein phosphorylation is the main key that controls and regulates the eukaryotic cell cycle (Errico 
et al., 2010). The cell progression and division critically requires the activation of a sub family of 
serine/threonine protein kinases known as Cyclin-dependent kinases (CDKs). This family must bind 
to its’ corresponding cyclins for activity. During the cell cycle, cyclin abundance oscillates through 
scheduled synthesis  and degradation as required in each phase, therefore regulating kinase activity 
is a timely manner (Figure 1.8) (Malumbres and Barbacid, 2009). In particular, at the end of M 
phase, ubiquitin-mediated proteolysis degrades mitotic cyclins, which leads to inactivation of CDKs 
and permits the return to interphase (Zachariae and Nasmyth, 1999).  
To date, 9 CDK complexes have been discovered and five of them drive the cell cycle.  During 
interphase CDK4, CDK6 and CDK2 are involved in G1, CDK2 in S and CDK1 also known as CCD2 (cell 
division control- protein 2) operates in both G2 and mitosis, whereas CDK3 is involved in G0. CDK 
activity is regulated throughout the cell cycle by binding to their activators and inhibitors. Activators 
includes four classes of cyclins: A, B, D and E- type (Malumbres and Barbacid, 2009). Progression 
through a specific cell cycle stage requires the participation of particular CDK/cyclin complex 
(table1.4 and Figure1.9). CDK/cyclin complexes are inhibited through cyclin-dependant kinases 
inhibitors including the INK4 inhibitors family (p15, p16, p18, p19) and CDK inhibitory protein/kinase 
inhibitor protein (Cip/Kip) family (p21, p27, p57) (Figure1.9) (Nakamura et al., 2003).  
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Figure1.8 Oscillation and abundance of Cyclins during the life of a cell cycle. Taken from 
https://commons.wikimedia.org/wiki/File:Figure_10_03_02.jpg .  
 
Table1.4 Shows the major cyclins and CDKs of vertebrates. *there are three D cyclins (D1, D2 and 
D3). 
 
 
 
 
 
 
 
 
 
Cell cycle phase 
activity 
Cyclin CDK Partner 
G0-CDK Cyclin C CDK3 
G1-CDK Cyclin D* CDK4,CDK6 
G1/S transition -CDK Cyclin E CDK2 
S-CDK Cyclin A CDK2,CDK1 
M-CDK Cyclin B CDK1 
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Figure1.9 Cell cycle and cyclin-dependent kinases (CDKs). CDK-cyclin complexes have direct 
functions in regulating the cell cycle. CDK3/cyclin C drives cell cycle from G0. During the G1 phase, 
CDK4/6/cyclin D complexes initiate phosphorylation on the retinoblastoma protein (pRb) to sequester 
p21Cip1and p27kip1 kip1, which are both inhibitors of CDK2 thus promoting the activation of 
CDK2/cyclin E complex. In late G1,   CDK2/cyclin E complex completes phosphorylation and 
inactivation of pRb, which releases the inhibition on the E2 family (E2F) transcription factors and 
leading to expression of the genes necessary for G1/S transition. CDK2/cyclin A complex regulates 
progression through S phase and CDK1/cyclin A complex through G2 phase in preparation for mitosis 
(M).  Mitosis is initiated by CDK1/cyclin B complex. The overall rate of cell cycle progression is 
determined by the relative activity of the activating cyclin-CDK complexes and the inhibitory proteins 
of the INK4 family that inhibit CDK4 and CDK6 in G1 phase, and the Cip/Kip family that has more 
widespread inhibitory action through the cell cycle. Adapted from (Lutful Kabir, Alvarez and Bird, 
2015). 
1.1.11.2.1. Cell cycle control and cancer treatment 
The defect in balance between cellular proliferation and differentiation is believed to be a key factor 
in human cancers. Neuroblastoma, for example, is thought to be a result of an aberration in the 
regulation of the cell cycle during embryo nervous system development (Wylie et al., 2015). 
Indeed, multiple mechanisms operate and coordinate together to regulate the cell cycle fate. CDK/ 
cyclin complexes tightly control the cell cycle events and their dysregulation may result in several 
human cancers (Hanahan and Weinberg, 2000; Malumbres and Barbacid, 2001; Malumbres, 2011). 
Of note, oncogene mutations  and altered – CDK activities  have been reported in human cancer 
genomes (Aleem and Arceci, 2015), whilst, mutations in tumour suppressor genes and cyclin-
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dependant kinase inhibitors (CKIs) also contribute to uncontrolled cell proliferation (Whitfield et al., 
2006; Malumbres and Barbacid, 2009; Santarius et al., 2010).  
Early work demonstrated that lengthening G1 phase of the cell cycle through CDK inhibitors induces 
the switch from neural progenitors (proliferative) to neuron-generating cells (Calegari et al., 2005). 
Yang and Herrup found that the duration of G1 phase and S phase is  a crucial factor in both the 
differentiation decision and precursor cell maintenance (Yang and Herrup, 2007).  
Mechanistically, inhibition of cell cycle entry (i.e by inhibiting CDK4/6) is likely to induce cell cycle 
arrest or quiescence but not apoptosis. For instance, inhibition of CDK4 prevents the development of 
lung tumours induced by K-Ras oncogene by triggering senescence, a permanent arrest in G0/G1 
(Puyol et al., 2010). Recent work  has demonstrated that treatment of adult neural stem cells with a 
cell permeable CDK4 inhibitor induced an increase in the percentage of cells in G1 and promoted 
neuronal differentiation in vitro (Roccio et al., 2013). Similarly, spontaneous differentiation is 
preceded by cell cycle arrest in G1 phase in human embryonic stem cells (Sela et al., 2012). On the 
other hand, accumulation of active CDK4/6/cyclin D complexes, during G1, resulted in inhibitory 
phosphorylation of SMAD2/3, thus preventing  cell specification (Pauklin and Vallier, 2014). 
In a study conducted on neuroblastoma primary tumours, CDK4 was found to be amplified and 
associated with  genomic aberrations in the G1 regulatory genes such as MYCN,  and hence inducing  
overexpression of E2F target genes (Molenaar, Koster, Ebus, et al., 2012).  Recently, there were 
some attempts to inhibit CDK4/6 /cyclin D1, using Palbociclib a small selective molecule inhibitor of 
cyclin D1 associated kinases. CDK4/6 inhibition induced cell cycle-arrest in G1, supressed the D1-pRb 
pathway via inhibition of phosphorylation of Rb and the expression of E2F target genes. This 
eventually resulted in proliferation inhibition of neuroblastoma cells in vitro (Rihani et al., 2015). This 
suggests that targeting CDK4/6 may provide a new and alternative therapeutic approach for 
neuroblastoma patients.  
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In contrast to cell cycle entry CDKs, the mitotic kinase CDK1 is essential for the cell division, and 
inhibition of CDK1 arrests cells in G2 phase and prevents entry into mitosis (Santamaría et al., 2007). 
Using genetically engineered mouse models, Santamaria and colleagues also showed that in the 
absence of interphase CDKs, CDK1 can recapitulate the function of other CDKs involved in regulating 
cell cycle transitions, for example CDK1 can bind to cyclin D and E, resulting in the phosphorylation 
of the retinoblastoma protein pRb and the expression of genes that are regulated by E2F 
transcription factors (Santamaría et al., 2007) and hence substitutes the effect of CDK4/6.  
Furthermore, CDK1 binds to its ordinary cyclins (A or B) and phosphorylate more than 70 
substrates in order to promote centrosome separation, chromosome condensation, nuclear 
envelope breakdown and mitotic entry (Malumbres and Barbacid, 2005).  
CDK1 knockout mouse germ line results in arresting embryonic development around the blastocyst 
stage and induced embryonic lethality, demonstrating the importance of CDK1 in early development 
(Diril et al., 2012). Overexpression of CDK1 has been described in many cancers including lymphoma, 
advanced melanoma and lung cancer (Zhao et al., 2009; Abdullah, Wang and Becker, 2011). 
However, CDK1 inhibitor treatment of MYC-dependent mouse hepatoblastoma and lymphoma 
tumours decreased tumour growth and prolonged their survival (Goga et al., 2007). 
1.1.11.2.2. Rationale for therapeutically targeting CDKs in cancer 
The activity of CDK/cyclin complexes activity is known to be  frequently deregulated in variety of 
human cancers  (Lapenna and Giordano, 2009). Some CDKs can be considered oncogenic, for 
example, CDK4 is found overexpressed in many cancers including melanoma (Sheppard and 
McArthur, 2013), lung carcinoma (Puyol et al., 2010), breast cancer (Peyressatre et al., 2015) and 
prostate cancer (Comstock et al., 2009), or amplified in others including osteosarcoma (Wei et al., 
1999), glioblastoma (Schmidt et al., 1994)and pancreatic cancer (Eggers et al., 2011), whereas CDK6 
was found mutated in a wide variety of cancers such as lymphoma (Chilosi et al., 1998), glioma 
(Bellail, Olson and Hao, 2014), medulloblastoma(Mendrzyk et al., 2005) and neuroblastoma (Easton 
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et al., 1998). In addition, CDK1 was found to be mutated in ovary carcinoma (Peyressatre et al., 
2015). Hence, controlling the cell cycle through targeting cyclin-dependant kinases and their 
associative regulators may provide a potential therapeutic approach for cancers. 
Due to the importance of CDK4/6 activity in regulating the cell cycle, targeted therapies aimed at cell 
cycle pathways of CDK4/6 have been conducted. Palbociclib (PD0332991, Pfizer) is an orally 
administered small molecule inhibitor of CDK4/6 (Fry et al., 2004),  and is undergoing active clinical 
trial testing. In the myeloma mouse model, Palbociclib treatment induced tumour suppression with 
significant improvement in survival (Menu et al., 2008). The Food and Drug Administration 
designated Palbociclib a breakthrough therapy in April 2013 (Brower, 2014). Therefore the use of 
highly selective CDK4/6 inhibitor, Palbociclib, is used to treat many patients with breast cancer 
leading to cellular senescence- like activity and  cell cycle arrest at G1 (Flaherty et al., 2012; Hamilton 
and Infante, 2016).  
The use of selective inhibitors for other CDKs was also trialled following the success of Palbociclib 
treatment. CDK1 inhibitor (RO-3306) was tested on mitotic Hela cells as a starting point to test its 
efficacy. In vitro experiments on HeLa cells confirmed again that CDK inhibitors are one of the most 
successful cancer treatments (Vassilev et al., 2006). 
Other small-molecule CDK1 inhibitors decrease tumour growth and prolong survival in mouse 
models of Myc-dependent lymphoma and hepatoblastoma (Goga et al., 2007). CDK1 inhibition 
induced a reduction of MYCN activity, which thereby decreased the transcriptional activation of 
MYCN on the survivin promoter, resulting in apoptosis induction (Chen, Tsai and Tseng, 2013). 
Similarly, targeting CDK1, but not CDK4/6, is selectively lethal to MYC-dependent human breast 
cancer cells (Kang et al., 2014). Hence, because there are currently no compounds directly targeting 
Myc, CDK1 inhibition may be an important therapeutic approach for human malignancies that 
overexpress MYC protein (see section 1.1.3.3.1).   
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CDK1 also phosphorylates ASCL1 in Xenopus at serine-proline (SP) motifs, inhibiting the ability of 
ASCL1 in driving differentiation. The overexpression of CDK1 and MYCN inhibits the wild type ASCL1 
driven-differentiation (Ali et al., 2014; Wylie et al., 2015). This suggests that the use of CDK1 
inhibitor may lead to ASCL1 dephosphorylation induced-differentiation, offer new approach for 
differentiation therapy in neuroblastoma.   
1.1.11.3. Tyrosine phosphatase inhibitors 
ALK, a receptor tyrosine kinase (RTK) oncogene identified in both familial and sporadic 
neuroblastoma (Mukherjee et al., 2004). ALK act through AKT, a common consequence of activation 
of phosphotyrosine signalling. Phosphotyrosine signalling is regulated by two protein families; 
protein tyrosine kinases and protein tyrosine phosphatases (PTPs), with PTPs being key positive and 
negative modulators of this signalling pathway (Badmaev, Prakash and Majeed, 1999; Bishayee et 
al., 2010). PTPs consists of 107 family members, some of them were reported to have implications in 
the biology of tumour cell (Bishayee et al., 2010). Approximately 70% of PTPs are considered as 
tumour suppressors, however, the rest of them are shown to contribute in tumour progression and 
resistance (MacKeigan, Murphy and Blenis, 2005), and may also act oncogenically in neuroblastoma 
(Shang et al., 2010). 
Oxovanadium, pan-inhibitors of PTP enzymes, is found to have an anticancer effect on several 
malignant cell lines and many preclinical in vivo cancer models (Evangelou, 2002; Ray et al., 2006; 
Klein et al., 2008; Kostova, 2009). Inside cells, oxovanadium complexes exist largely in two forms; 
vanadyl V(IV) and vanadate V(V) states, although the latter predominates and being associated with 
PTP inhibition (Ray et al., 2006). Vanadate to vanadyl transformation in cells can be brought about 
by reducing agents such as glutathione (GSH) (Bishayee et al., 2010).  
Bis(maltolato) oxovanadium (IV) (BMOV), is  found to inhibit tumour cell growth and induce 
senescence in Rhabdomyosarcoma cells (Dąbroś et al., 2011) while inducing senescence  or 
differentiation in certain neuroblastoma cell lines (Clark, Daga and Stoker, 2013; Clark et al., 2015). 
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In this research we sought to investigate the effect of effect of BMOV as tyrosine phosphatase 
inhibitor on neuroblastoma tumours. 
1.2. The Drug discovery and model systems 
Drugs discovery programs are both costly and lengthy. Before designing a pharmaceutical 
compound, the potential targets that interact with the compound must be identified and evaluated. 
Following this, the compound has to confirm its reproducibly on their intended targets in vitro and 
later in a preclinical model organism. The compound must considered as effective, safe and has a 
suitable therapeutic window before reaching human subjects in the clinical trials (Hughes et al., 
2011). Increased knowledge of human biology and the process of disease helps expand the number 
of potential therapeutic targets. However, only one in five to ten thousands compound enters 
research development and finally becomes licensed for human use (Azmi and Mohammad, 2014).  
Therefore, it is not surprising that pharmaceutical companies report the cost of developing a 
compound requires a cost of many millions of dollars and takes up to 15 years to complete (Paul et 
al., 2010; Hughes et al., 2011; Mestre-ferrandiz, Sussex and Towse, 2012).   A crucial step in the 
process of validating a new compound is the use of a pharmaceutically relevant preclinical model 
system.  
Animal models are vital to the development of novel anti- cancer agents. Over time, animal models 
have been used in therapeutic research to understand mechanisms, evaluate efficacy, optimise dose 
timing, determine in vivo distribution and characterise the metabolism of the drug. As our 
understanding of many areas of cancer biology and therapeutic approaches has increased, and so 
has those model organisms. Each model organism has some approximattion of reality, but also some 
inherent limitations; limitations might include time-consuming, and cost (Vandamme, 2014). 
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1.2.1. The Mouse Model 
The mouse model is the most common one used in therapeutic research. Several characteristics 
recognise the mouse model as an attractive organism for laboratory investigation, including its small 
size, propensity to breed in captivity, lifespan of 3 years, extensive physiological and molecular 
similarities to humans, as well as entirely sequenced genome (Frese and Tuveson, 2007).  
The mouse genome can be manipulated to produce a genetically engineered mouse model (GEMM). 
This involves delivering a foreign gene to the mouse germline and allowing consistent expression 
(Gordon and Ruddle, 1981). This technique is used to explore many oncogenes and tumour 
suppressor genes and their role in tumorigenesis and treatment (Capecchi, 1989).   
Improvement of several techniques relating to GEMM have led to significant increase in the use of 
GEMM over the past twenty years. For example, the degree of manipulation in terms of timing and 
the location of gene expression is ever evolving. In neuroblastoma the well-characterized TH-MYCN 
GEMM is increasingly used for a variety of molecular-genetic, developmental and pre-clinical 
therapeutics applications (Chesler et al., 2007; Hogarty et al., 2008; Rounbehler et al., 2009). The TH-
MYCN GEMM created in 1997 by Weiss and colleagues overexpresses MYCN and acts as a model for 
high risk neuroblastoma tumours (Chesler and Weiss, 2011).  
TH-MYCN was constructed using a first-generation, “transgenic” approach. This involved introducing 
exogenous DNA to the nucleus of fertilised murine oocyte resulting in random integration of 
transgenic construct into genomic DNA.  The construct incorporates exogenous human cDNA for 
MYCN, ligated downstream of the rat tyrosine hydroxylase (TH) promotor. A rabbit beta globin 
intron element enhancer was used to enhance expression, and a herpes simplex virus thymidine 
kinase gene sequence was used as a transcription terminator (Weiss et al., 1997). The use of rat TH 
promoter targets the expression of MYCN to the neuronal precursors of sympathoadrenal origin, the 
cell-of-origin for the initiation of neuroblastoma. In addition to investigating the specific role of 
MYCN in driving neuroblastoma tumorigenesis, this modelling approach has been used extensively 
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for molecular genetics, developmental biology, imaging technology and gene interaction and 
therapeutics (Chesler and Weiss, 2011). In neuroblastoma, other GEMM have been constructed 
using similar approach including ALKF1174L and ALKF1174L  and these have been crossed with the MYCN 
transgenic mouse model (Berry et al., 2012).  
GEMM models have many strengths, including the spontaneous growth of tumour in an 
immunocompetent host and in appropriate tissue and microenvironment (Chesler and Weiss, 2011). 
Thus, they give a better representation of the tumour reality in human patients and provide 
meaningful therapeutic research which can translate effectively in a clinical setting. Conversely, 
GEMM models have many criticisms that limit its significance.  It is difficult to reproduce the 
heterogeneity of gene mutations and expression seen throughout primary tumours in this model 
(Ruggeri, Camp and Miknyoczki, 2014). Another problem is that they often fail to recapitulate the 
metastatic patterns observed in patients (Teitz et al., 2013). The neuroblastoma cells are also mouse 
cells and not human cells.  This presents a significant limitation and the extent to which therapeutic 
effect can be modelled successfully using this model. Several other practical issues including cost, 
patents, long latencies to tumour development, low tumour penetrance as well as the difficulty in 
monitoring tumour development and therapeutic response limit the use of this model, especially in 
routine preclinical drug screening (Chesler and Weiss, 2011).     
Transplantation mouse models are another commonly cancer research tool. Various systems and 
techniques have been used to propagate tumour tissues in different hosts. Allograft mouse model is 
one of these model systems that involves transplanting of tumour tissues derives from the same 
host species (Yang et al., 2017). Similar to GEMM, these tumours and tissues is not humans and thus 
limit the value of the results obtained using this model system.  
Xenograft model is another transplant model system that involves transplantation of human tumour 
tissue into a mouse that must be immunodeficient to avoid host immune rejection (Vandamme, 
2014). Xenografting can be subcutaneous where cells injected under the host skin or orthotopic 
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whereby the tissue transplanted in the region form which it would have originated or intravenous. A 
subcutaneous mouse model allows monitoring the growth of the tumour without the need for 
sophisticated imaging techniques (Kumar et al., 2012). However, orthotopic model recapitulates the 
nature of tumour better in terms of cell-cell interactions of the local microenvironment in which the 
tumour grows, invade and metastasise (Ruggeri, Camp and Miknyoczki, 2014). The technique by 
which orthotopic models produced requires a highly and precise skills, time consuming and do not 
allow to direct visualisation of the tumour. Some non- invasive techniques have been developed to 
overcome the visualisation problem but still it adds more complexity and cost to the model 
(Albanese et al., 2013).  
The mouse models discussed have both strengths and limitations to their use in therapeutic 
research. One common limitation of all these models is the growing complexity and cost associated 
with their use. In the context of rapidly increasing potential targets new models are required which 
can help to screen which drugs should be used in these more complex and expensive systems.   
1.2.2. The Chick Embryo Model 
As discussed earlier, drug screening programs demand the use of huge number of animals mostly 
rodents; however,  these models are expensive, time-consuming, sometimes difficult to handle, and 
there are important ethical and legal issues (Vargas et al., 2007). There is a need for a preclinical 
model that is relatively cheap, cost-effective, easy to handle and ideally do not required a Home 
Office licence. The chick embryo model represents an alternative model to rodents for some types of 
experiments and  also has advantages over the other preclinical models (Ribatti, 2010, 2014; Rovithi 
et al., 2017).  
The chick embryo is a well-known model system with a long and fascinating history since Aristotle, 
who monitored the progression of chick embryo development by opening the egg shell daily (Stern, 
2005). Chick embryos have been instrumental not only to the field of developmental biology, but 
have also made significant contributions to research in cancer biology, virology, immunology and cell 
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biology (Kristin H. Kain et al., 2014). An example of several Nobel Prize winning discoveries made 
using the chick embryo model is that by Rita Levi-Montalcini who discovered Nerve growth factor 
(Kristin H Kain et al., 2014).  
As embryology advanced, more histological studies were carried out using the chick embryo. For 
example, in 1889, a first comprehensive morphological atlas of chick development was produced by 
Mathias Duval. Mathias’s works provided the foundations for Viktor Hamburger and Howard 
Hamilton's to published their 46  morphologically distinct stages of chick development, which is still 
widely in use (Hamburger and Hamilton, 1992).  The development time of the embryo is 21 days as 
illustrated by the Hamburger and Hamilton stages (Figure1.10) (Kristin H. Kain et al., 2014) . All the 
above mentioned work  on chick embryo has been further built upon making the chick embryo a 
well characterised model with a fully sequenced genome  (Vergara and Canto-Soler, 2012).  
 
Figure1.10 The stages of chick development. Image displaying the 46 Hamburger and Hamilton (HH) 
stages of chick development, and how they relate to the length of incubation (E). Adapted from 
(Kristin H. Kain et al., 2014) 
 
The chick embryo has an advantage over other (non-mammalian) preclinical models, due to the 
similarities of the chick to the human embryo at the anatomical, cellular and molecular levels.  They 
may be less similar than the mouse but much more so than drosophila or zebrafish. The accessibility 
of the developing embryo for visualization and experimental purposes is other key advantage of this 
model (Vergara and Canto-Soler, 2012; Kristin H. Kain et al., 2014). Like other vertebrates, chick 
embryos possess an immune system that contains both T-cells and B-cells. Its immune system begins 
to develop around E9 but then it requires until E18 to be fully developed (Vargas et al., 2007). This 
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gives the chick embryo model extra advantage of being immunodeficient when performing 
experimental work before E14.  
There are also many economical and practical advantages of the model which should be mentioned. 
Fertilised eggs are available almost anywhere in the world and they can be purchased in specific 
quantities and may be stored easily for several days prior to incubation. This, allows researchers to 
conveniently obtain embryos at the specific developmental stage that serve their research needs. 
Current UK legislation on protection of animals for scientific purposes allows experimentation on 
chick embryos without authorization up to the age of development day 14 (E14) (Vergara and Canto-
Soler, 2012). This makes the model extremely feasible to use and conduct experimental work up to 
E14.  
Furthermore, ethical considerations such as the 3Rs principle (reduce, refine and replace animal 
experiments) are also important to consider. This principle highlights the need to consider using 
none protected animal species when conducting research wherever possible. Humane protocols 
have been optimised to eliminate the distress on the chick up to E14 when performing experiments. 
Chick embryo model can serve as a replacement for other higher preclinical models however 
experiments that require a long time period cannot be conducted on the model, thus, the chick 
embryo could partially replace some model systems (Bjornstad et al., 2015). Altogether, the chick 
embryo provides an alternative potential model that can be used in increasing our understanding of 
tumour biology and testing new therapeutic agents. 
1.2.2.1.The Chorioallantoic membrane 
The most common use of the chick embryo model in cancer biology involves growing xenograft 
tumours on the CAM. Three extra-embryonic membranes protect and nourish the chick embryo until 
the hatching (Figure1.11). The chorioallantoic membrane (CAM) is one of them and serves multiple 
functions. The CAM serves as the respiratory organ for the embryo, has a role in calcium transport 
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from the eggshell, and is involved in acid-base homeostasis in the embryo and in ion and water 
reabsorption from the allantois sac.   
The CAM is formed by the fusion between of the allantois and the chorion membrane around days 
five to six of incubation. It develops progressively adhering to the inner side the eggshell and 
surrounds the embryo by day 11 (Ribatti et al., 2001; Gabrielli and Accili, 2010). The CAM is 
transparent and highly vascularised tissue composed of arteries and veins and with intricate capillary 
plexi (Figure1.12) (Vargas et al., 2007). 
Histologically, the CAM contains three major layers, from outside to inside they are; the ectodermal 
chorionic epithelium attached to the shell membrane ; an intermediate mesoderm enriched in blood 
vessels and stromal components; and the endodermal allantoic epithelium facing the allantoic cavity 
(Ribatti et al., 2001; Gabrielli and Accili, 2010).  
The CAM is a very thin structure ~100μm across the entire three layers. Haematoxylin–eosin staining 
of paraffin sections clearly identifies the ectoderm, represented by 1-2 cells epithelial layer; the 
capillary plexus visualized as tiny circular openings in the ectoderm frequently filled with 
erythrocytes; the mesoderm filled with the stromal cells, collagen fibres and blood vessels of 
different diameters, including terminal capillaries localized right under the ectoderm; and the one 
cell-layer of flat endoderm (Figure1.13). 
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Figure1.11 Diagram of the chick embryo highlighting the extraembryonic membranes. The chorion 
and allantosis (labelled in grey) fuse to form the chorioallantoic membrane at day 5-6 of embryonic 
development. Adapted from http://abacus.bates.edu/acad/depts/biobook/Verteb2.htm . 
   
 
  
 
 
 
 
 
Figure1.13 A section through the CAM 
demonstrating the three tissue layers 
(B-D). A: shell membrane. B:chorionic 
epithelium. C: mesoderm layer. D 
allantoic epithelium E: allantoic cavity. 
Adapted from (Gabrielli and Accili, 
2010). 
Figure1.12 The chick chorioallantoic 
membrane (CAM) - this image, taken 8 days 
after incubation (E8) demonstrates the 
highly vascular CAM by Grace Mather. 
54 
 
Given the highly vascular nature of the CAM, the CAM has been used widely for angiogenesis and 
wound healing studies however it has also been used in cancer research for decades (Vogel and 
Berry, 1975). Since the young embryos are not fully immunocompetent, they then provide a perfect 
host platform for cancer cell and biopsies. In 1982 Armstrong et al reported the ability of several 
different types of tumour cells to invade the CAM’s epithelial layer and form tumour beneath it. The 
authors illustrated that following light trauma to the CAM surface, tumour cells readily invaded the 
superficial epithelial layer to form the tumour nodule (Armstrong, Quigley and Sidebottom, 1982). 
Tumours grown on the CAM, were shown to express the typical features of a tumour in terms of 
complexity, angiogenesis and metastasis (Zijlstra et al., 2002; Bobek et al., 2004; Fergelot et al., 
2013; Kristin H Kain et al., 2014).  
Indeed, CAM model as a biological platform with all the advantages mentioned above provides an 
opportunity for transplanting human tumours (Bader, Kang and Vogt, 2006),  tumour xenografting 
(Klingenberg et al., 2014; Swadi et al., 2018), tumour-induced angiogenesis (Nowak-Sliwinska et al., 
2012; Nowak-Sliwinska, Segura and Iruela-Arispe, 2014), and cancer metastasis (Deryugina and 
Quigley, 2008; Kristin H. Kain et al., 2014; Herrmann et al., 2015). Here we aim to develop the CAM 
model as a high through-put, economically viable yet highly informative model system in the context 
of neuroblastoma drug discovery. 
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1.3. Hypothesis and Aims   
Differentiation is a key prognostic factor in neuroblastoma as the most differentiated pattern leads 
to favourable outcomes for patients. Neuroblastoma is thought to result from aberrations that occur 
during development leading to cells that have arrested in an undifferentiated form.  The ability of 
cells in the 4S tumour to spontaneously regress to a more differentiated form, GN, supports this 
hypothesis (Park et al., 2013). Thus therapies that promote differentiation are a particularly useful 
approach.  Here we hypothesise that reducing or blocking cell division will promote differentiation 
leading to tumour regression. 
To test our hypothesis we aimed to address the following points: 
1) Optimise drug delivery to the CAM tumours in the chick embryo using the well-characterised 
small molecule RA 
2) Characterise the effect of potential therapeutic molecules using in vitro assays. 
3) Study the effect of these molecules in vivo using the CAM model and identify whether they 
are promising and should be prioritised for further investigation. 
4) Determine the efficacy of these molecules in inhibiting neuroblastoma metastasis.  
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2.1. Introduction  
This chapter will introduce neuroblastoma cell lines and the techniques that been used to assess the 
efficacy of different drugs/ treatments on them. In addition, chick embryo work will also be 
presented later to illustrate the effect of those drugs/ treatments in vivo.  
2.1.1. Cell lines   
Several Neuroblastoma cell lines were established from samples of primary or metastatic tumours 
which are obtained from patients during bone marrow aspiration, surgical resection and occasionally 
from peripheral blood. Four cell lines were used in this research; each has different features that can 
be seen in Table 2.1. These cell lines were chosen as they are characteristic of two types of clinically 
high risk neuroblastoma tumours: MYCN amplified and chromosome 11q deleted. Wild type cells 
and cells transduced with green fluorescent protein (GFP) were used. 
Table2.1 Information on the origins and characteristics of the cell lines used in this project. 
Cell line Source Characteristics  
BE2C BE(2)-C is a sub-clone of SK-N-BE(2), a 
neuroblastoma cell line that was 
established from a bone marrow biopsy 
taken from a 2 year old child with 
disseminated neuroblastoma after 
repeated courses of chemotherapy and 
radiotherapy. 
 
MYCN amplified  
Chromosome 1p deletion  
Chromosome 17 translocation. 
  
IMR32 Isolated from an abdominal NB in a 13-
month-old child. 
 
MYCN amplified  
1p deletion 
KELLY Isolated from a metastatic brain lesion in 
a 13-month-old child. 
 
MYCN amplified  
ALK F1174L mutation  
SKNAS Metastatic site: bone marrow biopsy of a 
6 year old child. 
Single copy MYCN 
Chromosome 1p deletion 
Chromosome 11q deletion 
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2.1.1.1 Culturing Neuroblastoma cell lines 
Cell lines were generally cultured as monolayers in 25cm2 or 75cm2 culture flasks (Corning, UK), in 
their appropriate media (see Table2.2). Flasks were kept in a humidified incubator at 37°C, 5%CO2. In 
order to persistently supply the NB cells with the nutrients that they needed, 5ml of medium were 
regularly removed and replaced with 5mL of fresh medium. 
When cells were approaching 90% confluency, calcium- and magnesium-free Hanks Balanced Salt 
Solution (HBSS) (H9394, Sigma-Aldrich, UK) was used to wash the culture surface, followed by 
treatment with 1ml 0.05% trypsin EDTA 1x Solution (Gibco) per 75cm2 flask. Following 5 minutes 
incubation at 37°C, 9ml culture medium was added to the dislodged cells and pipetted in and out to 
disrupt cell clumps. The resulting cell suspension was then split into two to four 75cm² flasks and a 
further 10ml of fresh medium added to each flask. 
A haemocytometer was used to count cell after producing a single-cell suspension using 1ml pipette. 
The average number of cells was calculated from 4 counts, to give (average) x 104 cells/ml. Cells 
were then seeded at an appropriate density according to each experiment requirements. Cells were 
routinely tested for mycoplasma to ensure they remained free of contamination. GFP-labelled cells 
and wild type cells were cultured in the same medium using the same methods. 
For Hypoxia studies, cells were maintained at 37°C with 5%CO2 and 1%O2 (Don Whitley Scientific, 
Shipley, UK; Hypoxystation-H35) for 72hr,  or  cells were treated with a hypoxia mimic 
(Dimethyloxalylglycin DMOG) (Enzo Laboratories, Farmingdale, NY, USA)  at 0.5mM and incubated at 
37°C with  5%CO2 for 24hr. 
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Table2.2 Neuroblastoma cell lines and their culturing requirements. 
Cell line Culture media 
BE2C FCS - 10% , Pen Strep - 1%, and NEAA - 1% in DMEM  
 
IMR32 FCS - 10% ,Pen Strep - 1% and NEAA - 1% in RPMI  
 
KELLY FCS - 10%, Pen Strep - 1% in RPMI  
 
SKNAS FCS - 10% , Pen Strep - 1% and NEAA - 1% in DMEM 
 
2.1.1.2. Thawing of Neuroblastoma cells 
Cells were stored in 2ml cryovials (Starlab, UK) in liquid N2 tank. When needed, vials were removed 
from the storage and placed in the cabinet hood briefly to just thaw (but not warmed to room 
temperature). Upon thawing, cell suspension (1ml) was removed from the vial and placed into 20ml 
sterile universal bottle (Starlab, UK), and 1ml of the appropriate media added drop-wise with gentle 
mixing. A further 18ml medium was added over 30-60 seconds, following which the diluted cell 
suspension was spun using a GLC-4 General Laboratory Centrifuge (Sorvall Instruments) at 1000rpm 
for 10 minutes. After centrifugation the supernatant was discarded and the cell pellet resuspended 
in 7ml fresh media. Cells were seeded in 25cm2 flasks and transferred into 75cm2 flasks once 80-90% 
confluency was reached. 
2.1.1.3. Freezing of Neuroblastoma cells  
Following trypsinisation (see cell line culture), cells were diluted in 10ml of fresh media and 
centrifuged at 1000rpm for 5-10 minutes, the supernatant was removed and the cell pellet was 
resuspended on ice in “freezing medium” ( 10% dimethylsulfoxide DMSO in Foetal Bovine Serum 
FBS). Aliquots of 1ml were placed in cryogenic vial (Starlab, UK) and 2-3 vials per 90-100% confluent 
75cm2 flask of cells were produced. Vials were kept overnight in gas phase over liquid N2 to lower 
60 
 
the temperature slowly and limit cell damage. Next day, vials transferred to the liquid N2 tank for 
long-term storage. 
2.2. Therapeutic compounds 
2.2.1. All-trans retinoic acid  
All-Trans retinoic acid (RA) (Sigma-Aldrich) was dissolved in DMSO to make a 0.16M stock solution, 
which was stored at -80°C light protected. 
2.2.2. Bis(maltolato)oxovanadium(IV)  
Bis(maltolato)oxovanadium(IV) or BMOV (Sigma-Aldrich) was dissolved in DMSO to make 10mM 
aliquot and stored at -200C. 
2.2.3. Palbociclib (PD-0332991) HCI 
Palbociclib (Selleckchem, US) was reconstituted in Dulbecco‘s Phosphate Buffered Saline DPBS (Life 
Technologies) to obtain 10mM stock solution and then stored at -800C according to the 
manufacturer's instructions. 
2.2.4. RO-3306 (SML0569) 
RO-3306 (Sigma-Aldrich) was reconstituted in DMSO to obtain either 10mM or 14mM stock solution 
and stored at -800C according to the manufacturer's instructions. 
2.3. Functional assays 
2.3.1. Cell proliferation and morphological changes detection 
2.3.1.1 Seeding the cells and treatments  
Neuroblastoma cells were grown on 13mm glass cover slips (Appleton Woods Ltd, UK) in 24 well 
plates (Corning, UK). Cells were seeded at 2.5x 104 and 5x 104 cells/ml density for BE2C and IMR-32 
respectively and incubated with their appropriate cell culture medium (500μl per well) for 18-24hr 
to adhere and settle prior to treatment.  
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RA treatment 
A final 10μM concentration of RA was obtained by diluting the stock solution with the appropriate 
cell culture medium (see Table2.2).  
BMOV treatment 
Cells were cultured in 10μM BMOV alone and in combination with RA (10μM) in an appropriate cell 
culture medium (see Table2.2). 
Palbociclib treatment 
A final 7.5 or 5μM concentration of Palbociclib alone and in combination with RA were obtained 
using the appropriate cell medium (see Table 2.2). 
Following the treatments, cells were observed and imaged for morphology changes using Leica 
DMIRB microscope linked to a camera (Leica DFC420C) prior to staining with proliferation marker, 
Ki67.  
2.3.1.2. Fixing, quenching and permeabilisation of cells 
Cells grown on coverslips (section 2.3.1.1) were removed from the well containing medium using 
bent syringe needle and put in a staining plate; cells were fixed using 100μL of 4% paraformaldehyde 
(PFA) for 10 minutes and then washed with DPBS (+Ca2+/Mg2+). Subsequent to paraformaldeyde 
removal, fixation was quenched with 50μl of 0.1M glycine pH7.4 for 15 minutes at room 
temperature. Cells were permeabilised with 100μL of blocking buffer (1% BSA, 0.1%Triton X100, 
0.12M phosphate PH 7.4) for one hour at room temperature to allow blockage of non-specific 
binding sites for antibodies.  
2.3.1.3. Antibody labelling and counterstaining 
Following the removal of the blocking buffer the primary antibody, Rabbit anti Ki67 (Abcam, 
Ab15580), was diluted in the blocking solution at 1:50, added and left at 4°C overnight. A control 
62 
 
coverslip was prepared by omitting the primary antibody. Ki67 was then removed and cells were 
washed 3X with DPBS (+Ca2+/Mg2+). Secondary antibody, Alexa 594 Goat anti Rabbit IgG (Thermo 
Fisher Scientific, A-11037) at concentration 1:500 diluted in 1% BSA, 0.1% Triton X100 in 0.12M 
phosphate pH7.4, plus 0.1μg/ml of 4',6-diamidino-2-phenylindole DAPI (Thermo Fisher 
Scientific,D3571) were added and incubated, protected from light, for one hour at room 
temperature. Secondary antibody were removed in dip wash in DPBS 2X and in dH2O once and left 
to dry for 10min. A drop of Dako fluorescent mountant medium was applied to each sample before 
the addition of a cover slip to each slide. Slides were again stored at 4°C and protected from light 
until analysis. 
2.3.1.4. Cell proliferation quantification 
Cell proliferation was quantified manually under a Leica fluorescent microscope using a x40 oil 
immersion objective. The number of Ki67 positive cells (red) in each field were counted and 
expressed as percentage of the total number of DAPI stained cells (blue) in the same field. For each 
coverslip a minimum of four fields were examined and 100-200 cells were counted in each field. To 
eliminate bias, counting was performed blind; this was achieved by covering the identity of the cover 
slip and assigning cardinal numbers to each slide and checking the identity of the cover slip only 
after counting. Each experiment was conducted independently 3 times. 
2.3.2. Cell viability detection 
2.3.2.1. Determination of cell number to be used 
SKNAS and BE2C cells were set at ten 2-fold dilutions in triplicates in a 96 well plate (corning, UK), 
from 5 x 106 cells/ml to 4.88 x 103 cells/ml. The procedure was carried out as described in table2.3.  
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Table2.3 Ten 2-fold dilutions procedure used to optimise the cell number for MTT assay.  
Label Tubes 
(cells/mL) 
Add Cell Culture 
Medium 
Add Cells 
5.00 x 106 _ 400 µl of 5.00 x 106 cells/ml stock 
2.50 x 106 400µl 400 µl of 5.00 x 106 cells/ml stock 
1.25 x 106 400µl 400 µl of 2.50 x 106 cells/ml stock 
6.25 x 105 400µl 400 µl of 1.25 x 106 cells/ml stock 
3.13 x 105 400µl 400 µl of 6.25 x 105 cells/ml stock 
1.56 x 105 400µl 400 µl of 3.13 x 105 cells/ml stock 
7.81 x 104 400µl 400 µl of 1.56 x 105 cells/ml stock 
3.91 x 104 400µl 400 µl of 7.81 x 104 cells/ml stock 
1.95 x 104 400µl 400 µl of 3.91 x 104cells/ml stock 
9.77 x 103 400µl 400 µl of 1.95 x 104 cells/ml stock 
4.88 x 103 400µl 400 µl of 9.77 x 103 cells/ml stock 
Medium (Control) 400µl _ 
 
Cells were plated at 100 µl /well including 3 control wells of cell culture medium alone. Cells then 
incubated at 37°C with 5% CO2 for 12 - 18hr. 10μl of aqueous MTT solution (5mg/ml) was added to 
each well, the plate was shaken gently with a shaker for 1 minute. The plate was wrapped in foil to 
prevent light exposure and incubated for 4hr at 37°C. 100μl stop solution (5% sodium dodecyl 
sulphate SDS 0.01 M HCl) was added to each well, without mixing, and incubated at 37°C overnight. 
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Absorbance was detected at 570nm using Spectrophotometer (FLUOstar Omega microplate reader) 
(Molecular Devices, UK). Average values from triplicate readings were adjusted by subtracting the 
‘blank’ average value reading (MTT dye and media only) to determine the optical density OD of 
viable cells. Absorbance plotted on the y-axis versus cell number per ml on the x-axis providing a 
curve that has a linear portion. Selection of a cell number that falls within the linear portion of the 
curve (i.e. providing values between the range of 0.75 and 1.25) allows for the measurement of both 
stimulation and inhibition of cell proliferation.  
2.3.2.2. Determination of cell viability following CDK4/6i and CDK1i 
Following optimisation the cell density (section 2.3.2.1), BE2C and SKNAS cells were seeded  in 
triplicate at 7.81 x 104cells/ml density in 96 well plates (Corning, UK) and left to settle and adhere for 
12-18 hrs in presence of three blank wells for each cell line ( culture medium only).  
Palbociclib and RO-3306 treatment 
After cells adhered, culture medium was removed and replaced with medium containing 1μM, 5μM, 
10μM and 20μM of Palbociclib and RO-3306. Controls were cultured with medium supplemented 
with DPBS or DMSO at the same concentration of Palbociclib and RO-3306 respectively in each cell 
line. Cells were treated for a total of 3 days prior to analysis with MTT assay. 
DMOG treatment 
In some, after cells adhered; cells were treated with further 24hr with DMOG (Enzo Laboratories, 
Farmingdale, NY, USA) at 0.5mM and incubated at 37°C with 5%CO2. In parallel, controls were 
cultured with medium containing DMSO at the same concentration for each cell line. Following 
DMOG treatment, cells were treated with 5μM Palbociclib and RO-3306 for 3 days prior to analysis 
with MTT assay. 
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Analysis of cell viability  
MTT assay was used to measure cell viability following treatments as described previously (section 
2.3.2.1).  The average of absorbance values were adjusted by subtracting the ‘blank’ reading (MTT 
and media only). Absorbance values from treated wells were compared with control wells (i.e. cells 
treated with DMSO/DPBS) to determine the effect of the treatment on the number of viable cells. 
Each experiment was performed in triplicates and repeated 3 times. 
2.3.3. Determination of Apoptosis in cultured cells in response to Palbociclib 
and RO-3306 
 BE2C and SKNAS cells were grown on 13mm glass coverslips (Appleton Woods Ltd, UK) in 24 well 
plates (Corning, UK) at density of 2.5x 104 cells/ml and incubated with their appropriate cell culture 
medium (500μl per well) for 18-24hr to adhere and settle prior to treatment. After cells adhered, 
culture medium was removed and replaced with 5μM of Palbociclib and RO-3306 containing 
medium and incubated for further 3 days. Controls were cultured with medium supplemented with 
DPBS or DMSO at the same concentration of Palbociclib and RO-3306 respectively in each cell line. 
Apoptosising cells were identified using Apoptotic/Necrotic/Healthy Cells Detection Kit from 
Promokine (PK-CA707-30018) according to the kit instructions. Cells grown on coverslips were 
removed from wells using bent syringe needle and put in a staining plate; cells washed twice with 1X 
Binding Buffer and then incubated, without prefixation, with a staining solution (5μl of FITC-Annexin 
V, 5μl of Ethidium Homodimer III and 5μl of Hoechst 33342 in 100μl 1X Binding Buffer, 1:20 dilution) 
for 15 minutes at room temperature, protected from light. Coverslips were then washed a further 2 
times with 1X Binding Buffer and mounted on a glass slide with Dako fluorescence mountant. Images 
were taken within 24hr using Leica LEITZ DMRB florescent microscope together with camera Leica 
DFC450C. 
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2.4. Quantitative PCR (qPCR)  
The Polymerase Chain Reaction (PCR) allows amplification of small amounts of DNA. SYBR green is a 
fluorescent dye which specifically binds to double-stranded DNA and fluoresces only when bound to 
dsDNA. This property can be used to assess the relative changes in gene expression of samples 
compered to control. During the exponential phase of the reaction, fluorescence is directly 
proportional to amplification, thus allowing measurement of copy number. The cycle at which 
fluorescence exceeds the pre-determined threshold value is termed the cycle of quantification (Ct) 
value. 
2.4.1. RNA extraction 
RNA extraction was completed using the RNeasy Mini Kit (Cat no. 74104, QIAGEN). All reagents were 
stored in a dedicated RNase-free area in the lab,  all surfaces and pipettes were decontaminated 
using RNAzap cleaning agent (R2020, Sigma-Aldrich), and samples kept on ice throughout to prevent 
degradation. Cells were first trypisinised and pelleted as for at 1000rpm for 10 minutes. The 
supernatant was then removed and the pellet disrupted by gentle tapping of the tube. RNA was 
extracted using spin-column based isolation and utilised 3 buffers: RLT, RW1 and RPE. To inactivate 
RNases, 1%ß-Mercaptoethanol was added to buffer RLT. 350μL of the buffer RLT was then added to 
lyse the cells. The cells were repeatedly drawn up and down using a 19G needle and 1ml syringe to 
simultaneously disrupt and homogenise the cells. A 1x volume of 70% ethanol was subsequently 
added to the lysate and mixed by pipetting, the resulting solution transferred to an RNeasy Spin 
Column and centrifuged at 800 x g for 15 seconds. The flow through was then discarded and 700μL 
of buffer RW1 was added to the column and centrifuged at 800 x g for 15 seconds. The flow through 
was again discarded and 500μl of buffer RPE was added and spun as before. The RNeasy Spin 
Column was transferred to a fresh collection tube and 40μl of RNAase free water was applied to the 
column membrane before spinning for 1 minute at 8000 x g. RNA concentration (ng/μl) and quality 
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(A260/280) were recorded using a NanoDrop spectrophotometer (Thermo Scientific, USA) and RNA 
was stored in aliquots at -80°C. 
2.4.2 cDNA synthesis 
cDNA synthesis was completed using a GoScript reverse transcription system (A5000, Promega, UK) 
according to the manufacturers protocol. A total of 1μg of RNA was used per reaction. Volume and 
reagents indicated in the table below (Table2.4). For the no reverse transcriptase controls nuclease-
free water was added instead of reverse transcriptase. 1μg of RNA were mixed, on ice, with Oligo dT 
primers to give a volume of 5μl, and heated (block heat) at 70°C for 5 minutes then chilled on ice 
prior to the addition of the other reagents. After combining the reagents, the reaction mix was 
placed in a thermocycler to anneal for 5 minutes at 25°C, extend for 60 minutes at 42°C and the 
reverse transcriptase was inactivated at 70°C for 15 minutes. The resulting cDNA was aliquoted and 
stored at -20°C. 
Table2.4 Reagents and corresponding volumes used during reverse transcription according to the 
manufacturer’s protocol. MgCl2 (Magnesium Chloride), OligodT primers and RNAsin Ribonuclease 
Inhibitor were optimised. 
cDNA reaction mix reagents  Volume per reaction  
RNA + Oligo dT primers  5μl  
GoScript Reaction Buffer  4μl  
MgCl2  2μl  
PCR Nucleotide Mix (NdTP)  1μl  
Reverse Transcriptase  1μl  
RNAsin Ribonuclease Inhibitor  0.5μl  
Nuclease Free Water  6.5μl  
Final reaction mix 20μl 
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2.4.3. Reference gene selection 
Reference genes were selected to allow normalised relative quantification of genes of interest to be 
calculated.  According to a literature search on reference genes in neuroblastoma 
cells,(Vandesompele et al., 2002), three genes, glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), hypoxanthine phosphoribosyltransferase 1 (HPRT1) and ubiquitin C (UBC) were reported 
to be stably expressed in neuroblastoma cell lines and therefore were selected by Grace Mather 
from our lab as a reference genes to assess the effect some drugs on neuroblastoma cells (Grace 
Mather, University of Liverpool ). 
2.4.4. Target gene selection 
The effect of retinoic acid on gene expression in several cell lines in culture has been described (Sung 
et al., 2013). We selected the three genes having the largest fold increase/decrease (at least one in 
each direction)from this paper; Kruppel-like factor 4 (KLF4), roundabout, axon guidance receptor, 
homolog 2 (ROBO2), stathmin-like 4 (STMN4). MYCN is also included due to its significance in 
neuroblastoma differentiation. 
2.4.5. Primers 
Primer sequences were identified in published papers using the same target or reference genes in 
qPCR experiments (Vandesompele et al., 2002; Sung et al., 2013). Primer sequences were ordered 
from Sigma-Aldrich.Once the primers were received they were reconstituted in nuclease-free water 
(ThermoFisher Scientific, UK) and stored at -20°C in small 10mM aliquots to avoid freeze-thawing 
process. Table2.5 below details all primer pairs used. 
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Table2.5 List of the primers used in qPCR experiments.  
 
 
 
 
 
 
 
 
 
2.4.5.1 Primer Efficiency  
Primer efficiency for GAPDH, HPRT1, UBC, KLF4, MYCN, ROBO2 and STMN4 had been previously 
determined (Grace Mather, University of Liverpool).  
2.4.6. qPCR Protocol design 
Protocols were designed according to the recommendations of the ITaq SYBER green mastermix 
manufacturer (BioRad) specifically for the CFX Connect system. Each reaction comprised of 7.5μl of 
ITaq Universal SYBR® Green (1x) (172-5121, BioRad), 0.75μl of the forward primer (500nM final 
concentration), 0.75μl of the reverse primer (500nM final concentration), 2μl of the diluted cDNA, 
and the volume was adjusted to 15μl with nuclease free PCR grade water. The samples were 
vortexed to mix the cDNA with the SYBR green and were plated into hard shell white-coated 96 well 
plates (HSP-9645, BioRad). The cycling programme used is shown in Table2.6. All samples were run 
as triplicates for each gene per reaction plate. Target experimental values were normalized to 3 
housekeeping genes using the relative quantification method with 3 independent biological samples 
per condition. 
Gene  Forward 5’-3’ Reverse 5’-3’ 
GAPDH AATCCCATCACCATCTTCCA TGGACTCCACGACGTACTCA 
HPRT1 TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT 
UBC ATTTGGGTCGCGGTTCTTG TGCCTTGACATTCTCGATGGT 
KLF4 CGCCGCTCCATTACCAAGAGC CGGTCGCATTTTTGGCACTG 
MYCN CACAAGGCCCTCAGTACCT ACCACGTCGATTTCTTCCTCT 
ROBO2 GATGTGGTGAAGCAACCAGC TGGCAGCACATCTCCACG 
STMN4 CCTAGCAGAGAAACGGGAACA GGCGTGCTTGTCCTTCTCTT 
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Table2.6.  qPCR cycling conditions 
Step  Details  
1  Polymerase activation and DNA denaturation  95°C (30 seconds) 
2  Amplification (Denaturation)  95°C (5 seconds)  
3  Amplification (Annealing/Extension + plate read)  60°C (30 seconds)  
4  Amplification (Cycles)  40  
5  Melt curve  65 C to 95 C (0.5 C 
increment)  
5 seconds/step  
 
2.4.6.1. Controls 
For all experiments a no template control (NTC) was included to monitor genomic DNA 
contamination and primer-dimer formation. A no reverse transcriptase control (NRT) was also 
included whenever a new preparation of RNA was used, to monitor genomic DNA contamination 
(see Figure2.1). 
 
Figure2.1 Example plate layout for controls. NTC, no template control, NRT, no reverse 
transcriptase. 
2.4.6.2. Plate design 
Reaction supermixes were prepared in triplicates and 15μl of reaction supermix was carefully 
pipetted into a single well of a 96-well hard-shell PCR plate (HSS9641, BioRad, UK). The plate was 
covered by a clear seal (MSB1001, BioRad, UK) and centrifuged briefly in a microplate centrifuge. An 
example plate design can be seen in Figure2.2. The plate was transferred to a CFX connect 
GAPDH NTC NTC NRT NRT RA RA NTC NTC NRT NRT DMSO DMSO
UBC
HPRT1
KLF4
MYCN
ROBO2
STMN4
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RG1 NTC NTC NTC cDNA cDNA cDNA cDNA cDNA cDNA cDNA cDNA cDNA
RG2
RG3
TG1
TG2
TG3
TG4
TG5
T1 T2 T3
thermocycler (BioRad, UK), which was used for all experiments. The thermocycler employed precise 
temperature control and rapid temperature changes for optimal cDNA amplification. Figure 2.3 
outlines the cycling control for PCR amplification. 
Figure2.2 Example plate layout for qPCR. T, treatment, RG, reference gene; TG, target gene; NTC, no 
template control. 
 
 
 
 
 
 
 
 
Figure2.3 Outlines the cycling control for PCR amplification.  
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2.4.7. Analysis of qPCR data 
Data was viewed using Bio-Rad CFX Manager 3.1 software. An initial inspection of both the 
amplification plot and melt curve ensured that there were no obvious anomalous results. Fold 
change in target gene expression was calculated relative to the control. Results were normalised to 
the three reference genes (GAPDH, HPRT1 and UBC). 
The mean Ct value for 3 technical replicates from a single biological replicate was calculated, 
followed by the mean Ct value for 3 independent biological replicates. A commonly used method of 
calculating relative gene expression using qPCR data is the 2-ΔΔCt method (Schmittgen and Livak, 
2008). To conduct statistical analysis NRQ data of 3 independent biological replicates were 
compared to control to standardise the fold change.  
∆ Ct = Ct (TG) – Ct (RG) 
∆ ∆ Ct = ∆ Ct Treatment - ∆ Ct control 
Fold change due to treatment = 2-∆ ∆Ct 
 Ct, threshold cycle; TG, target gene; RG, reference gene. 
2.5. Chick embryo work 
Chick embryo experiments were carefully carried out according to the current UK Home Office 
legislation, 2013.  All the steps are illustrated in Figure2.4. 
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The Procedure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure2.4 Visual display of the steps in chick embryo experiment. E0: fertilised white leghorn eggs 
were incubated in Multihatch Mark II. E3: albumen removal with subsequent "windowing" of the 
shell with power tool, and resealing window with adhesive tape. E7: the CAM was lightly traumatised 
using sterile lens tissue improves tumour formation followed by topical implantation of BE2C cells 
onto surface of CAM. E10- E13 was injection of drug solution into allantois. E14: Visualisation and 
dissection of any resultant tumours occurred. 
Day 0 
Day 3 
Day 7 
Day 11 and 
13 or Day 10 
and 12 
Day 14 
74 
 
2.5.1. Egg preparation  
Fertilised white leghorn chicken eggs were obtained from Lees Lane Poultry, Wirral, or Tom Barron, 
Preston, UK. The eggs were placed into and egg incubator (Multihatch Mark II, Brinsea, UK) and 
maintained at approximately 38°C and 35% relative humidity. In order to ensure easy access to the 
embryo at later stages in development, eggs were laid horizontally as they would be in normal 
physiological settings. The day the eggs were placed in the incubator was “day 0” and referred to as 
“Embryonic day 0”.  
2.5.2. Egg Fenestration  
On embryonic day 3 (E3), the eggs were removed from the incubator and gently cleaned using 70% 
ethanol, a small hole was poked in the rounded base of the egg, and 4ml of albumin were removed 
using a 19G needle (Terumo) and 5ml syringe (Terumo) inserted at 45° angle. The removal of 
albumin was to prevent the embryo and surrounding vessels from fusing to the inner surface of the 
shell. The hole was then sealed using a small triangle of adhesive tape to prevent any further 
seepage from the hole site. A small rectangular window approximately 1cmx1.5cm was cut into the 
top of egg’s shell using Power Craft PKW-160N Combitool. Next windows were resealed tightly using 
Scotch Magic adhesive tape and eggs were again incubated under the same conditions until E7.   
2.5.3. Cell preparation 
Prior to implantation, cells were harvested from 75cm2 culture flasks using 1ml 0.05% trypsin EDTA, 
and following 5 minutes incubation at 37°C, diluted into 10ml total volume with the appropriate 
medium containing, triturated using 1 ml pipette tip to obtain a single-cell suspension. An 
appropriate number of cells (typically 2x106 cells per egg) in culture medium were transferred into a 
sterile 1.5ml eppendorf tube and centrifuged at 1000 rpm for 5 minutes. After centrifugation the 
supernatant was discarded and the cell pellet resuspended in 5-10μl fresh media and kept in ice until 
implantation. 
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2.5.4. Implantation of cells on to the CAM 
At E7, eggs were removed from the incubator and assessed for survival. GFP-labelled BE2C, IMR32, 
Kelly and SKNAS cells were harvested and counted as described previously. Eggs were removed 
individually from the incubator and the surface of the chorioallantoic membrane (CAM) was lightly 
traumatised using a small piece of sterilised lens tissue. 5μl of 0.05% trypsin was applied to the 
surface of the CAM and 2x106 cells (10-12μl) were implanted. 
2.5.5 Drug delivery 
2.5.5.1 Retinoic acid delivery optimisation in chick embryos  
The initial dose was measured on the presumption that each egg weighed 50g, 10% of this value was 
deduced to represent the weight of the shell, giving 45g (45ml assuming the density is one) of the 
actual weight.  Doses were given as 30mg/kg equivalent to 100µM, 3mg/kg equivalent to 10µM and 
12mg/kg equivalent to 40µM.  
Two methods were tested to optimise drug delivery starting with 100µM dose. A 28µl of RA (0.16M) 
diluted to 56µl with DMSO, 1:1 dilution, and made up to 200µl in DPBS, was initially administered 
topically onto the surface of the CAM.  RA is soluble to 40mg/ml in DMSO, however is extremely 
insoluble in water (Sigma-Aldrich). The topical administration was abundant because of precipitation 
issues. 
 The other method used was diluting the required amount of RA up to 200µl in DPBS and injecting it 
under the CAM into the allantois. A cloudy solution was resulted when RA mixed with DPBS 
therefore a serial of needle with different sizes (19, 21and 23G) attached to a 5ml syringe were used 
to triturate and homogenise the solution before injection. In addition, the embryo movement, inside 
the egg, also assist RA to dissolve more. Injection was initially on E11, E12 and E13 before reducing 
the dose to two, at E11 and E13. A 23G needle attached to a 1ml syringe was used. Careful attention 
was made to avoid injecting into and damaging any large blood vessels to prevent major bleeding.  
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For the control 28ul of DMSO was diluted up to 200ul and injected.  Following RA administration, 
fresh adhesive tape placed over the window and the eggs were returned to the incubator. This 
procedure carried out at approximately the same time after each day.  The drugs administrated 
using the latter procedure (injection) in this project. 
2.5.5.2. Palbociclib and RO-3306 administration to chick embryos 
Palbociclib and RO-3306 were given at 6mg/kg equivalent to 20µM.  90µl of 10mM stock Palbociclib 
and 65µl  of 14mM stock RO-3306were both made up to 200µl of DPBS. Drugs were injected to the 
allantois of embryos at E11 and E13 or E10 and E12 using 23G needle connected to 1ml syringe. 
Control groups were injected with either 200µl DPBS (control for Palbociclib) or 65µl DMSO diluted 
up to 200µl DPBS (control for RO-3306). Following drug administration, eggs were resealed and 
returned to the incubator until E14.  
2.5.6. Harvesting of tumours  
On E14, each surviving embryo was observed under the fluorescent light of a Leica M165 FC stereo 
microscope for the presence of any tumours. The visual field was maximized by breaking away shell 
surrounding the egg "window". Eggs were examined thoroughly for the presence of tumour 
formation and fluorescently labelled cells.  Tumours present were dissected using 6" straight tips 
dissection forceps and Castro-Viejo 4"straight tips dissecting scissors. Once the tumour was removed 
it was placed in HANKS’ and the embryo was humanely destroyed or for some dissected to assess for 
the presence of metastatic cells. Tumours were imaged before and after dissection using the Leica 
DFC425C camera and imaged using the LAS V4.0 software system. Tumours then weighed and stored 
in RNAlater (QIAGEN), or fixed in PFA or formalin. 
2.5.7. Chick embryo dissection and metastasis detection 
Following tumour harvesting, chicks were pulled out the shell using a curved tweezers, and placed in 
a 60mm petri dish (Appleton Woods). They were decapitated using 4"straight scissors, washed with 
Hanks’ to remove blood and NB cells slicked to the skin/feathers before opening the abdomen. 
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Organs were removed into 35mm petri dish (Appleton Woods), washed with Hanks and images in 
bright field and fluorescent were captured using a Leica DFC425 C camera connected to the 
microscope. 
2.6. Immunohistochemistry (IHC) 
2.6.1. Tumour block preparation and sectioning  
The tumours were embedded in paraffin in the histology lab of the University of Liverpool.  
Following fixation, tumours were dehydrated in 70% ethanol in dH2O for one hour and then 100% 
ethanol for another hour. 100% ethanol was replaced twice and left overnight. The 100% ethanol 
was replaced with two changes of 100% isopropanol, agitated gently for 15 min each time on rocking 
platform. Tumours were placed in a glass vial, and immersed with 50% paraffin in isopropanol and 
incubated for 1hr at 65°C, agitating gently every 10-15 min. Following this, the tumours were placed 
in 100% fresh paraffin from the embedding station (Shandon Histocentre 3, ThermoFisher, UK) and 
left overnight at 65°C. Next tumours were placed in a preheated stainless steel mould (filled with 
some molten paraffin) and orient accordingly, mould was put on a small cooling plate to allow the 
tumour to adhere to the mould. Cassette was placed onto the mould and filled fully with paraffin, 
then carefully the mould placed on large cooling plate and then left to harden for 30 min and then 
the mould is removed.  The embedded specimens were then sectioned using the Shandon FINESSE 
325 Microtome and S35 microtome blade (JDA-0100-00A, Feather). The blocks were initially cooled 
on ice prior to sectioning, to prevent the cut sections from rolling up.  After initially trimming the 
blocks by cutting thick 20-25μm sections to expose the specimen, thin 4μm sections were cut in a 
ribbon of approximately four and transferred to a water bath set at 37°C.  Once in the water bath, 
curved forceps were used to separate each section before mounting onto APES coated microscope 
slides (Leica).  The slides were placed in metal racks and “baked” overnight at 37°C to remove any 
remaining water. The following day, slides were kept in a plastic container at 4°C until time for 
staining. 
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2.6.2. Antigen retrieval and deparaffinisation 
Prior to performing immunohistochemistry, slides were placed in a slide rack compatible with the 
Dako PT Link (Dako, UK) in order to deparaffinise, rehydrate and heat induced antigen retrieval. The 
slide rack was inserted into pre-heated high pH retrieval solution (Tris/EDTA, pH 9.0) for 
deparaffinisation, high-pH (buffer, pH 9.0) antigen retrieval was performed at 96 °C for 20 minutes. 
Slide racks were allowed to cool in the PT Link, after which slides were rinsed with FLEX wash buffer 
(50mM Tris-base, 150mM NaCl, 0.05% Tween 20, pH 7.6) to remove excess paraffin. 
2.6.3. Ki67 staining  
Slide racks were transferred to the automated Dako autostainer system. IHC was performed using 
FLEX EnVisionTM reagents (Dako, UK). All steps were carried out at room temperature. Endogenous 
peroxidase was blocked by incubating slides with Peroxidase-Blocking Reagent (phosphate buffer 
containing hydrogen peroxide, 15mM NaN3) (DM821) for 5 minutes. Primary antibody, mouse anti 
Ki67 (Leica Biosystems, KI67-MM1-L-CE), was diluted (1:250) in antibody diluent (K8006) and slides 
were incubated the primary antibody for 30 minutes, followed by incubation a goat anti-mouse 
secondary antibody conjugated with horseradish peroxidase HRP (Dako, DM822) for 20 minutes.  
Negative control was stained by replacing Ki67 with mouse IgG1 Negative control (Dako, X0931) at 
1:250. Positive staining was visualised with the chromogen, 3,3’-Diaminobenzidine (DAB), prepared 
by adding 1 drop of stock solution to 1 ml of substrate buffer (DM823). Slides were washed with 
FLEX wash buffer (50mM Tris-base, 150mM NaCl, 0.05% Tween 20, pH 7.6) between steps of 
staining. 
2.6.4. Counterstain and mounting 
Haematoxylin has a deep blue-purple colour and stains the nucleus of the cells within the tissue. 
Counterstaining with haematoxylin helps identifying chick cell-type- from neuroblastoma cell-type. 
Slides were immersed in haematoxylin solution for 20 seconds, washed with running tap water, 
cleared in 0.5% acid alcohol and incubated in Scott’s tap water blueing agent for 30 seconds. Slides 
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then underwent dehydration in a series of alcohol and xylene incubations before mounting with DPX 
mountant (Sigma, UK) on 22 x 50mm cover slips (630-2210, Menzel Gläser, UK). Tissue known to 
express the protein of interest (ki67)  was included as a positive and negative control.  
2.6.5. Cell proliferation quantification of sections  
Slides were observed under bright field microscopy and manual counting of histological sections was 
used to determine Ki67 proliferative index. For each section ≥4 fields were assessed and ~ 200 cells 
were counted per field. Ki67 positive nuclei are stained in brown. Negative nuclei are counterstained 
in blue by haematoxylin. The percentage of the brown-stained nuclei of the total number of cells 
determined the Ki67 index. Haematoxylin staining allowed identification of both chick tissue and 
tumour nuclei. Chick tissue cells could be identified as they had a small nucleus whereas tumour 
tissue cells had a relatively larger nucleus with less cytoplasm. 
2.7. Tumour mounting for morphology studies 
For some experiments the CAM was seeded with 90% wild type BE2C cells and 10% GFP BE2C cells 
and the resultant tumour used to analyse the morphology of the GFP cells in response to RA.Tumour 
specimens <2mm were mounted on a glass slide using DAKO fluorescence mounting medium. A 
circular cover slip was laid over the top with slight pressure to both remove trapped air and flatten 
the specimen.The morphology of cells within the tumours was observed using confocal microscopy 
with the Leica DMIRE2 microscope and X40 objective, together with the Leica Confocal Software 
program.  
2.8. Apoptosis assay by TUNEL (Terminal Deoxynucleotidyl 
Transferase Mediated Nick End Labelling)  
Paraffin sections were prepared as described previously (section 2.6.1).  TUNEL is used to assay 
apoptotic (programmed) cell death by measuring nuclear DNA fragmentation. Biotinylated 
nucleotide is incorporated at the 3’end of the fragmented DNA using a Terminal Deoxynucleotidyl 
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Transferase, (TdT) enzyme. Streptavidin HRP (HRP Horseradish peroxidase-labelled) is bound to the 
biotinylated nucleotides and detected using hydrogen peroxide and diaminobebzidine (DAB). Hence 
nuclei of apoptotic cells stained dark brown. The Dead End
TM 
Colorimetric TUNEL System (Promega) 
was used. Paraffin sections underwent deparaffination with Histo-clear II. Slides were washed with 
100% ethanol followed by rehydration in a decreasing ethanol series (95%, 70%, and 50%) and 
washed in 0.85% NaCl at room temperature (RT). After washing with phosphate-buffered saline 
(PBS) the tissue was fixed in 4% (PFA) and washed with PBS. The tissues were permeabilised with 
Proteinase K solution (20μg/ml) for 10 minutes at RT and washed again in PBS before re-fixing in 4% 
PFA. The sections were washed in PBS and equilibrated with 1 x TdT buffer at RT. The slides were 
incubated at 37°C for 1hr in a humidified chamber with TdT reaction mix containing 98μl 
equilibration buffer, 1μl biotinylated nucleotide mix and 1μl TdT enzyme (1U/μl), per slide. For 
negative control a slide was prepared without TdT and for positive control a slide was treated with 1 
μl DNase 1 (1U/μl, Promega). The slides were washed in PBS and treated with 0.3% hydrogen 
peroxide to block endogenous peroxidases and washed in PBS. Slides were treated with streptavidin 
HRP for 30 minutes at RT and washed in PBS before the colour reaction. DAB was added to the slides 
and allowed to develop (6 minutes), before washing with deionised water. Covers slips were 
mounted using DPX Mountant (44581, Sigma-Aldrich). 
2.8.1. Cell apoptosis quantification 
Slides were observed and imaged under bright field Leica microscopy, ~ 600 cells counted in ≥4 fields 
per section. TUNEL positive nuclei are stained in brown. The percentage of the brown-stained nuclei 
of the total number of cells determined the TUNEL index.  
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2.9. Quantitative PCR (qPCR) in tumours  
2.9.1. RNA extraction  
Tumours dissected from the chick CAM were placed in RNAlater (QIAGEN) and stored at 4°C for up 
to 2 weeks prior to RNA extraction. The tissue was first removed from the RNAlater and transferred 
to a clean RNase free falcon tube. Liquid nitrogen was used to freeze the tissue before a pestle and 
mortar was used to disrupt it. RNA was then extracted as per the culture protocol (section 2.4.1). 
2.8.2 cDNA synthesis 
cDNA synthesis was completed using the same protocol mentioned previously (section 2.4.2).  
2.8.3. Reference gene selection 
Same reference genes described in section 2.4.3 were used. 
2.9.4. Target gene selection 
The effects of hypoxia on several prometastatic genes on neuroblastoma cell lines in vitro and in vivo 
has been described (Herrmann et al., 2015). We selected eight genes having the largest fold 
increase/decrease from this paper; glucose transporter 1 (GLUT1), vascular endothelial growth 
factor (VEGF), matrix metallopeptidase 9 (MMP9), A disintegrin and metalloproteinase with 
thrombospondin motifs 1 (ADAMST1), vascular cell adhesion molecule 1 (VCAM), integrin alpha V 
(ITGαV), integrin beta 5 (ITGβ5), versican (VCAN). 
2.9.5. Primers 
Primer sequences were identified in published papers using the same target or reference genes in 
qPCR experiments ((Vandesompele et al., 2002; Herrmann et al., 2015). Reference primer sequences 
were ordered from Sigma-Aldrich, whereas target genes were kindly given by Anne Herrmann, 
University of Liverpool. Once, primers received, they were reconstituted in nuclease-free water 
(ThermoFisher Scientific, UK) and stored at -20 C in small 10mM aliquots to avoid freeze-thawing 
process. Table2.7 below details all primer pairs used. 
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Table2.7 List of the primers used in qPCR of tumours experiments 
 
 
 
 
 
2.9.6. qPCR Protocol design 
Protocols were designed as described previously in section 2.4.6. 
2.9.7. Analysis of qPCR data 
Data was viewed using Bio-Rad CFX Manager 3.1 software. An initial inspection of both the 
amplification plot and melt curve ensured that there were no obvious anomalous results. Fold 
change in target gene expression was calculated relative to the control. Results were normalised to 
the three reference genes (GAPDH, HPRT1 and UBC). Fold change calculated by comparing the Ct 
value of each tumour condition and then taking the mean from 3 independent biological replicates. 
2-ΔΔCt method was used to calculating relative gene expression using the normalised  qPCR data 
(Schmittgen and Livak, 2008). To conduct statistical analysis NRQ data of 3 independent biological 
replicates were compared to control to standardise the fold change. 
Gene  Forward 5’-3’ Reverse 5’-3’ 
GAPDH AATCCCATCACCATCTTCCA TGGACTCCACGACGTACTCA 
HPRT1 TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT 
UBC ATTTGGGTCGCGGTTCTTG TGCCTTGACATTCTCGATGGT 
ADAMST1 CCCTCACTCTGCGGAACTTT GGACCCACACAAGTCCTGTC 
GLUT1 GAACTCTTCAGCCAGGGTCC ACCACACAGTTGCTCCACAT 
ITGαV CGCTTCTTCTCTCGGGACTC AGAAACATCCGGGAAGACGC 
ITGβ5 GGGAGCCAGAGTGTGGAAAC GGATCGCTCGCTCTGAAACT 
MMP9 TTCTGCCCGGACCAAGGATA ATGCCATTCACGTCGTCCTT 
VCAM TGTTTGCAGCTTCTCAAGCTTTTA GTCACCTTCCCATTCAGTGGA 
VCAN ACCAGACAGGCTTCCCTCCCC GGGTGATGCAGTTTCTGCGAGGA 
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2.10. Statistical analysis of data 
The data from each experiment were first averaged and presented as means with standard error bar 
(±SEM). The statistical analysis was performed using either a student T test or a one-way ANOVA to 
determine statistical significance between groups. This was followed by a post-hoc Tukey test 
multiple-comparison test to determine significance between data sets. A p value of <0.05 was 
considered significant. All statistical data was analysed using GraphPad Prism version 6.00 for 
Windows. 
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Chapter Three: Results I  
Optimisation of the chick embryo model system for 
neuroblastoma treatment 
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3.1. Introduction 
Neuroblastoma is a neural crest-derived malignancy which has an unusually high rate of 
spontaneous regression. Differentiation status is a key prognostic factor in neuroblastoma with the 
least differentiated phenotypes displaying the worst prognosis for patients (Craig et al., 2016). 
Interestingly, Park et al reported in his review that neuroblastoma is an aberration of normal 
development and 4-S stage tumours may spontaneously regress to leave more differentiated benign 
ganglioneuromas (Park et al., 2013). This therefore indicates that drugs that stimulate differentiation 
may also offer a potential therapy for in neuroblastoma (Thiele, Reynolds and Israel, 1985). 
Retinoic acid (RA) is a differentiation agent known to induce a more neuronal phenotype of some 
neuroblastoma cell lines, especially MYCN amplified cells. RA is been used in clinic, as a standard 
treatment for patients with high risk neuroblastoma (Reynolds et al., 2003). Therefore, 
differentiation therapy including RA was a prime target on which to verify the effectiveness of the 
chick embryo model. 
Commonly, mouse model is used for the in vivo assessment of potential new therapeutic targets in 
many cancers (Cekanova and Rathore, 2014). However, mouse models are expensive and time 
consuming. Other models, such as the chick embryo chorioallantoic membrane (CAM), are therefore 
an attractive alternative model of cancer studies. The chick embryo model has many advantages 
includes 1) the nature of the CAM highly vascularized which promotes the efficiency of tumour cell 
grafting, 2) immuno-deficient nature which means that the chick can eccept the cancer cells 
regardless their origin, 3) high reproducibility, simplicity and cost effectiveness (Ribatti, 2008; 
Lokman et al., 2012).  
The CAM model has been used extensively to study angiogenesis and tumour xenografting 
(Richardson and Singh, 2003; Balciūniene et al., 2009; 2014; Durupt et al., 2012; Lokman et al., 2012; 
Yuan et al., 2014; Kavaliauskaite et al., 2017). However, to date, there have been few studies that 
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have used CAM assays to assess the effect of therapeutic agents on cancer behaviour (Richardson 
and Singh, 2003; Rytelewski et al., 2014; Sathe et al., 2016). 
Interestingly, MYCN amplified neuroblastoma is closely correlated with unfavourable prognostic 
features and therefore patients with MYCN amplification denotes high risk neuroblastoma (Rubie et 
al., 1997; Chan et al., 2007). Thus these are the cells that are known to be more aggressive and 
therefore would be expected to form tumours more readily on the CAM (Mather, 2014). Moreover 
in representing high risk disease, new therapies are required to treat these cells. 
3.1.1. Aims of the chapter 
The work described in this chapter aimed to establish the value of the CAM model by demonstrating 
the effect of the known differentiation agent RA on MYCN amplified neuroblastoma cells. This was 
divided into the following sub-aims.  
 Set up assay systems in vitro to analyse the response of neuroblastoma cells to RA.  
 Develop neuroblastoma tumours in vivo.  
 Determine an appropriate method of drug delivery to tumours. 
 Analyse the effect of RA on tumour assays set up in vivo. 
3.2. Results 
3.2.1. Retinoic acid reduces cell proliferation and induces changes in 
morphology in BE2C and IMR32 cells 
To investigate the effect of Retinoic acid on MYCN amplified cell lines, in culture, in terms of 
proliferation and cell morphology, cells were treated with RA for a period of 72hr and observed 
under the Leica DMIRB microscope before carrying out Ki67 staining.  
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Morphology assessment  
Following 3 days with RA, both BE2C and IMR32 cells showed a change in morphology compared to 
DMSO treated cells. RA- treated cells showed more elongated shape with neurites outgrowth (refers 
to any projection from the cell body which length equals or exceeds the cell body diameter) as can 
be seen in Figure3.1.   
Proliferation assessment  
Assessment of cell proliferation (Ki67) was crucial in determining the behaviour of the 
neuroblastoma in culture first before assessing their behaviour in vivo, in response to RA treatment. 
Ki67 is expressed during the G1, S, G2 and M phases of the cell cycle, whereas, in G0 stage of the cell 
cycle it found to be absent (Gerdes et al., 1984) .  Many subsequent studies have reported that Ki67 
expression level is crucial for normal proliferation across various cell lines (Kausch et al., 2003; Zheng 
et al., 2006, 2009; Rahmanzadeh et al., 2007) .   
Cell proliferation appeared to be reduced in the RA treated cells relative to control based on visual 
inspection of the culture. We therefore performed Ki67 staining on these cells to quantify this effect. 
Cells were stained with a rabbit anti-Ki67 antibody and labelled with goat anti-rabbit (secondary 
antibody) conjugated with Alexa Fluor 594 (red) to enable identification of proliferating cells whilst 
counterstaining with DAPI allowed identification of the total number of nucleus cells present.  Cell 
counts were performed comparing the number of Ki67 positive cells to the number of DAPI stained 
cells in the treated as well as in control cells (Figure3.2 A&B). Overall a 68% reduction was observed 
in the level of Ki67 staining in the IMR32 cell line and a 70% decrease in BE2C cell line (Figure3.2 C). 
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Figure3.14 Changes in cell morphology after72 hrs of RA treatment. A and B are IMR32 cells, C and D 
are BE2C cells. A and C are images taken of the control cells and B and D are the treatment. Black arrows 
indicate morphological changes as neurite outgrowth.  
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Figure3.2 Effect of RA treatment on IMR32 and BE2C cell proliferation.  A  DAPI stained (blue) and 
Ki67 stained (red) IMR32 cells following three days of treatment with 10µM RA (RA was replenished 
following 48hr of treatment hence 10 (X2)) or DMSO. B  DAPI stained (blue) and Ki67 stained (red) 
BE2C cells following three days of treatment with 10µM RA or DMSO. C Graph to show the reduction 
in cell proliferation following treatment with RA. Ki67 displayed by setting the control to 100%, Ki67 
index= number of Ki67 positive expressed as a percentage of the total number of cells. Data 
presented relative to control. Data represents mean ± SEM (n=9). Each bar represents the mean ± 
SEM of three biological replicates and at least 9 fields per experiment.  ** P< 0.01 and ***P<0.001.   
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3.2.2. Retinoic acid change the gene expression of differentiation markers in 
IMR32 and BE2C cells 
To further investigate the effect of RA on gene expression, quantitative assessment of cellular 
differentiation was undertaken using qPCR. Genes which demonstrate large fold changes upon 
neuroblastoma cell differentiation were selected: KLF4, STMN4 and ROBO2 (Sung et al., 2013) and 
MYCN (Huang and Weiss, 2013). KLF4 is a stem cell marker involved in the regulation of 
differentiation and its expression would be expected to decrease in differentiated cells (Zhang et al., 
2010). STMN4 and ROBO2 are involved in neuronal differentiation. ROBO2 is also involved in 
regulation of the actin cytoskeleton and axon development and guidance. Expression of both would 
be expected to increase in differentiated cells (Beilharz et al., 1998; Andrews et al., 2008).  MYCN is 
an oncogene, and is known to be involved in the regulation of the neural crest development and  
initiation of  neuroblastoma (Olsen et al., 2017). 
In keeping with previous results, there was a significant change in the expression of the 
differentiation markers KLF4 and STMN4 but not ROBO2 and MYCN in RA treated cells compared 
with DMSO treated cells.  In IMR32 cells, KLF4 decreased by 5.5 fold and STMN4 increased more 
than 6 fold, ROBO2 also showed an increase which was not significant and MYCN showed a slight 
decrease (Figure3.3 A, B).  Similar to IMR32 cells, BE2C cells results showed a decrease by more than 
4 fold in KLF4 and an increase of 14.5 fold in STMN4 and they both were significant. ROBO2 showed 
an expected trend but did not reach significance whereas a small decrease in MYCN (Figure3.3 C, D).    
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Figure3.3 Graphs showing the level of target gene expression in IMR32 (A) and BE2C (C) cells 
following 72hr of RA treatment. Graphs display the results of three biological repeats. Results are 
displayed relative to control. Error bars were calculated using standard error (SE). Tables give a 
summary of the QPCR data for the 4 target genes for IMR32 (B) and BE2C (D). 
  KLF4 MYCN ROBO2 STMN4 
Fold change -5.53 -1.28 3.41 6.52 
Log fold change -2.47 -0.36 1.77 2.70 
Regulation  down regulated no change no change up regulated 
  KLF4 MYCN ROBO2 STMN4 
Fold change -4.89 -1.17 3.37 14.6 
Log fold change -2.29 -0.23 1.75 3.87 
Regulation  down regulated no change no change up regulated 
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3.2.3. Assessing the effect of RA on MYCN amplified cell lines in vivo using the 
chick embryo model 
 
3.2.3.1. Efficiency of tumour formation on the CAM among MYCN amplified cell lines 
In culture RA has behaved as expected and we have established differentiation markers that are 
sensitive to RA treatment.  Next we aim to confirm that neuroblastoma cells respond to RA in vivo in 
our model and that these assays can successfully detect the response. Preliminary experiments 
started with the two MYCN amplified cell lines; IMR32 and BE2C cells; to test the potential of these 
cells to form tumours on the CAM successfully. The outcomes revealed, in the majority of 
experiments, that MYCN amplified cells were seen as a flat sheet on the surface of the CAM 
(Figure3.4 a & b) indicating that those cells failed to invade the CAM and form a tumour therefore 
they remained on the surface.  This was surprising as MYCN amplified cell lines are known to be very 
invasive and extravasate following intravenous injection (Carter et al., 2012). In some instances, cell 
lines had formed tumours beneath the CAM (Figure3.4 c-f).  
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Figure3.4 MYCN amplified neuroblastoma tumours formed on the CAM of chick embryo 
model. Left side is bright field images, right side is GFP images. a and b are GFP-labelled 
neuroblastoma cells dried on the surface of the CAM indicating that those cells failed to 
invade the CAM and form a tumour. c-f tumours formed successfully beneath the CAM of 
the chicks.  
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The efficiency of tumour formation was 27% of surviving embryos had formed a BE2C tumour and 
only 7% in IMR32. The efficiency of tumour formation quantified for each cell line during dissection 
(E14), was achieved by dividing the number of the number of eggs with tumours by the number of 
eggs surviving until this time to give the tumour success rate for each cell line (Figure3.5 A). Due to 
the poor efficiency shown by IMR32 and BE2C cells, another MYCN amplified cell line, Kelly cells, was 
included to investigate whether this cell line could form tumours on the CAM more efficiently than 
the other two cell lines. Unfortunately, this cells line seemed to have similar efficiency to the IMR32 
cells in forming tumours (Figure 3.5 A).  
A work done by others, in our laboratory illustrated that SKNAS cells (non-MYCN amplified cells) 
form tumours much more efficient on the CAM than BE2C, IMR32 and Kelly cells (MYCN amplified 
cells), therefore they sought to enhance the ability MYCN amplified cells to form tumours on the 
CAM by mixing them with SKNAS. Their results were showing a significant increase in the yield of 
tumour formation within this environment suggesting that the problem lay with the invasion ability 
of MYCN amplified cells (Mather, 2014).This prompted us to treat the CAM surface with trypsin prior 
to adding the cells. Trypsin is a protease whose cleaves peptides on the C-terminal side of lysine and 
arginine amino acid residues and therefore we asserted that it may aid the penetration of 
xenografted tumour cells through the superficial epithelial cell surface of the CAM (Olsen, Ong and 
Mann, 2004). Trypsin addition indeed improved the efficiency of the tumour formation for MYCN 
amplified cells to more than 70% for BE2C cell, IMR32 is 33% and Kelly 37% (Figure3.5 B). Tumours 
grown on the CAM became visible under the fluorescent stereomicroscope three to four days 
following implantation (Figure3.6 a-f). Large tumours (~5mm) were occasionally identifiable without 
fluorescence by E14, It was noticed that where dried blood was evident on the surface of the CAM 
tumours were present; however the vast majority of tumours were only identifiable under the 
fluorescent microscope (Figure3.6 g-h).  In most instances, one tumour formed however in rare 
cases multiple smaller masses could be seen (Figure3.7 a-b). Tumours were highly vascular with 
blood vessels clearly recognisable on their surface (Figure3.7 c-j). Among cell lines, tumours showed 
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or revealed different morphological features, IMR32 tumours had an elongated appearance 
(Figure3.6 a-b), BE2C tumours were more rounded (Figure3.6 c-d), and Kelly were irregular shape 
(Figure3.6 e-f). 
To be consistent with the in vitro experiments and as the Kelly cells did not add to the efficiency of 
tumour formation rate, it was decided that IMR32 and BE2C cell lines would be used in experiments 
designed for testing the effects of RA in vivo. 
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Figure3.5 Graph of the tumour success rate of IMR32, BE2C and Kelly without and with 
trypsin treatment. A is the tumour success rate without trypsin treatment,  the success 
percentage was between 7-27% indicating a low yield of tumour formation, BE2C tumour 
production compared to IMR32 and Kelly is evident. B is the tumour success rate with trypsin 
treatment, the success percentage increased dramatically over the three cell lines, BE2C 
tumour production compared to IMR32 and Kelly still evident though.  
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Figure 3.6 Images of tumours formed on the CAM of chick embryo.  a-f  in vivo GFP and 
corresponding bright field images of 100% GFP labelled tumour cells- a and b are IMR32, c and 
d are BE2C, and e and f are Kelly tumours. g and h are  Large tumours (~5mm) were 
identifiable without fluorescence by E14 where dried blood on the surface of the CAM tumours 
were present. White arrows indicate the evidence of tumour formation. 
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Figure3.7  In vivo and harvested CAM tumours in GFP and its corresponding bright field.  
a-b more than one tumour grown in the CAM can be seen , white arrows indicate the 
tumours.  c-j a group of harvested tumours . Tumours were highly vascular with blood 
vessels clearly recognisable on their surface. Black arrows indicate the blood vessels.  
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3.2.3.2. Histology characterisation of CAM tumours 
To characterise the histology of the CAM tumours, tumours were harvested out of the egg and fixed 
in 4%PFA. After harvesting, the tumours were processed into paraffin sections and haematoxylin and 
eosin (H&E) staining was performed to observe the histological appearance of the tumour. Dissected 
tumours were seen as separate masses which had a smooth outer surface (Figure3.8 a & b). They 
were typically covered by and penetrated by evident network of blood vessels (Figure3.8 a & b).  
Paraffin sections demonstrated that the tumours were made up of densely packed tumour cells form 
of solid mass (Figure3.8 c, d & e). This indeed reflects the histology of patient tumours suggesting 
that the CAM tumours are a good model for preclinical studies (Dr Rajeev Shukla, Alder Hey 
Children’s Hospital, personal communication). 
 
 
 
 
 
 
 
 
 
 
 
Figure3.8  Harvested CAM tumours and their sections stained with haematoxylin and eosin (H&E). a 
and b GFP CAM tumours with its relative bright field showing that tumours  have a smooth outer surface 
that  penetrated by evident network of blood vessels. c , d and e are tumour sections stained with H&E. 
Black arrows indicate tumour tissue. Red arrows indicate chick tissue.  
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3.2.3.3. Proliferation reduction and morphological alterations in CAM tumours 
caused by RA 
RA had demonstrated a reduction in cell proliferation and induced changes in morphology in both 
IMR32 and BE2C cells; here we sought to investigate the effect of RA in vivo on tumours generated 
using same cell lines. 
Tumours could be reliably observed by E11 therefore RA treatment was initiated at E11 and 
repeated at E13. RA treatment was started by replicating the dose used for cell culture experiments 
(10µM). Dose calculations used the weight of an average egg less the weight of its shell. Although 
the survival of embryos at 10µM was good, the effect of RA on proliferation was not significant. In 
order to observe therapeutic effects of RA in tumours, we decided to apply the dose that used to 
treat xenograft mouse models which was 30mg/Kg (100µM)(Shalinsky et al., 1995). 100µM dose 
showed a significant reduction in CAM tumours proliferation. Survival of the embryos was 
unaffected by the introduction of three injections of 28µl (Ξ100µM) of RA or DMSO compared to no 
treatment (Figure3.9). Later, we sought to reduce the dose and the number of drug application; 
therefore we used 40µM with two injections. The effect of RA on cell proliferation of BE2C cells 
within the tumour was assayed. A notable reduction on proliferation of cells within tumours that 
were treated with RA could be seen in Figure3.11 compared to Figure3.10. The percentage of 
dividing cells was reduced significantly by 43% following three injections of 100µM RA whereas 
10µM RA reduced proliferation by 22% while two doses of 40µM reduced proliferation significantly 
by 37% (Figure3.12). Interestingly, our results showed that decreasing the dose to 40µM (x2) 
reduced the proliferation almost effectively as the 100µM(x3)  did and the percentage increase of 
Ki67 positive cells in the 40µMRA treatment group was only 6.67% higher than the percentage of 
stained cells in the 100µM treatment group(Figure3.12). Thus four fold the dose used in culture was 
sufficient to reduce the proliferation statistically. This result prompted us to investigate whether 
40µM RA had an effect on differentiation state within the tumour.  
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Here, CAM tumours generated from 90% wild type BE2C cells mixed with 10% of GFP-labelled BE2C 
cells were examined (Figure3.13). RA treated cells exhibited a more elongated  body shape of cells 
with small extensions resembling neurites, suggesting a more differentiated state compared to cells 
treated with DMSO (Figure3.14). 
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Figure3.9 Embryo survival rate following RA and DMSO treatments compared to those were non-
treated. Neither DMSO (28 μl injections X3) nor RA (100 μM injections X3) affected the survival of the 
chick embryos (n > 50 for all conditions). Each bar represents the mean ±SEM of three biological 
replicates. 
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Figure3.10 Ki67 treated sections. a and b tonsil tissue used as a Ki67 negative (without Ki67) and 
positive (with Ki67) control respectively. Cells undergoing mitosis could be seen (red arrow). c-f tumour 
sections treated with DMSO injected into the allantois. Red arrow indicates Ki67 stained nucleus, white 
arrow indicates unstained cell.  
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Figure3.11 RA treated BE2C tumours. a-c tumour sections treated with 10µM RA, d-f  tumour sections 
treated with 40µM RA ad g-i tumour sections treated with 100µM RA injected into the allantois. Note 
the decreasing number and staining intensity of the cell nuclei as the concentration of RA is increased. 
Red arrow indicates Ki67 stained nucleus, white arrow indicates unstained cell and black arrow 
indicates chick tissues.  
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RA µM No. of injections % proliferation  % proliferation reduction 
0 3 76.95±1.13 0 
10 3 59.99±5.79 22.33 
40 2 48.31±3.45 37.67 
100 3 43.21±3.67 44.33 
Figure3.12 Ki67 quantification of BE2C tumours after different RA treatments. A graph showing the 
percentage of proliferation in RA treated tumours compared to DMSO. B table summarising the 
details of RA doses, percentages of proliferation and percentage reduction. Results suggested that 
both 40μM of RA (2 injections) and 100μM (3 injections) reduces the number of proliferative cells 
significantly (*p < 0.05) compared to the control. 
** 
** 
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Figure3.13  In vivo and dissected 10% GFP-labelled tumours formed on the CAM of chick embryo 
model. a and b images of 10% GFP BE2C tumours are taken in vivo. c and d images of 10% GFP BE2C 
tumours are taken following dissection. e is enlarged image of a harvested 10% GFP IMR32 tumour. f-i 
images of harvested 10% GFP tumours with their relative bright field.  f and g are BE2C, h and i are 
IMR32. 
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Figure3.14 confocal image of tumour treated with 40μM twice with RA or DMSO. a is DMSO 
treated, b is RA treated and c is enlarged  image of RA treated tumours. Tumours were formed 
from BE2C cells of which 10% expressed GFP.  RA treated tumours exhibited a more elongated  
body shape of cells with small extensions resembling neurites, suggesting a more differentiated 
state compared to cells treated with DMSO. 
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3.2.3.4. RA promotes differentiation of CAM tumours 
A further validation, done by Grace Mather, University of Liverpool, to investigate the effect of RA 
on differentiation of CAM tumours, tumours treated with and without RA were evaluated for 
changes in the differentiation markers and also for MYCN. For IMR32 cells the results were similar to 
those observed in culture with KLF4 down regulated 4.2 fold and STMN4 upregulated 4.4 fold.  
ROBO2 and MYCN showed an appropriate trend but it was not statistically significant (Figure3.15 a 
&b).  For BE2C cells both ROBO2 and STMN4 were significantly upregulated (5.9 fold and 5.0 fold 
respectively) and KLF4 and MYCN were down regulated by 3.4 and 2.2 fold respectively although 
these latter results were not statistically significant (Figure3.15 c &d). Nevertheless the cells within 
the tumours shown a similar change in expression of the differentiation markers compared to cells 
in culture.   
Taken together, the CAM tumours respond as expected to RA treatment confirming the value of the 
CAM tumour model for screening new therapeutic agents. 
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Figure3.15 Graphs showing the level of target gene expression in IMR32 (A) and BE2C (C) tumours 
following 72 hr of RA treatment. Graphs display the results of three biological repeats. Results are 
displayed relative to control. Error bars were calculated using standard error (SE). Table gives a 
summary of the QPCR data for the 4 target genes for IMR32 (B) and BE2C (D). 
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3.3. Discussion 
In this chapter we aimed to establish the potential of the chick embryo to act as a therapeutic model 
system for neuroblastoma research. By optimising the protocol for tumour production within the 
CAM, the tumour success growth rate with the MYCN amplified cell line BE2C reached 72%. We 
hoped to show the effect of RA on neuroblastoma tumour cells in this system, and then detect the 
effects exerted by other drugs in a quantifiable way. A simple but effective drug delivery system was 
developed ensuring complete distribution of the drug treatment to any tumours present. Ultimately 
we wished to validate the model by confirming the efficacy of existing standard therapy, RA, on 
neuroblastoma tumours within chick embryo model. 
3.3.1. Growing tumours on the chick CAM 
We used the shell windowing technique in the chick embryo experiments as it has been used by 
others for different means (Wang, Wang and Cai, 2009; Sys et al., 2013). This technique allows us 
visualise the embryo and tumour growth throughout the experiments. While the windowing method 
allows us continual visualisation and access to great area of the CAM, it has been reported to 
compromise the survivals (Lokman et al., 2012). We were able to detect tumour formation after 3-4 
days following the cell implantation as well as being able to apply treatment and monitor the effect 
on tumours following the treatments. This ability confers significant advantage of chick embryo 
model over murine models that require palpable tumour growth and a more complex technique of 
imaging in order to establish the presence of a tumour and monitor tumour growth (Young et al., 
2009; Puaux et al., 2011; Miller et al., 2012).  
To graft cells into the CAM, various methods has been used such as matrigel grafts (Celik et al., 2005; 
Lokman et al., 2012), plastic rings (Balke et al., 2010) and collagen implants (Zijlstra et al., 2006; 
Tiemi Egoshi et al., 2015). Furthermore, cancer cells can also be administered intravenously to study 
metastasis of cancer cells in the chick embryos (Palmer, Lewis and Zijlstra, 2011). In our research, we 
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were applying the cells directly into the CAM surface avoiding any unnecessary complexity or 
manipulation. 
 Furthermore, we were placing the cells on the CAM at E7 and allowing 7 days for tumour to grow. 
Others however were grafting cells or explanting tumour to the CAM at late stage as E9 or E10 
(Jefferies et al., 2017; Vu et al., 2018). Nevertheless, others  have found that this period of time did 
improve the survivals of embryos and increased the tumour formation (Wang, Wang and Cai, 2009). 
Our data showed a good rate of tumour formation achieved when placing the cells on the CAM at 
the earlier stage. In addition, it allows us to complete experimental work on chick embryos prior to 
E14 without the need for the Home Office licence. This perhaps makes the model more accessible 
for many laboratories. Considering the 21 days of the embryo development, tumours formed earlier 
provide longer period to test therapeutic compounds and allows analysing the consequent effect of 
these compounds within the model. In either case, the time of conducting and obtaining the results 
using this model is faster than murine models. 
Implantation of several neuroblastoma cell lines on to the surface CAM allowed us observe the 
ability of the cells to form tumours in this environment. Interestingly, we observed low yield of 
tumour formation (less than 25%) in BE2C, IMR32 and Kelly cells. This contradicts with the clinical 
classification that considers MYCN amplified tumour as aggressive and metastatic disease (Dzieran et 
al., 2018), and thus MYCN amplified cells are expected to form tumours in the CAM more readily. 
When MYCN cell failed to form tumours in the model, they were seen as a flat sheet on the surface 
of the CAM rather than beneath it as a mass.  
The degradation of basement membrane to penetrate into the underlying stroma is known to be 
one of the hallmarks of cancer (Hanahan and Weinberg, 2011). Matrix metalloproteinases (MMPs) 
are a group of zinc-dependent endopeptidases that show proteolytic activity for many components 
of the extra-cellular membrane (Al-Dasooqi et al., 2010). Among the proteases, MMPs are believed 
to be involved in tumour invasion and metastasis (Hanahan and Weinberg, 2011). 
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The expression profile of MMPs and their inhibitors has been studied in several neuroblastoma cell 
lines (Ara et al., 1998; Sugiura et al., 1998; Bjørnland et al., 2001; Roomi et al., 2013; Arumugam et 
al., 2016).For instance, Sugiura et al reported that a number of neuroblastoma  cell lines such as 
IMR32, BE2, SKNSH, LAN1, LAN2, LAN5, LAN6, and HT1080 were seen to overexpress certain MMPs 
but in an inactive proform (Sugiura et al., 1998). Interestingly, in another study conducted in other 
neuroblastoma cell lines, SKNAS were found to have the highest expression of MMPs among other 
cell lines, and of those tested, was the only cell line expressed the biological activator of MMP 
(Bjørnland et al., 2001).  
The above findings may explain why the cells we used in experiments failed to form tumours as the 
lack of active MMP enzymes affects cell ability to penetrate through superficial epithelial layer of the 
CAM, and so they remained on the surface, fail to grow and consequently died. In support to this, a 
significant improvement of tumour formation was noticed following the addition of Trypsin, a 
proteolytic enzyme. Trypsin allowed for the invasion of cells under the superficial epithelial layer of 
the CAM, the neuroblastoma cells had a near optimum environment to expand, draw in blood 
vessels and exponentially grow.   
Following the addition of Trypsin, tumour success formation of BE2C increased to 70% whereas in 
IMR32 and Kelly increased to almost 40%. These results supports what seen in  other studies that 
also observed variable levels of cell line specific success when investigating the tendency of 
malignant cell lines to form tumours in the chick embryo model (Balke, Neumann et al. 2010).  
Ultimately, the success of tumour formation demonstrate that human neuroblastoma cells, like 
many other malignancies  (Khanna et al., 2002; Balciūniene et al., 2009; Cecilia Subauste et al., 2009; 
Fergelot et al., 2013; Sys et al., 2013; Manjunathan and Ragunathan, 2015; Jefferies et al., 2017; Vu 
et al., 2018), are able to form tumours in CAM model. The improvement of tumour yield following 
the addition of Trypsin may have significance, not only in establishing the chick embryo as a suitable 
111 
 
in vivo model system for neuroblastoma, but may aid research into other malignancies being used in 
the model. 
3.3.2. Retinoic Acid in culture 
In culture, three days of RA administration showed some morphological changes such as neurites 
outgrowth in both IMR32 and BE2C cells. Many in the literature have described these morphological 
changes as being a differentiation characteristic (Sidell, 1982; Sidell et al., 1983; Wu et al., 1998). Cell 
proliferation has been quantified using Ki67 staining.  A reduction in Ki67 positive cells was seen in 
both cell lines, also suggesting that cell differentiation is taken place.  
 Changes in the level of target gene expression after exposure to RA were detected using qPCR. In 
keeping with previous results, showing the reduction of proliferation and the morphological 
changes, there was a significant change in the expression of the differentiation markers KLF4 and 
STMN4 but not ROBO2 and MYCN in RA treated cells compared with DMSO treated cells.   
Expression levels of KLF4 fell significantly after 3 days of RA treatment in both cell lines. KLF4 results 
further support Sung et al observation and extend it to show similar changes in the BE2C cell line 
(Sung et al., 2013). KLF4 is a stem cell marker and expected to be down regulated when 
differentiation is taken place. Interestingly, human neural stem cells (NSCs) exhibits high 
endogenous expression levels of KLF4, and together with other genes,  KLF4 can be reprogram NSCS 
to become a pluripotent termed  Induced Pluripotent Stem Cells (iPSCs) (Kuan et al., 2017). 
Cotterman and Knooepfler have reported that N-myc regulates the expression of KLF4 in both 
tumours and stem cells. They suggest that N-myc may enforce expression of stem-like state of KLF4 
driving undifferentiated phenotype of neuroblastoma (Cotterman and Knoepfler, 2009) .Thus, 
together with our results; the more differentiated pattern of neuroblastoma displays a decreased 
KLF4 expression. 
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Against our expectations, MYCN expression level remained unchanged after 3 days of RA treatment 
in culture. MYCN is a transcription factor known to be involved in the regulation of expression of 
many target genes. RA treatment is thought to down-regulate MYCN expression prior to enhancing 
differentiation. However, our results indicated no change in MYCN expression under RA influence. A 
paper has been published by Guglielmi et al in which the authors indicated a crucial need for MYCN 
in the onset of neuroblastoma differentiation (Guglielmi et al., 2014). In contrast to others (Thiele, 
Reynolds and Israel, 1985; Varlakhanova et al., 2010; Huang et al., 2011), Guglielmi et al reported 
that in the first few days of RA treatment- induced differentiation, MYCN expression elevates prior 
to differentiation. The authors suggested that MYCN expression is necessary for the initiation of 
neuronal differentiation as well as is important in the regulation of some target genes involved in 
the subsequent phases  (Guglielmi et al., 2014). Our results did not support the increased level of 
MYCN expression, however as we observed expression after 3 days only, it is possible that a rise in 
MYCN could have occurred prior to day 3 and levels may have begun to fall again by day 3.  
Expression of ROBO2 was increased by almost 4 fold in both cell lines; however the rise was not 
statistically significant following 3 days of RA in cell culture. Nevertheless, our results follow the 
trend of what seen in Sung et al paper and extended them to demonstrate similar changes in the 
BE2C cell line (Sung et al., 2013). ROBO gene has been studied extensively to have an important role 
in the axon guidance (Andrews, Barber and Parnavelas, 2007; Andrews et al., 2008; Curinga and 
Smith, 2008).  In particular, ROBO2 is shown to be involved in the regulation of axonogenesis and 
actin cytoskeleton pathways (Oe et al., 2005).The morphological changes observed in response to RA 
also support the trend towards an increase in ROBO2.  
Following the RA treatment, STMN4 was up regulated in both BE2C and IMR32 cells. Again this result 
was very similar to that published by Sung et al. STMN4 is identified to be essential in the regulation 
of dynamic microtubules which are known to be aid growth cone advance and responses to 
guidance cues (Duncan et al., 2013; Lin and Lee, 2016) 
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Changes observed in the gene expression of KLF4, STMN4 and ROBO2 correlated with the 
proliferation reduction and the morphological changes of the cells, and thus the results are largely 
consistent. Furthermore our results were in line with other published works indicating the 
significance of those markers in determining the differentiation status in neuroblastoma cells.  
3.3.3. RA drug delivery  
Because of the precipitation issue with RA, mentioned in section 2.5.5, and after exploring multiple 
methods for the delivery of drugs onto the CAM, it was found that the most successful was the 
injection of treatment underneath the allantois. As the allantois is filled with approximately 5-10ml 
of fluid, the injected solution of RA in PBS was hypothesised to be evenly distributed (Corral et al., 
2007). From experimentation with RA solubility it was found that by adding 1µl of 10mM RA solution 
to 1000µl of PBS resulted in no RA crystal formation.  This provided evidence that the distribution of 
RA in the allantoic fluid would result in the RA crystals dissolving in this volume.  
3.3.4. Retinoic Acid in tumours 
In order to demonstrate the suitability of the chick embryo xenograft model for therapeutic 
research, the model was assessed using RA. 
In line with culture experiments, tumours treated with RA had a reduction in proliferation seen 
through IHC staining using the antibody Ki67.  
Confocal microscopy supported the hypothesis of there being morphological alterations in the 
differential state of cells as an increase in neurite extensions was seen in cells within the tumours. 
Interestingly, the cell shape alterations were observed at 40µM dose of RA. Cells were less rounded 
and less clustered in appearance compared to the DMSO control group.  This supports previous work 
that RA is a successful treatment in the reduction of proliferation and increased differential state of 
cells within neuroblastoma tumours. In conclusion, RA has demonstrated the expected effect on 
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MYCN-amplified tumours so the need now is to find other potential therapeutic molecules of 
differentiation other RA resistant tumours e.g 11q deletion tumours (SKNAS cells). 
Taken together, many others have suggested the suitability of the chick embryo model for 
therapeutic research; however this is the first time, outside the field of angiogenesis, that the 
efficacy of a known compound used in the treatment of neuroblastoma has been reproduced in the 
chick embryo model. These positive results encourage the use of the CAM model for further 
screening of potential molecules treating resistant neuroblastoma prior to clinical testing.  
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Chapter Four: Results II 
Characterisation of some potential therapeutic molecules 
using the chick embryo model system 
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4.1. Introduction 
The work discussed in chapter 3 suggested that chick embryo model is a reliable model system that 
can be used in therapeutic research for neuroblastoma. In vivo, Retinoic acid effect was seen to 
induce differentiation and reduce proliferation of neuroblastoma CAM tumours (both BE2C and 
IMR32 tumours).   
As the principle has been proved following the use of Retinoic acid on CAM tumours, we decided to 
test new potential molecules that may boost the effect of RA further. Dysregulation in the 
phosphorylation state can lead to uncontrolled cell proliferation and survival (Tonks, 2006). 
Targeting the enzymes that control the phosphorylation in the cell cycle such as PTP may boost the 
effect of RA or open another potential route to treat neuroblastoma. Here, we hypothesised that the 
use of tyrosine phosphatase inhibitor, (Bis(maltolato)oxovanadium(IV) (BMOV)), may enhance the 
effect of Retinoic acid in decreasing proliferation and inducing differentiation of neuroblastoma 
tumours. 
The reduction of proliferation following Retinoic acid treatment is due to increasing the levels of 
p27(Kip1), an inhibitor of Cyclin-Dependent Kinases 2, 4 and 6 (Borriello et al., 2000) and reducing 
the proliferation is shown to be tightly linked with the differentiation state in normal development 
(Hardwick and Philpott, 2014). Furthermore, as mentioned previously, neuroblastoma may develop 
due to an aberration of the cell cycle that happens during normal development and prevents the 
cells from differentiating (Park et al., 2013). Given that CDKs are important regulators of the cell 
cycle which facilitate cell division. Hence we hypothesise here that inhibiting the cell cycle using 
agents such as CDK inhibitors may provide an additional or alternative approach to promoting 
differentiation of neuroblastoma.  The first molecules came to our attention to test was Palbociclib, 
a CDK 4/6 inhibitor. Palbociclib has been tested clinically in a range of cancers including breast 
cancer (Palanisamy, 2016). We included also another molecule to investigate which is RO-3306. RO-
3306 is an inhibitor of CDK1 and has been tested in some preclinical models (Kang et al., 2014). 
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Ultimately, we sought to investigate the effect of CDK4/6 and CDK1 inhibitors on neuroblastoma 
tumours using the chick embryo model. 
4.1.1. Aims of the chapter 
The aims of the work described in this chapter to:  
 Examine the effect of BMOV alone and in combination with RA on BE2C cells, in vitro and in 
vivo. 
 Investigate the effect of Palbociclib alone and in combination with RA on BE2C and SKNAS 
cells. 
 Investigate the effect of Palbociclib on BE2C and SKNAS CAM-tumours. 
 Determine the effect of RO-3306 on BE2C and SKNAS cells vitro and in vivo. 
4.2. Results 
4.2.1. Bis(maltolato)oxovanadium (IV) (BMOV) reduces cell proliferation and 
induces changes in morphology in MYCN-amplified cell line, BE2C cells 
Cells were cultured with BMOV alone and in combination with RA for a period of 72hr. Cells then 
observed using Leica DMIRB microscope to identify the effect of BMOV on cell morphology prior to 
carrying out proliferation assessment.  
Morphological assessment  
Cells with BMOV appeared to have similar or less pronounced morphological changes to that noticed 
with RA. The combination treatment showed more neurite outgrowths but not more strikingly than 
RA alone. As the morphological changes were not much different following the single of BMOV or 
even when combined with RA, we sought to investigate whether BMOV reduced proliferation using 
Ki67 staining (Figure4.1).  
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Proliferation assessment  
Assessing cell proliferation (Ki67) was crucial in determining the behaviour of the neuroblastoma in 
culture first before assessing their behaviour in vivo, following BMOV or BMOV+RA treatment. 
To quantify cell proliferation, we performed Ki67 staining in all BMOV alone, RA alone, BMOV+RA 
and control-treated cells. Cells were stained with a rabbit anti-Ki67 antibody and labelled with goat 
anti-rabbit (secondary antibody) conjugated with Alexa Fluor 594 (red) to enable identification of 
proliferating cells whilst counterstaining with DAPI allowed identification of the total number of 
nucleus cells present.  Cell counts were performed comparing the number of Ki67 positive cells to 
the number of DAPI stained cells in the treated as well as in control cells (Figure4.2 A). Overall, 
BMOV alone reduces the cell proliferation to 51% in BE2C cells compared to the control and a 
reduction of 60 % was observed in both RA treatment and the combination treatment (Figure4.2 B). 
Of note, there was no significant difference between the combination treatment compared to RA 
alone or BMOV alone.  
Ultimately, both morphological assessment and proliferation assessment suggested that the BMOV 
alone or in combination with RA reduced proliferation effectively and induced morphological 
changes compared to the control but no more effectively that RA alone. 
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Figure4.1 Changes in cell morphology of BE2C cells after72 hr of BMOV alone or in combination with 
RA treatment.  A represents the control (DMSO), B is RA alone (10µM), C is BMOV alone (10µM) and 
the D is BMOV (10µM) +RA treatment (10µM). Black arrows indicate morphological changes as neurite 
outgrowth. Scale bar =100µM. 
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Figure4.15 Effect of BMOV alone and in combination with RA treatment on BE2C cell proliferation.  
A  DAPI stained (blue) and Ki67 stained (red) BE2C cells following three days of treatment with 10µM 
BMOV alone or in combination with 10µM RA or DMSO.  B displayed the percentage of proliferative 
cells after setting the control to 100%, proliferation index = number of Ki67 positive expressed as a 
percentage of the total number of cells divided by the % in the control. Data presented relative to 
control. Data represents mean ± SEM (n=9). Each bar represents the mean ± SEM of three biological 
replicates and at least 9 fields per experiment. ***P⩽0.001.   
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4.2.2. Effect of BMOV alone and in combination with RA on gene expression of 
differentiation markers in BE2C cells 
To further investigate the effect of BMOV alone and in combination with RA on gene expression, 
quantitative assessment of cellular differentiation was undertaken using qPCR.  The same genes 
used in assessing the effect of RA alone in chapter 3 were used: KLF4, STMN4 and ROBO2 (Sung et 
al., 2013) and MYCN (Huang and Weiss, 2013).   
In keeping with these results, there was a significant change in the expression of the differentiation 
marker STMN4 but not ROBO2, KLF4 and MYCN in BMOV treated cells compared with DMSO treated 
cells (Figure4.3). The combination treatment induced a significant change in the expression of 
STMN4, KLF4 and MYCN but not ROBO2 compared with DMSO treated cells. In BMOV and RA 
combination treatment, STMN4 increased by 8 fold whereas KLF4 and MYCN decreased by 4.5 fold 
(Figure4.4).   
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  KLF4 MYCN ROBO2 STMN4 
Fold change -1.45 1.05 0.01 3.05 
Log Fold change -0.54 0.01 -0.41 1.50 
Regulation  no change no change no change up regulated 
 
Figure4.16 The effect of BMOV on gene expression of BE2C cells. A Relative mRNA levels for the 
target genes were determined by qPCR. Cells were cultured with 10µM of BMOV or DMSO for 3 days.  
At least three independent experiments (n = 3) were analysed for each gene and relative mRNA levels 
are displayed relative to GAPDH, UBC and HPRT1 and normalised to cells cultured for 3 days with 
DMSO(control). Each bar in the graph represents the log of normalised mean± SEM of three 
independent experiments. *P⩽0.05 compared with control. B Table gives a summary of the qPCR 
data for the 4 target genes for BE2C cells. 
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Figure4.4 The effect of BMOV and RA on gene expression of BE2C cells. A Relative mRNA levels for 
the target genes were determined by qPCR. Cells were cultured with 10µM of BMOV+ 10µM of RA or 
DMSO for 3 days.  At least three independent experiments (n = 3) were analysed for each gene and 
relative mRNA levels are displayed relative to GAPDH, UBC and HPRT1 and normalised to cells 
cultured for 3 days with DMSO(control). Each bar in the graph represents the log of normalised 
mean± SEM of three independent experiments. **P⩽0.01 and ***P⩽0.001 compared with control. B 
Table gives a summary of the qPCR data for the 4 target genes for BE2C cells. 
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4.2.3. Assessing the effect of BMOV alone and in combination with RA on 
MYCN amplified cell line in vivo using the chick embryo model 
In culture, treatment with the BMOV and RA has suggested that differentiation markers are sensitive 
to the synergic effect of BMOV and RA.  Next we aimed to test whether BE2C cells respond to BMOV 
alone and BMOV+RA in vivo.  Tumours were grown on the CAM as described in chapter 2 using GFP-
labelled BE2C cells.  
The treatment initially started using BMOV alone.  Previously we have found that using four times 
the in vitro concentration of RA in the chick CAM tumours gave a significant reduction in cell 
proliferation and change in the differentiation markers (Swadi et al., 2018). We therefore injected 
40µM of BMOV to the allantois of the embryos at E11 and E13.  The embryos were observed daily 
under the microscope following the treatment.  It was noticed there was a drop in survival rate 
following the second treatment with BMOV. The vast majority of embryos did not survive up to E14 
hence indicting a toxic effect of BMOV in vivo.   
As the BMOV revealed a toxic effect in vivo, the search was started to test new active molecules that 
can tackle neuroblastoma. CDK4 found to be amplified in neuroblastoma cells  (Molenaar, Koster, 
Ebus, et al., 2012) and because CDK4 synergise together with CDK6 in pushing the cell cycle toward 
mitosis, we sought to inhibit both CDK4 and CDK6 using selective inhibitor of CDK4/6, Palbociclib. 
Here we tested the effect of Palbociclib on neuroblastoma cells in vitro and in vivo.     
4.2.4. Palbociclib reduces cell proliferation and induces changes in 
morphology in MYCN-amplified cell line and cell death in non-MYCN-amplified 
cell line 
Morphology assessment  
We tested Palbociclib in two neuroblastoma cell lines, the RA-sensitive cell line (MYCN-amplified cell 
line, BE2C) and the RA-resistant cell line (non- MYCN-amplified cell line SKNAS). SKNAS cells have not 
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been found to differentiate or indeed respond at all to RA alone (Clark, Daga and Stoker, 2013) so it 
was interesting to test the effect of Palbociclib.  GFP-labelled BE2C and SKNAS cells were cultured as 
described in chapter 2 using 24-well plates. Treatment of Palbociclib was used as 0, 5, 7.5,10 and 
20µM to determine the optimal concentration that affects the neuroblastoma cell lines. In BE2C 
cells, 5µM Palbociclib induced neurite outgrowth strikingly compared to control (PBS) treated cells. 
Similarly, 7.5 µM Palbociclib showed a similar effect to that observed with 5µM. In contrast, this 
effect started to change from differentiation induction to induction of cell death following the 
increase of Palbociclib dose. 10 and 20µM Palbociclib resulted in massive cell death in a dose-
dependent manner (Figure4.5). However, in SKNAS cells, the effect of cell death induction was 
observed even when low concentration (5µM) of Palbociclib was used (Figure4.6).    
Following observation of cell death by phase microscopy, we sought to investigate the cell death/cell 
viably after applying the treatment of Palbociclib using the MTT assay. MTT is a colorimetric assay 
for assessing cell metabolic activity. NAD(P)H-dependent cellular oxidase enzymes reflect the 
number of viable cells present. Thus MTT assay measures NAD(P)H-dependent cellular 
oxidoreductase by converting this to formazan crystals and then the latter dissolves in SDS to form 
soluble solution to be measured using Spectrophotometer. Cell density was optimised using MTT 
assay prior to carrying out experiments.  
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Figure4.5 BE2C cells after 72hr of treatment with different concentration of Palbociclib (CDK4/6 
inhibitor).  5µM and 7.5µM are showing the morphological changes as the neurite outgrowth.10µM 
showing less of differentiation than cell death. The latter effect has been observed extensively within 
the 20µM concentration. The red arrows indicate dead cells. Scale bar is 250µm. 
Figure4.6 SKNAS cells after 72hr of treatment with different concentration of Palbociclib (CDK4/6 
inhibitor).  Palbociclib induced cell death at 5 and 7.5µM and this effect observed to be extensive 
at10 and 20µM concentrations. The red arrows indicate dead cells. Scale bar is 250µm. 
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4.5.5. Optimising the cell density for MTT assay 
To perform the MTT and for best results, an optimisation step was required to identify the optimum 
cell number to plate out for the experiments. Selection of a cell number that falls within the linear 
portion of the curve (i.e. providing values between the range of 0.75 and 1.25) limiting the lag phase 
following plating of the cells. Both cell lines were seeded for 24hrs in flatted bottom multi-well plate 
at 10 serial two-fold dilutions starting with stock solution of 5x106 to end up with 4.88x103. Each 
dilution was performed as triplicate with three wells of blank control (culture medium) and 
incubated at 37C° and 5%CO2. After 24 hrs, 10 µL of MTT reagent has added to the wells and 
incubated for 4hrs in order to form the formazan crystals, 100µl of 10% SDS solution have added to 
each well and incubated at room temperature overnight. The plate was read at 570nm and the blank 
was subtracted from the experimental readings.  The optimal density after 24hr was determined to 
be 1.56x105cells/ml for both BE2C and SNKAS cells (Figure4.7).   
Our results from the preliminary optimising experiment suggested that 1.56x105 cells/ml is the best 
after 24 hr, however, because of the time  of the real experiment is much longer (72hr) than the 
preliminary and to do not exceed the maximum reading (OD) of the plate reader, we decided to set 
the cells as 0.5x105 cells/ml. 
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Figure 4.7 The optimisation of cell density using MTT assay. BE2C and SKANS cells were seeded for 
24hr in flatted bottom multi-well plate at 10 serial two-fold dilutions starting with stock solution 
from 5x106 to 4.88x103cells/ml. Each dilution was performed as triplicate with three wells of blank 
control (culture medium). The optimum cell density after 24hr was 1.56x105cells/ml. 
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4.2.6. Increasing Palbociclib concentration elicits a reduction in cell viability in 
both BE2C and SKNAS cells 
SKNAS and BE2C cells were seeded in cover slips inside 96 well plate at 0.5x105 cells/ml for 24hr 
prior to drug administration. After 24hr, cells were treated fresh medium including 0, 1, 5, 10, and 
20µM of Palbociclib in order to determine the cell viability following the treatment. Palbociclib 
treated cells with the presence of controls were incubated for 72hr (refeed after 48hr) at 5%CO2 and 
37C°. Following this, MTT assay was carried out as described previously. MTT results indicated that 
increasing the concentration of Palbociclib reduces the cell viability and prompts cell death as shown 
in Figure4.8. In BE2C cells, the cell viability has decreased by 30% compared to the control following 
the application of 5µM of Palbociclib whereas SKNAS cell viability was reduced by 20% under similar 
condition. At 20µM of Palbociclib, however, both BE2C and SKNAS cell viability has dropped 
significantly by more than 50% compared to the control.  
In keeping with MTT assay results we sought to identify the proliferation status of BE2C and SKNAS 
cells following the treatment of Palbociclib.  
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Figure4.8 Cytotoxicity of Palbociclib to Neuroblastoma cell lines (BE2C and SKNAS). Cells were 
treated with different doses of Palbociclib for 72hr as indicated in the Materials and Methods. Green 
line is SKNAS and Red line is BE2C. The graph represents cell viability based on the MTT assay. Each 
point represents a mean value and standard error of 3 experiments with 3 replicates per 
concentration. Cell viability of BE2C in 5, 10, and 20µM are significantly different compared to the 
control. SKNAS cell viability has dropped more significantly at 20 µM compared to control according 
to ANOVA Tukey’s test. *P⩽0.05 **P⩽0.01 and ***P⩽0.001. 
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4.2.7. Cell death assessment following Palbociclib  
To further investigate the cell death of BE2C and SKNAS following Palbociclib treatment, we 
performed Annexin V staining. When apoptosis occurs, phosphatidylserine (PS) is translocated from 
the inner side of the plasma membrane to the outer layer exposing PS at the surface of the cell. 
Hence, we used Annexin V that can stain the translocated PS  in cells to identify apoptotic event.  
Cells were seeded as for the proliferation assessment. Apoptosis was noticed following the 
application of Palbociclib on both cell lines (Figure4.12).  
Ultimately, we showed that Palbociclib induces apoptosis as well as reduces cellular proliferation 
and induces differentiation at the lowest concentration (5µM) for BE2C however for the SKNAS cells; 
Palbociclib promotes apoptosis in them.   
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Figure4.9  Palbociclib induces apoptosis in BE2C and SKNAS cells. A is BE2C and B is SKNAS. 
Immunofluorescent analysis of live BE2C and SKNAS cells using Annexin V-FITC Conjugate 
(green) and Hoechst 33342 (blue). Cells were treated for 72 h with media contains either PBS 
as control or Palbociclib (5µM). The staining shows apoptotic nucleus after Palbociclib 
application on both BE2C and SKNAS cells. Scale bar =250µM.  
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4.2.8. Proliferation assessment of Palbociclib alone and in combination with 
RA 
Palbociclib alone or in combination with RA induced changes in cell morphology on BE2C cells. Here 
we sought to investigate its effect on proliferation using Ki67 staining.  
Prior to treatment, cells were seeded on coverslips inside 24 well plate as described in chapter 2. 
Cell then treated with Palbociclib and left for further 72hr at 5%CO2 and 37C°. Following that, cells 
were observed first under the inverted microscope, initial observation showed lots of cells were 
floating in the top of the medium in each well in both cell lines except 5µM Palbociclib and BE2C. 
The number of floating cells increases where the concentration of the drug was higher.  
Staining was carried out using Ki67 as primary antibody and Goat anti Rabbit as a secondary 
antibody and slide kept in dark overnight. Under the microscope it was pretty difficult to distinguish 
the nucleus of cells in both cell lines after Palbociclib treatment (except for 5µM in BE2C) because of 
the abnormality on cell shape and nuclei fragmentation. Therefore, proliferation quantification was 
only carried out for the 5µM concentration in BE2C cells (Figure4.8 A&B).  
Interestingly, Palbociclib has different effect on BE2C cells from SKNAS; it induces differentiation and 
reduces cellular proliferation at the lowest concentration (5µM) in BE2C however for the SKNAS 
cells, Palbociclib promotes cell death.   
As the 5µM concentration of Palbociclib indicates a significant reduction in cell proliferation, we 
sought to test this concentration in combination with RA (10µM) on BE2C cells. Overall, both 
Palbociclib alone and the combination treatment reduced the cell proliferation to 40% in BE2C cells 
compared to the control, suggesting there was neither a synergistic nor an additive effect between 
the two drugs (Figure4.8 A&B). 
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Figure4.10 Effect of Palbociclib alone and in combination with RA treatment on BE2C cell 
proliferation.  A  GFP stained green, DAPI stained (blue) and Ki67 stained (red) BE2C cells following 
three days of treatment with 5µM Palbociclib alone or in combination with 10µM RA or DMSO.  B 
displayed the percentage of proliferative cells after setting the control to 100%, proliferation index = 
number of Ki67 positive expressed as a percentage of the total number of cells divided by the % in the 
control. Data presented relative to control. Data represents mean ± SEM (n=9). Each bar represents 
the mean ± SEM of three biological replicates and at least 9 fields per experiment. ***P<0.001.   
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4.2.9. Palbociclib effect on gene expression of differentiation markers in BE2C 
cells 
To investigate the effect of Palbociclib alone and in combination with RA on gene expression, 
quantitative assessment of cellular differentiation was undertaken using qPCR.  The same genes 
used in assessing the effect of BMOV and RA this chapter and in chapter 3 were used: KLF4, STMN4 
and ROBO2 (Sung et al., 2013) and MYCN (Huang and Weiss, 2013).   
 
In previous results, we showed that Palbociclib alone and in combination with RA treatment reduced 
proliferation significantly and induced evident morphological changes at 5µM concentration. In 
support to these results, here we observed a significant change in the expression of the 
differentiation marker STMN4 and ROBO2 and stem cell marker KLF4 but not MYCN in Palbociclib 
alone and Palbociclib plus RA treated cells compared with control treated cells (Figure4.10, 4.11). In 
Palbociclib alone treatment, KLF4 decreased by 3 fold whereas STMN4 and ROBO2 increased by 4 
fold (Figure4.10). Similarly, the combination treatment decreased KLF4 by 2 fold and increased 
STMN4 and ROBO by 5 fold. Although there was no significant difference between the single and the 
combination treatment, indicating that the combination do not have a synergetic or additive effects 
on gene expression (Figure4.11). 
 
In keeping with the positive results found with Palbociclib as a CDK4/6 inhibitor on BE2C and SKNAS 
cells, we sought to investigate the effect of another CDK inhibitor on neuroblastoma cells. 
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  KLF4 MYCN ROBO2 STMN4 
Fold change -3 -1.21 4.07 4.26 
Log fold change -1.58 -0.28 2.03 2.09 
Regulation down regulated no change up regulated up regulated 
 
Figure4.11 The effect of Palbociclib on gene expression of BE2C cells. A Relative mRNA levels for the 
target genes were determined by qPCR. Cells were cultured with 5µM of Palbociclib or PBS for 3 days.  
At least three independent experiments (n = 3) were analysed for each gene and relative mRNA levels 
are displayed relative to GAPDH, UBC and HPRT1 and normalised to cells cultured for 3 days with PBS 
(control). Each bar in the graph represents the log of normalised mean± SEM of three independent 
experiments. *P⩽0.05 and ***P⩽0.001 compared with control. B Table gives a summary of the qPCR 
data for the 4 target genes for BE2C cells. 
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KLF4 MYCN ROBO2 STMN4 
Fold change -1.68 -1.24 4.76 4.94 
Log fold change -0.75 -0.31 2.25 2.30 
Regulation down regulated no change  up regulated up regulated 
 
Figure4.12 The effect of Palbociclib in combination with Retinoic acid on gene expression of BE2C 
cells. A Relative mRNA levels for the target genes were determined by qPCR. Cells were cultured with 
5µM of Palbociclib+10µM of RA or PBS for 3 days.  At least three independent experiments (n = 3) 
were analysed for each gene and relative mRNA levels are displayed relative to GAPDH, UBC and 
HPRT1 and normalised to cells cultured for 3 days with PBS (control). Each bar in the graph 
represents the log of normalised mean± SEM of three independent experiments. *P⩽0.05 **P⩽0.01 
and ***P⩽0.001 compared with control. B Table gives a summary of the qPCR data for the 4 target 
genes for BE2C cells 
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4.2.10. RO-3306 induces cell death in both BE2C and SKNAS cells 
Both BE2C and SKNAS cells were cultured with RO-3306 for a period of 72hr at 0, 5, 10 and 20µM to 
determine the optimal concentration that has an effect on these cell lines. Cells then observed using 
Leica DMIRB microscope to identify the effect of RO-3306 on cell morphology prior to carrying out 
proliferation assessment.  
Morphology assessment  
As shown in Figure4 .13 the response of both BE2C and SKNAS to RO-3306 was cell death at 5µm. A 
reduction of living cell was noticed to increase significantly as the concentration of RO-3306 
increased. Following the observation of cell death by inverted microscopy, we sought to investigate 
the cell death/cell viably after applying the treatment of RO-3306 using MTT assay.  
4.4.11. RO-3306 reduces cell viability in both BE2C and SKNAS cells 
SKNAS and BE2C cells were seeded in cover slips inside 96 well plate at 0.5x105 cells/ml for 24hr 
prior to drug administration. After 24hr, cells were treated fresh medium including 0, 1, 5, 10, and 
20µM of RO-3306 in order to determine the cell availably following the treatment. RO-3306 treated 
cells with the presence of controls were incubated for 72hr at 5%CO2 and 37C°. Following this, MTT 
assay was carried out as described previously. MTT results indicated that increasing the 
concentration of RO-3306 reduces the cell viability and prompts cell death as shown in Figure4.14. In 
both BE2C and SKNAS cells, the cell viability has decreased by more than 40% compared to the 
control following the application of 5µM of RO-3306. At 20µM of Palbociclib, both BE2C and SKNAS 
cell viability has dropped significantly by more than 60% compared to the control.  
In keeping with the morphology assessment and MTT assay results we sought to investigate the 
extent of cell death further following RO-3306 treatment using Annexin v staining. 
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Figure4.13 The response of BE2C and SKNAS cells after 72hr of treatment with different 
concentration of RO-3306 (CDK1 inhibitor).  RO-3306 induced cell death at 5µM in both 
cell lines and this effect observed to be extensive at 10 and 20µM concentrations. Scale 
bar is 250µm. 
 
142 
 
 
 
0 5 10 15 20 25
0.00
0.25
0.50
0.75
1.00
1.25
BE2C
SKNAS
RO-3306 (µM)
A
b
s
o
rb
a
n
c
e
 (
5
7
0
n
m
)
 
Figure 4. 14 Cytotoxicity of RO-3306 to Neuroblastoma cell lines (BE2C and SKNAS). Cells were 
treated with different doses of RO-33306 for 72hr as indicated in the Materials and Methods. Green 
line is SKNAS and Red line is BE2C. The graph represents cell viability based on the MTT assay. Each 
point represents a mean value and standard error of 3 experiments with 3 replicates per 
concentration. Cell viability at 5, 10, and 20µM are significantly reduced in both cell lines compared 
to control according to ANOVA Tukey’s test. *P⩽0.05 **P⩽0.01 and ***P⩽0.001. 
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4.2.12 Cell death assessment following RO-3306 
To further investigate the cell death of BE2C and SKNAS following RO-3306 treatment, we performed 
Annexin V staining. As mentioned previously in section 4.3.9, we used Annexin V to identify 
apoptosis event in cells. Cells were seeded as for the proliferation assessment. Apoptosis effect was 
noticed following the application of RO-3306 on both cell lines (Figure4.15).  
To conclude, RO-3306 reduced cell viability and induced cell death in both MYCN-amplified cell line 
(BE2C) and non-MYCN amplified cell line (SKNAS). Interestingly, 5µM RO-3306, which is CDK1 
inhibitor, has shown different effect on BE2C cells to that observed with Palbocilcib (CDK4/6 
inhibitor) where induce differentiation.  
 
In keeping with the effect of Palbociclib on SKNAS in terms of cell death, we decided to reduce the 
exposure time for both Palbociclib and RO-3306 to 24hr instead of 72 followed by 48 in normal 
media. Here, we sought to investigate whether 24hr of Palbociclib or RO-3306 can reduce the cell 
proliferation effectively and potentially prompt differentiation. 
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Figure4.15 RO-3306 induces apoptosis in BE2C and SKNAS cells. A is BE2C and B is SKNAS. 
Immunofluorescent analysis of live BE2C and SKNAS cells using Annexin V-FITC Conjugate 
(green) and Hoechst 33342 (blue). Cells were treated for 72h with media contains either 
DMSO as control or RO-3306 (5µM). The staining shows apoptotic nucleus after RO-3306 
application on both BE2C and SKNAS cells. Scale bar =250µM.  
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4.2.13. Palbociclib and RO-3306 reduce cell proliferation of BE2C and SKNAS 
after 24hr treatment  
Prior to treatment, cells were seeded on coverslips inside 24 well plate as described in chapter 2. 
Cell were then treated with 5µM Palbociclib (or PBS as a control) and RO-3306 (or DMSO as a 
control) and left for further 24hr at 5%CO2 and 37C°. Following that, old medium contains drug was 
discarded; cells were washed and left with fresh normal medium for further 48hr.  
To quantify cell proliferation, we performed Ki67 staining in all conditions. Cells were stained with a 
rabbit anti-Ki67 antibody and labelled with goat anti-rabbit (secondary antibody) conjugated with 
Alexa Fluor 594 (red) to enable identification of proliferating cells whilst counterstaining with DAPI 
allowed identification of the total number of nucleus cells present.  Cell counts were performed 
comparing the number of Ki67 positive cells to the number of DAPI stained cells in the treated as 
well as in control cells (Figure4.16 A). Overall, both of Palbociclib and RO-3306 reduce the cell 
proliferation significantly in both cell lines. For instance, in BE2C, cell proliferation has been reduced 
by 45% and 60% compared to the controls following the administration of Palbociclib and RO-3306 
respectively. In SKNAS, however, both Palbociclib and RO-3306 reduced cell proliferation by more 
than 40% (Figure4.16 B).  
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Figure4.16 Effect of Palbociclib and RO-3306 treatment on BE2C and SKNAS cell proliferation.  A 
displayed the percentage of BE2C proliferative cells after setting the control (PBS and DMSO) to 
100%, proliferation index = number of Ki67 positive expressed as a percentage of the total number of 
cells divided by the % in the control. Data presented relative to control. Data represents mean ± SEM 
(n=9). Each bar represents the mean ± SEM of three biological replicates and at least 9 fields per 
experiment.  B is same for SKNAS. **P⩽0.01.  
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4.2.14. Effect of Palbociclib and RO-3306 on cell proliferation in BE2C and 
SKNAS tumours  
Similar to RA treatment, we used two injections of 20µM (≡6mg/kg) Palbociclib and RO-3306 into the 
allantois sac at E11 and E13. This dose has been calculated in respect to culture experiments. The 
chick embryos tolerated the doses well with no significant change in embryo survival.  Tumours were 
harvested and analysed at E14. To quantify proliferation following the treatments Ki67 staining was 
carried out on tumour sections. 
A significant reduction in cell proliferation was revealed in response to both Palbociclib and RO-3306 
(Figure4.17 &18).  Palbociclib reduced cell proliferation of BE2C cells by 35% (Figure4.17).  
Surprisingly RO-3306 proved more efficient, reducing cell proliferation almost 50%.   
Similar experiments were carried out with SKNAS cells.  The reduction in proliferation was similar to 
that seen with BE2C cells (40-50%) although there was no statistical significance between the two 
inhibitors (Figure4.18). 
Since RO-3306 reduces cell survival in culture we used TUNEL staining to test for apoptosis of cells in 
the tumours.   
4.2.15 Cell death assessment in tumours following Palbociclib and RO-3306 
Similar to proliferation assessment, TUNEL assay was carried out on tumour sections following the 
treatment to determine apoptotic (programmed) cell death by measuring nuclear DNA 
fragmentation. Surprisingly, unlike in culture, the number of apoptosing cells was very small.  For 
BE2C cells it was less than 1% and neither inhibitor prompted a significant increase (Figure 4.19).  
For SKNAS cells, Palbociclib doubled the number of apoptosing cells to 1.3% but RO-3306 had no 
effect (Figure4.20).    
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Figure4.17 Palbociclib and RO-3306 reduce cell proliferation of BE2C cells forming tumours. A FFPE 
BE2C sections stained with Ki67 (brown). GFP-labelled BE2C cells were implanted on the CAM of E7 
chick embryos. Treatments were two injections (20µM Palbociclib or 20µM RO-3306 CDK1i plus 
control (PBS or DMSO)) into the allantoic membrane of embryos at E11 and E13. B Quantification of 
Ki67-positive cells out of the total cell number indicates a reduction in cell proliferation following 
treatment with 20µM Palbociclib or 20 µM RO-3306 compared to their control.  Each bar represents 
the mean ±SEM of three independent experiments and at least 9 fields counted per experiment, 
*P⩽0.05 and ***P⩽0.001 compared with the control. Scale bar is 100µm.  
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Figure4.18 Palbociclib and RO-3306 reduce cell proliferation of SKNAS cells forming tumours. A 
FFPE SKNAS sections stained with Ki67 (brown). GFP-labelled SKNAS cells were implanted on the CAM 
of E7 chick embryos. Treatments were two injections (20µM Palbociclib or 20µM RO-3306 plus 
control (PBS or DMSO)) into the allantoic membrane of embryos at E11 and E13. B Quantification of 
Ki67-positive cells out of the total cell number indicates a reduction in cell proliferation following 
treatment with 20µM Palbociclib and 20µM RO-3306 compared to their controls.  Each bar 
represents the mean ±SEM of three independent experiments (n = 3) and at least 9 fields counted per 
experiment, *P⩽0.05 and **P⩽0.01 compared with the control. Scale bar =100µm. 
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Figure 4.19 Palbociclib and RO-3306 effect on cell death of BE2C cells forming tumours. A FFPE 
BE2C sections stained with TUNEL staining (brown). a and b indicate the positive (DNase-treated 
cells) and negative control of staining. c is DMSO, d is RO-3306, e is PBS and f is Palbociclib. B 
Quantification of TUNEL-positive cells out of the total cell number.  Each bar represents the mean 
±SEM of three independent experiments (n = 3) and at least 9 fields counted per experiment. Scale 
bar =250µm. 
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Figure4.20  Palbociclib and RO-3306 effect on cell death of SKNAS cells forming tumours. A FFPE 
SKNAS sections stained with TUNEL staining (brown). a and b indicate the positive (DNase-treated 
cells) and negative control of staining. c is DMSO, d is RO-3306, e is PBS and f is Palbociclib. B 
Quantification of TUNEL-positive cells out of the total cell number.  Each bar represents the mean 
±SEM of three independent experiments (n = 3) and at least 9 fields counted per experiment, 
*P⩽0.05 and **P⩽0.01 compared with the control. Scale bar =250µm. 
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4.3. Discussion  
The chick embryo model has been proven to be a powerful tool which can be readily grow tumours 
and analyse the effect of drugs efficiently. Retinoic acid is a standard treatment used in clinic to treat 
high- risk disease although some patients did not respond to such treatment which means additional 
treatment is needed urgently. Here in this chapter we aimed to evaluate the effect of new and 
potential therapeutic molecules on neuroblastoma behaviour in vitro and in vivo.  
We quantified the effect of vanadium-based PTP inhibitors such as BMOV in combination with RA in 
vitro, and found that BMOV alone or in combination with RA inhibits proliferation and induces 
change in gene expression of BE2C cells, but there was no significant difference between BMOV and 
RA. Thus we begun to investigate the effect of other targets and molecules such Cyclin- dependent 
kinase inhibitors. By introducing Palbociclib (CDK4/6 inhibitor) and RO-33306 (CDK1 inhibitor) into 
tumours formed on the CAM, the proliferation has been reduced significantly by25% and 50% 
respectively in BE2C tumours whereas in SKNAS tumours the reduction in proliferation 40% 
following Palbociclib treatment and 25% following RO-33306. We showed that CDK4/6 inhibitor 
changes the expression of differentiation markers in BE2C cells. The effect of CDK inhibitors was 
more pronounced than the effect of RA and in addition CDK inhibitors shown to have an effect on 
RA- resistant cell line, the SKNAS cells. Thus, Cyclin- dependent kinase inhibitors seen to have the 
potential to provide an alternative treatment for the RA- resistant neuroblastoma tumours.  
4.3.1. Bis(maltolato)oxovanadium (IV)  
In culture, three days of 10µMBMOV alone administration showed small morphological changes 
compared to the combination between BMOV and RA in BE2C cells. The combination of BMOV with 
RAis thought to enhance both differentiation and senescence in neuroblastoma cells (Clark, Daga 
and Stoker, 2013). The reduction in proliferation is thought to be tightly associated with the 
initiation of differentiation during normal development (Hardwick and Philpott, 2014). Hence, cell 
proliferation has been quantified to more accurately provide insight into the differentiation status. 
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The results indicated a reduction in cellular proliferation in BE2C cells following 72hr with 10µM 
BMOV alone or BMOV in combination with RA. Thus, it is suggested that differentiation is taken 
place. 
Interestingly, Clark et al found that all the tested cell lines exhibited a robust p21 response to BMOV, 
and a further p21 elevation after the combination treatment, indicating the role of RA in inducing an 
increase of p21 (Clark, Daga and Stoker, 2013). Some in vitro studies reported a cytotoxicity of 
prolonged exposure to BMOV against three human cancer cells lines (Cruz et al, 1995). Nevertheless, 
in the same study, continuous exposure of human bone marrow cells to BMOV was seen to have 
only a slight myelosuppressive effect at concentrations of BMOV that were cytotoxic to all three 
tumour cell lines. These findings confirmed the potential anticancer effect of BMOV against cancer 
cells. 
Change in the levels of target gene expression after exposure to BMOV alone was detected, 
although the change was not significant except for STMN4. However, BMOV in combination with RA 
showed a more pronounced change in the expression of the differentiation markers KLF4 and 
STMN4 and MYCN but not ROBO2 compared with DMSO treated cells. This supports what seen in 
the morphology as the combination treatment showed more of outgrowth neurites compared to the 
single treatment of BMOV. 
As we showed the effect of BMOV in vitro, in vivo effect of BMOV could not be observed on tumours 
because of toxicity.  We have used 12mg/Kg (40µM) of BMOV injected to the allantois cavity of chick 
embryos at E11 and E13. The survival dropped significantly following the first injection. These 
findings are in support to the toxicity observed with intraperitoneal administration of (200 mg/kg) 
BMOV in which rats were lethargic and under stress immediately following injection and this was 
followed by weight loss (Chakraborty et al., 2006). Similarly, rapid bolus intravenously injections of 
BMOV at 10mg/kg to rats induced sluggish and mild cyanotic and had diarrhoea for 2-4hr after 
administration of the drugs (Jackson et al., 1997). In contrast, 10mg/kg of BMOV; five times per 
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week for 4weeks, delays tumour progression and prolongs survival time in severe combined 
immunodeficient mouse xenograft models of human malignant glioblastoma (D’Cruz and Uckun, 
2002). Despite numerous pharmacokinetic and toxicity studies in animal models, more clear 
understanding of the relevant biological and biochemical basis of vanadium is needed to the 
contribution in cancer treatment.  
4.3.2. Palbociclib (CDK4/6 inhibitor) 
RA-induce differentiation is commonly used in clinic to treat high-risk neuroblastoma patients 
however it has failed sometimes to treat resistant tumours. CDK4/6 is shown to be involved in the 
tumorigenesis of neuroblastoma (Cheung and Dyer, 2013; Rader et al., 2013), suggesting that 
neuroblastoma tumours may result in response to activated oncogenes in the process of cell cycle 
regulation. Thus, inhibiting CDK4/6 could play a role in neuroblastoma treatment. 
Within differentiation context and to tackle resistance to RA of neuroblastoma, we selected 
Palbociclib, a selective CDK4/6 inhibitor that shown promising antitumor activity in several clinical 
trials in other cancer types (Musgrove et al., 2011). Currently, Palbociclib is used in clinic to induce 
differentiation and treat the aggressive form of breast cancer (Finn et al., 2015). In culture, we have 
shown that 5µMof Palbociclib alone or in combination with the well characterised drug RA (10µM) 
induced neurites outgrowth strikingly compared to control, and moreover, reduced proliferation in 
BE2C cells. Neuroblastoma cell lines have been shown to have a variable sensitivity to Palbociclib 
with BE2C being more resistant than most (Rihani et al., 2015). Nevertheless Palbociclib proved to 
reduce cell proliferation and induce differentiation for BE2C cells and whilst for SKNAS cells it 
reduced cell viability and initiated apoptosis. Of note, BE2C cells harbour a p53 mutation which may 
be one of the reasons why this cell line showed less level of apoptosis (Carr et al., 2006). 
Interestingly, at lower concentrations (1µm) in culture there was no change in either proliferation or 
decrease in cell viability.  
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Since Palbociclib reduced cell proliferation in BE2C cells and induced some morphological changes, it 
was logical to investigate the differentiation pathway. MYCN expression did not change in response 
to the treatment however KLF4 was decreased by 3 fold. Both STMN4 and ROBO2 were increased by 
almost 5 fold following the treatment of Palbociclib or Palbociclib with RA.  
In support to previous result, although Palbociclib dose used in mouse models is far much than that 
we used (75-120mg/kg)(Bollard et al., 2017; Cook Sangar et al., 2017) our in vivo experiments 
showed that four times (20µM≡6mg/kg)) the concentration used in culture decreased cell 
proliferation significantly by 25% in BE2C and by 40% SKNAS tumours.  
Interestingly, Palbociclib inhibited tumour progression and reduced proliferation by >80% in  a 
preclinical trail performed on myeloma patients (Niesvizky et al., 2018). Others, have found that 
inhibiting CDK4/6 using another CDK4/6 inhibitor such as LEE011 on MYCN amplified neuroblastoma 
tumours formed in murine xenograft models reduced the tumour growth effectively (Rader et al., 
2013).  
4.3.3. RO-3306 (CDK1 inhibitor) 
RO-3306, CDK1 inhibitor, was thought to prompt cell differentiation in neuroblastoma cell lines 
(Wylie et al., 2015), however, in culture, RO-3306 at 5µM promoted cytotoxicity and apoptosis in 
both MYCN amplified and non-MYCN amplified neuroblastoma cells. CDK1 plays a key role in 
regulating the cell cycle by governing the transition from G2 to M phase, and the use of CDK1 
inhibitors induce G2 arrest in various cell types including fibroblasts, retinal pigmented epithelial 
cells, lymphoma cells, and hepatoblastoma cells (Goga et al., 2007). In this study, the authors 
showed that apoptotic events were only detected in the cells expressing MYC proto-oncogene. In 
neuroblastoma, MYCN expression level denotes aggressive and  invasive form of neuroblastoma,  
and moreover MYCN amplification is the primary adverse prognostic indicator for neuroblastomas 
(Shimada, 2003). MYCN amplification is significantly associated with low level of p21 induction which 
is a CDK1 inhibitor, and failed G1 arrest in neuroblastoma cell lines (Tweddle et al., 2001; Bell et al., 
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2006). However, CDK1 inhibition by RO-3306 induced cellular apoptosis only in tumour cells with 
MYCN amplification but not in MYCN single copy cells (Otto et al., 2009). In contrast to the previous 
study, we observed that CDK1 inhibitor induced cellular apoptosis irrespective to MYCN status. In 
support to our findings, a study conducted mRNA profiling of primary neuroblastoma tumours 
showed that high expression of CDK1 linked to significantly worse outcome and this was 
independent of the MYCN amplification status. Nevertheless, CDK1 expression was significantly 
higher in MYCN-amplified tumour. Of the tested genes, only CDK4 was significantly associated with 
MYCN amplification status (Schwermer et al., 2015). In the same study, Schwermer et al also 
reported that viability was dropped significantly in neuroblastoma cell lines following knocking down 
CDK1 in vitro, and similar effect was noticed when using inhibiting CDK1 with RO-3306. Because the 
cell lines in our study were either an amplified or single copy of MYCN showed apoptosis after RO-
3306, then MYCN copy number is not necessarily correlated with its expression levels (Cohn et al., 
2000; Hansford et al., 2004; Chen, Tsai and Tseng, 2013).The copy number might not be the most 
critical factor in CDK1 inhibition induced apoptosis. However, the expression levels of MYCN might 
be more important (Chen, Tsai and Tseng, 2013).  
Whilst two doses of 20µM (≡6mg/kg) of RO-3306 reduced cell proliferation significantly in tumours 
others demonstrated that using 4mg/kg, seven injection per mice at four-day intervals reduced 
tumour volume significantly (Yang et al., 2016).  
Surprisingly there was little or no increase in apoptosis in vivo.  This may be due to differing 
concentration of inhibitor experienced by the cells however at lower concentrations in culture (1µm) 
there was no change in either proliferation or decrease in cell viability. Therefore, the cellular 
response to agents in 3D tumour environment can be different to that seen in 2D culture 
environment as described by others (Gandellini et al., 2015; Anastasiou, 2017). 
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Overall, in order to boost the differentiation therapy of RA and to tackle the aggressive and resistant 
form of neuroblastoma tumours, it is highly significant employing new agents involved in mediating 
cell cycle and differentiation. 
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Chapter Five: Results III 
Hypoxic preconditioning promotes metastasis of 
neuroblastoma cells and cyclin-dependent kinase 
inhibitors reverse this in vivo 
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5.1. Introduction 
The ability of the chick embryo chorioallantoic membrane to efficiently support the growth of 
grafted-tumour cells greatly facilitates further analysis of drug efficacy against tumour growth. Upon 
tumour progression, cells become invasive and penetrate surrounding tissues to colonise distant 
tissues. This phenomenon is termed metastasis and involves several steps beginning with initial 
separation from the primary tumour, diffusion through surrounding tissues and penetration of their 
basement membranes, intravasatation into the blood vessels and survival within blood, and 
extravasation to proliferate in the metastatic site to form secondary tumours. It has been reported 
that more than 60% of neuroblastoma cases are invasive (Jogi et al., 2002)and despite treatment 
advances in the last decade, metastasis is still one of the major obstacles to overcome. Hypoxia 
occurs in solid tumours such as neuroblastoma and has been suggested to promote reprogramming 
of neuroblastoma cells leading to metastatic dissemination and tumour aggressiveness (Herrmann et 
al., 2015). Increased cancer dissemination has been shown to tightly associated with poorly 
oxygenated (hypoxic) regions in primary tumours (Lu and Kang, 2010). Taken together, in this 
chapter we aimed to develop a system to test drugs (Palbociclib and RO-3306) for ability to inhibit 
the metastatic process.   
5.2. Aims of the chapter 
The work described in this chapter aimed to examine the effect of RA, Palbociclib and RO-3306 on 
hypoxic and metastatic CAM formed tumours using both MYCN amplified and non-MYCN amplified 
neuroblastoma cell lines. Specifically: 
 Test the effect of RA, Palbociclib and RO-3306 on hypoxic neuroblastoma cells  
 Confirm the behaviour of hypoxic tumours specifically with respect to metastasis 
 Analyse the effect of RA, Palbociclib and RO-3306 on hypoxic tumour. 
 Assess metastasis in response to RA, Palbociclib and RO-3306. 
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5.3. Results 
During normxic conditions, in cells, prolyl-hydroxylated 2 (pOH) (PHD2) activated-degradation and 
hypoxia factor inhibiting HIF (FIH) degrades and inactivate Hypoxia induced factor HIF-1α. In 
contrast, this mechanism is inhibited when cells are incubated under hypoxic conditions (1% O2 for 3 
days). This enables HIF-1α accumulation and activation permitting the expression of specific hypoxia 
induced genes. In the absence of hypoxia, HIF-1α may be stabilised by treating cells with 
Dimethyloxalyl Glycine (DMOG) for 24hr. DMOG is a PHD inhibitor hence its presence permits a 
direct HIF activation (Figure5.1).  
 
Figure5.1 Mechanisms of HIF-1α degradation and activation. Left panel represents PHD2 targets 
HIF-1α for ubiquitination by the von Hippel–Lindau ubiquitin ligase complexand subsequent 
proteasomal degradation HIF-1α degradation by proteasome under normoxic conditions. Middle 
panel represents HIF-1α stabilization under hypoxic conditions mediated by the oxygen deficiency 
which causes the inhibition of PHD2 activity, leading to increased stability of HIF-1α, enhanced 
binding of coactivators, and increased transcription of HIF-1 target gene. The right panel represents 
chemical-induced HIF-1α stabilization under normoxic conditions by the inhibition of PHD2 activity 
through DMOG treatment. Adapted from (Menon et al., 2018). 
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Furthermore, preconditioning neuroblastoma cell lines for three days in 1% oxygen or pre-treating 
them for 24hr with DMOG promote metastasis of cells into the embryo (Herrmann et al. 2015). We 
were interested to discover whether treatment with the differentiation agent (RA) or CDK inhibitors 
(Palbociclib and RO-3306) may have an effect in inhibiting metastasis.  
5.3.1. Effect of the Retinoic acid on DMOG pre-treated BE2C cells 
We started by assessing the effect of RA on cell proliferation of DMOG-treated BE2C cells in vitro to 
see whether RA has an effect on DMOG-treated cells. DMOG treatment increased cell proliferation 
significantly by 45% in DMOG- treated cells compared to non-DMOG treated cells (Figure5.2). 
Interestingly, 3 days with RA reversed this increase to the level of control cells but not RA treated 
normoxic cells.  
DMOG- treated BE2C cells were sensitive to RA treatment. Because RA so far has not been reported 
to have any effect on SKNAS cells, we did not test RA on them and instead sought to investigate the 
effect of Palbociclib and RO-3306 on cell viability in both SKNAS and BE2C cells.  
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Figure5.2 The effect of Retinoic acid on DMOG-treated BE2C cells. A  BE2C cells were pretreated 
with DMOG for 24hr followed by 3 days with or without 10 µM ATRA.  For comparison cells without 
DMOG were also treated with ATRA.  Cells were then stained with Ki67 (red) and DAPI stained (blue)  
Scale bar =100 µM. B Quantification of percentage of Ki67-positive cells indicates a reduction in cell 
proliferation following treatment with 10 µM of ATRA in both DMOG- treated and control BE(2)C 
cells. Each bar represents the mean ±SEM of three independent experiments (n = 3) and at least 9 
fields per experiment. ***p⩽0.001 compared with the control. 
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5.3.2. Effect of Palbociclib and RO-3306 on the viability of DMOG pre-treated 
cells 
The effect of Palbociclib and RO-3306 on the viability of normoxic cells was shown in the last 
chapter. In the presence of normoxic cells as a control, here we assessed the effect of Palbociclib 
and RO-3306 on the viability of DMOG pre-treated cells using MTT assay.  
 In RA-sensitive cell, BE2C cells, both inhibitors reduced the viability of cells irrespective of the 
DMOG treatment (Figure5.3). In normoxic BE2C cells, Palbociclib and RO-3306 reduced cell viability 
between 49% and 67% whereas to 38% and 23% in DMOG- treated BE2C cells, compared to their 
controls.   
Similar results were observed in SKNAS cells, although RO-3306 was more effective than Palbociclib 
(Figure5.4). In normoxic SKNAS cells, Palbociclib reduced the cell viability by 42% whereas RO-3306 
reduced it by 68%. However, in DMOG-treated SKNAS cells, Palbociclib decreased cell viability to 
39% while RO-3306 by 45%.  
Ultimately, Palbociclib and RO-3306 showed a pronounced effect on cell viability of both cell lines 
regardless hypoxic preconditioning.   
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Figure5.3 The effect of Palbociclib and RO-3306 on cell viability of DMOG-treated and normoxic 
BE2C cells. BE2C cells were grown +/- DMOG for 24 h and then treated with Palbociclib, RO-3306 or 
medium with now drug for 3 days.  The number of viable cells was assessed using the MTT assay.  
Palbociclib and RO-3306 both reduced the cell number irrespective of whether the cells were 
precondition in DMOG. Displayed is the mean ±SEM of at least three independent experiments (n = 
3), with 3 technical replicates in each treatment.*P⩽0.05 and **P⩽0.01 compared with the control.  
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Figure5.4 The effect of Palbociclib and RO-3306 on cell viability of DMOG-treated and normoxic 
SKNAS cells. SKNAS cells were grown +/- DMOG for 24 h and then treated with Palbociclib, RO-3306 
or medium with now drug for 3 days.  The number of viable cells was assessed using the MTT assay.  
Palbociclib and RO-3306 both reduced the cell number irrespective of whether the cells were 
precondition in DMOG. Displayed is the mean ±SEM of at least three independent experiments (n = 
3), with 3 technical replicates in each treatment.*P⩽0.05 and **P⩽0.01 compared with the control. 
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5.3.3. SKNAS and BE2C tumours formed on CAM model  
5.3.3.1. Tumour differences – Normoxic versus DMOG or hypoxia-Precultured cells 
SKNAS is found to form tumours efficiently without the need to trypsin addition but for comparison 
and to be consistent, we added 5µl of Trypsin to the CAM before implanting the SKNAS cells similar 
to the procedure for BE2C cells. 
In the presence of normoxic controls, both SKNAS and BE2C cells were cultured with 0.5mM DMOG 
for 24hr at 37C° and 5%CO2. Cells were then spun down and counted.  Cells were grafted on CAM 
following the addition of trypsin and left to grow up to E14. Untreated BE2C cells were overall less 
efficient at forming tumours on the CAM than SKNAS cells (65% vs 85% for SKNAS).  Following 
treatment with DMOG the efficiency of BE2C tumour formation fell to 30% whereas SKNAS. We 
therefore tried growing BE2C cells in 1% oxygen for 3 days. Following this modification, the 
efficiency of BE2C tumour formation returned to almost 65%. 
On E14, tumour cells surviving upon the CAM were observed under the microscope, imaged and 
harvested. They were washed, imaged again in different planes determining tumour characteristics, 
and stored appropriately for further analysis.  
Compared to normoxic SKNAS tumours, hypoxic tumours were found to be heavily vascularised. 
Some tumours depict haemorrhagic lesions forming upon the CAM, and moreover were often 
accompanied by a large sac filled with blood (Figure5.5). Although the primary tumour morphology 
was variable, they were often leaky and surrounded by haematoma, a morphology commonly 
present in neuroblastoma (Fletcher, 2013) (Figure5.6). For BE2C, however, no difference were 
noticed between hypoxic and normoxic BE2C tumours in terms of size and characteristics 
(Figure5.7).  
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Figure5.17 SKNAS tumours formed on the CAM of chick embryo model. a,b,e,f,I and j are tumours 
formed on the CAM from normoxic SKNAS cells. c,d,g,h,k ,l,m and n are tumours formed on the CAM 
from DMOG-treated SKNAS cells.  Black arrows depict hematoma/haemorrhagic lesions. Blue 
arrows indicate big blood sac attached to tumours. Scale bar is 2mm.  
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Figure5.7 BE2C tumours formed on the CAM of chick embryo model. a-d are in vivo CAM tumours. e-h 
are dissected tumours. a,b, e and f are normoxic BE2C tumours formed on the CAM before and after 
dissection . c,d,g and h are hypoxia-treated BE2C tumours formed on the CAM  in vivo and following 
dissection.  Scale bar is 2mm. 
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Figure5.6 Images of DMOG-treated SKNAS tumours formed on the CAM of chick embryo.  a and b in 
vivo GFP and corresponding bright field . c, d,e and f are in vivo GFP tumours shows variable 
morphology of SKNAS tumours formed on the CAM. g and i are bright fields of dissected tumours with 
their corresponding GFP , h and j. Black arrows depict  a leaky tumour.  
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5.3.3.2. Invasion differences – Normoxic versus hypoxic tumours 
Following identification and harvesting of SKNAS and BE2C tumours.  The chick was decapitalised 
and removed from egg shell, washed 3 times with DPBS and placed in a clean 60mm petri dish. At 
this point, the chick was systematically dissected with each organ carefully removed and analysed 
for the presence of migrated/ invading tumour cells and more importantly, to identify metastatic 
secondary tumours.  
Rigorous examination of all chick tissues/ organs was unsuccessful in identifying metastatic SKNAS or 
BE2C cells precultured in normoxia. Therefore, although the CAM was proven to be an excellent 
supporter of normoxic tumorigenesis, formation of metastatic secondary tumours did not occur 
within the chick over 7 days post-implantation. Invasion could not be found in any organ or tissue of 
the chick embryo upon implantation of normoxic precultured SKNAS or BE2C cells as had been seen 
previously. 
In contrast, both DMOG-treated SKNAS and hypoxia –preconditioned BE2C cells were successful in 
forming tumour metastasis. Cells had the ability to migrate and invade embryonic tissues or organs. 
Subsequently this resulted in the formation of multiple metastatic foci. Highly favoured locations for 
tumour cell invasion were the intestines, adjoining tissues in the trunk and crucially, the liver which 
is a very common site for tumour metastasis in patients with neuroblastoma. Other less frequently 
affected regions of the embryo were gizzard and meninges (Figure5.8). 
Although, we induced hypoxic effect pathologically for 24hr using 0.5mM DMOG for BE2C and 
physiologically in SKNAS using hypoxia chamber equipped with 1% O2 for 3 days, there were no 
significant difference between the two approaches in tumorigenesis and invasion induction 
(Figure5.9).   
 
 
 
169 
 
 
 
 
 
 
 
Location of Metastastic deposits Frequency of 
Presentation  
Gizzard 
 
 
32% 
Intestine 
 
 
 
75% 
Liver  80% 
Trunk  65% 
Meninges  26% 
Figure5.8 Invasion of organs/tissues following implantation of DMOG-treated SKNAS and 
hypoxia-treated BE2C. Left side is bright field images, right side is GFP images. All embryos with 
CAM tumours formed from DMOG-treated SKNAS and hypoxia-treated BE2C were dissected at 
E14 and the percentage of metastatic cells in each organ or tissue was calculated.  A minimum 
of 25 embryos per condition was analysed (n=25-30).  GFP panel exhibits the metastatic foci 
proliferating within chick organs. Invasion on the liver and intestinal mesentery was the highest 
among other organs and tissues. Scale bar is 100um. 
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Figure5.9 SKNAS and BE2C tumourigenesis and metastasis assayed at E14. Tumourigenesis (red), 
Metastasis (green). Normoxia1 is the control for DMOG-SKNAS treated.  Normoxia2 is the control for 
hypoxic BE2C. Tumourgensis occurred regardless of preculture condition in both cell lines. Metastasis 
in each condition was investigated over 3 independent experiments, n>15 per condition. Error bars 
express Standard Error (SE).  
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5.3.4. Effect of Retinoic acid, Palbociclib and RO-3306 on hypoxic tumours 
5.3.4.1. Quantifying tumour invasion for drug delivery 
Before testing the effect of the drugs we first screened embryos at E9 – E13 for tumour formation. 
Next, embryos were dissected to determine time taken from implantation of cells to the first 
metastatic cells being observed.  Tumour formation could first be detected at E10 for SKNAS and E11 
for BE2C, and no metastasising cells were ever observed before E10 and were more often after E12. 
Following this observation, we therefore changed the dose regime from injections at E11 and E13 to 
E10 and E12 to ensure that the drugs were introduced before cells had begun to metastasise.  RO-
3306 and Palbociclib were used as 20µM whereas RA was used as 40µM. 
5.3.4.2. Effect of drugs on proliferation in DMOG- treated SKNAS and hypoxia-
treated BE2C tumours 
Following Palbociclib and RO-3306 treatment at E10 and E12, DMOG - treated SKNAS tumours were 
harvested and analysed for Ki67 staining at E14. Approximately 80% of tumour cells were Ki67 
positive in the control tumours (PBS or DMSO) which was similar to the proportion of Ki67 positive 
cells in tumours that had never been exposed to DMOG (Figure4.16A & Figure5.10). Both of 
Palbociclib and RO-3306 treatments reduced cell proliferation in tumours by between 24-39%.   
For BE2C, Retinoic acid, Palbociclib and RO-3306 were injected to the allantois of embryos at E10 
and E12, and the cell proliferation in the tumours was assessed by Ki67 staining at E14. 
Approximately 65% of tumour cells were Ki67 positive compared to 70% for cells grown in normoxia 
(Figure4.16B & Figure5.11).  As shown in Figure5.11 approximately 8% decrease in proliferation was 
observed following RA treatment compared to 12% decrease with Palbociclib and a 14% decrease 
with RO-3306, all reductions are not significant though. Thus a similar but smaller trend is observed 
with these agents on tumours formed from cells grown in normoxia.   
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Figure5.10 The effect of Palbociclib and RO-3306 on cell proliferation of DMOG-preconditioned 
SKNAS cells in tumours. SKNAS cells were pre-treated with DMOG for 24 hr prior to implantation at 
E7 on the CAM of chick embryos. Two doses of 20µM of Palbociclib and RO-3306, or PBS, or DMSO as 
control respectively were made up to 200µl injected into the allantoic sac of embryos at E10 and E12.  
Tumours were sectioned and stained for Ki67.  The percentage of Ki67 positive cells is shown and 
each bar represents the mean ±SEM of three independent experiments (n = 3) and at least 9 fields per 
experiment.*P⩽0.05 and **P⩽0.01 compared with the control.  
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Figure5.11 The effect of Retinoic acid, Palbociclib and RO-3306 on cell proliferation of hypoxia-
preconditioned BE2C cells in tumours. BE2C cells were cultured in 1% O2 for 3 days prior to 
implantation at E7 on the CAM of chick embryos. Two doses of 40µM RA or 20µM of Palbociclib and 
RO-3306 or DMSO, or PBS as controls were made up to 200µM were injected into the allantoic sac of 
embryos at E10 and E12. Tumours were sectioned and stained for Ki67.  The percentage of Ki67 
positive cells is shown and each bar represents the mean ±SEM of three independent experiments (n 
= 3) and at least 9 fields per experiment. 
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5.3.5. Effect of drugs on metastasis  
DMOG-treated SKNAS cells were treated with either RO-3306 or an equivalent volume of DMSO. 
Injections at E10 and E12 reduced metastasis from 95% (no injection) to 25% for both DMSO alone 
and RO-3306.  DMSO above 100µl in total is reported to compromise chick survival (Wyatt and 
Howarth 1976) and although chick survival was not affected we concluded that a final volume of 
130µl might be affecting the ability of tumour cells to metastasise.  Next we gave a single injection of 
RO-3306 at E10 and as shown in Figure5.12 a reduction of embryos with metastasis from 80% (with 
65ul of DMSO) to 33% (with RO-3306) was observed. Palbociclib was dissolved in PBS but for 
comparison we also gave only one injection at E10.  Here the metastasis was reduced from 92% to 
44%.   
Similar experiments were conducted with BE2C cells and again RO-3306 reduced metastasis by 
almost 60% while Palbociclib reduced metastasis by 56% (Figure5.13). RA could be introduced into 
the allantoic sac in 28µl of DMSO so the effect of one and two injections was compared.  One 
injection reduced metastasis from 80% to 60% while two injections reduced it from 64% to 27% 
(Figure5.14).Thus RA was less efficient at reducing metastasis than either of the CDK inhibitors but it 
was interesting that the 2nd injection was able to significantly reduce metastasis supporting the 
notion that metastasis was gathering pace between E12 and E14 in this model.   
In conclusion, all drugs were showing a significant tendency to inhibit invasion and metastasis of 
CAM tumours.  At this point, because of time limitation, we sought to investigate the effect of only 
RO-3306 on gene expression of hypoxic CAM tumours.  
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Figure5.12 The effect of Palbociclib and RO-3306 on SKNAS metastasis. Embryos with SKNAS cells 
implanted on the CAM at E7 were treated with a single injection of 20µM Palbociclib and RO-3306 
made up to 200µl or PBS or DMSO at E10. All embryos with CAM tumours formed from DMOG-
treated SKNAS were dissected at E14 and the percentage of embryos with metastatic cells for each 
treatment was calculated. The percentage of metastasis is shown and each bar represents the mean 
±SEM of three independent experiments and a minimum of 15 embryos per condition was analysed 
(n=15-18). ***P⩽0.001 compared with the control. 
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Figure5.13 The effect of Palbociclib and RO-3306 on BE2C metastasis. Embryos with BE2C cells 
implanted on the CAM at E7 were treated with a single injection 20µM Palbociclib and RO-3306 
made up to 200µl or PBS or DMSO at E10. All embryos with CAM tumours formed from hypoxia-
treated BE2C were dissected at E14 and the percentage of embryos with metastatic cells for each 
treatment was calculated. The percentage of metastasis is shown and each bar represents the mean 
±SEM of three independent experiments and a minimum of 12 embryos per condition was analysed 
(n=12-19). **P⩽0.01 compared with the control. 
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Figure5.14 The effect of different doses of Retinoic acid on BE2C metastasis. Embryos with BE2C 
cells implanted on the CAM at E7 were treated with either a single of 40µM of RA made up to 200µl 
DMSO at E10 or two injections at E10 and E12. All embryos with CAM tumours formed from hypoxia-
treated BE2C were dissected at E14 and the percentage of embryos with metastatic cells for each 
treatment was calculated. The percentage of metastasis is shown and each bar represents the mean 
±SEM of three independent experiments and a minimum of 12 embryos per condition was analysed 
(n=12-19).*P⩽0.05 compared with the control. 
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5.3.6. Gene expression in hypoxic tumours  
Because we observed profound metastatic effects triggered by pre-culture in DMOG or hypoxic 
environment, we sought to investigate the transcriptional outputs of the primary hypoxic tumours 
using qPCR. Genes which demonstrate large fold changes in response to hypoxia were selected: 
hypoxia induced genes such as GLUT1 and VEGF,  intravasation genes such as MMP9 and ADAMST1,  
and extravasation genes such as  VCAN, ITGβ5, ITGαV and VCAM (Herrmann et al., 2015).  GLUT1 is 
the predominant glucose transporter and found to be overexpressed in neuroblastomas compared 
to maturing ganglioneuromas or intermixed ganglioneuroblastomas (Ramani, Headford and May, 
2013), reflecting the altered metabolism and proliferation in neuroblastoma tumours. VEGF is a 
specific mitogen for cells of endothelial origin that stimulates angiogenesis and is found to be 
overexpressed in neuroblastomas (Jakovljević et al., 2009). MMP9 is endopeptidase that belongs to 
zinc-dependent metalloproteinases family that degrade several components of the extracellular 
matrix. Of interest, elevated expression of MMP9 drives cell division in human neuroblastoma cells 
(Sans-Fons et al., 2010). ADAMTS1 belongs to A Disintegrin and Metalloprotease with 
Thrombospondin motifs metalloprotease family. Increased ADAMTS1 expression enhances pro‐
metastatic alterations such remodelling of the extracellular matrix environment promoting tumour 
progression and metastasis (Tan, Ricciardelli and Russell, 2013). VCAN is anti-adhesive belongs to 
hyaluronan-binding proteoglycans family.  VCAN is found to be negatively regulated in migratory 
neural crest cells (Henderson, Ybot-Gonzalez and Copp, 1997). ITGβ5 and ITGαV are transmembrane 
receptors that facilitate cell - extracellular matrix (ECM) adhesion; both of them are reported to be 
linked to tumour invasion and metastasis (A., Graf and G., 2013; Hoshino et al., 2015). VCAM belongs 
to the cell adhesion molecules family and is found to facilitate firm adhesion and transmigration to 
cancer cells (Wu, 2007). 
There was a significant change in the expression of the tested genes in both DMOG- and hypoxia-
treated tumours compared to normoxic tumours as was reported previously. DMOG-treated SKNAS 
tumours showed a significant increase by more than 7 fold for VEGF, 6 fold for ADAMTS1 and 10 fold 
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for VCAM compared to normoxic SKNAS tumours. GLUT1, MMP9 and ITGαV were also upregulated 
by approximately 3 fold whereas VCAN was reduced by 50% (Figure5.15). Similar to DMOG –treated 
tumours, in hypoxic BE2C, VEGF possesses the highest fold change with almost 5 fold increase while 
MMP9 increases by ~4 fold. GLUT1, ADAMTS1 and VCAM also found to be upregulated by roughly 3 
fold increase compared to MMP9 in normoxic tumours. ITGβ5 and ITGαV expressed small increase 
while a significant decrease was observed for VCAN (Figure5.16). 
 
Taken together, we confirmed that preculture in DMOG or hypoxia chamber induced a long-lasting 
change in 8 premetastatic genes involved in tumour progression and metastasis. As RO-3006 showed 
a significant reduction in invading and metastatic BE2C and SKNAS cells in vivo, we sought to 
investigate whether this drug has an effect in changing or reversing the alterations of transcriptional 
outcomes caused by hypoxia signature.  
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Figure5.15 The effect of DMOG preconditioning on gene expression of SKNAS tumours. A Relative 
mRNA levels for the target genes were determined by qPCR. Cells were cultured for 24hr with DMOG 
prior to implantation on CAM at E7. At least three independent experiments (n = 3) were analysed for 
each gene and relative mRNA levels are displayed relative to GAPDH, UBC and HPRT1 and normalised 
to cells cultured for 3 days with DMSO (control). Each bar in the graph represents the log of 
normalised mean± SEM of three independent experiments. *P⩽0.05 **P⩽0.01 and ***P⩽0.001 
compared with control. B Table gives a summary of the qPCR data for the 8 target genes for DMOG-
treated SKNAS tumours. 
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Figure5.16 The effect of hypoxia preconditioning on gene expression of BE2C tumours. A Relative 
mRNA levels for the target genes were determined by qPCR. Cells were cultured for 3 days at 1% O2 
prior to implantation on CAM at E7.  At least three independent experiments (n = 3) were analysed 
for each gene and relative mRNA levels are displayed relative to GAPDH, UBC and HPRT1 and 
normalised to cells cultured for 3 days with DMSO (control). Each bar in the graph represents the log 
of normalised mean± SEM of three independent experiments. *P⩽0.05 **P⩽0.01 and ***P⩽0.001 
compared with control. B Table gives a summary of the qPCR data for the 8 target genes for hypoxia-
treated BE2C tumours. 
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5.3.7. Effect of RO-3306 on gene expression of hypoxic tumours 
QPCR quantification on hypoxia or DMOG –treated tumours indicated significant changes in the 
expression of genes thought to be important in the metastatic process (Section 5.3.6). Here we 
aimed to identify the effect of RO-3306 on the gene expression of those tumours. RO-3306 was 
introduced to the allantois at E10. Following one injection of 20µM RO-3306, in DMOG-treated 
SKNAS tumours, seven genes were reduced significantly (except VCAN) showing a reversal of 
expression towards the normoxic levels. Expression of VEGF, MMP9 and VCAM dropped by more 
than 4 fold while GLUT1, ADAMTS1, ITGβ5 and ITGαV reduced by 2 fold approximately compared to 
the levels seen in hypoxic tumours (Figure5.17). 
The effect of RO-3306 on BE2C hypoxia –treated tumours was similar to that observed in DMOG-
treated SKNAS tumours, a significant reduction of expression was noted in all genes, except VCAN.  
Glut1, ITGαV and VCAM reduced by more than two fold while ADAMTS1 fell by 3 fold. A small 
reduction of VEGF expression by < two fold whereas MMP9 reduced by almost 20 fold, both were 
significant though (Figure 5.18). 
Taken together these result strongly suggest that a single injection of RO-3306 reduces the 
metastatic activity of cells pre-conditioned in hypoxia by reducing the increase in expression of 
genes that are implicated in hypoxia-driven metastasis.   
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Figure5.17 The effect of RO-3306 on gene expression of DMOG-Preconditioned SKNAS tumours. A 
Relative mRNA levels for the target genes were determined by qPCR. Tumours were treated with 
single injection of 20µM RO-3306 at E10. At least three independent experiments (n = 3) were 
analysed for each gene and relative mRNA levels are displayed relative to GAPDH, UBC and HPRT1 
and normalised to cells cultured for 3 days with DMSO (control). Each bar in the graph represents the 
log of normalised mean± SEM of three independent experiments. *P⩽0.05 and ***P⩽0.001 
compared with control. B Table gives a summary of the qPCR data for the 8 target genes for DMOG-
treated SKNAS tumours following RO-3306 treatment. 
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Figure5.18 The effect of RO-3306 on gene expression of hypoxia-Preconditioned BE2C tumours. A 
Relative mRNA levels for the target genes were determined by qPCR. Tumours were treated with 
single injection of 20µM RO-3306 at E10.  At least three independent experiments (n = 3) were 
analysed for each gene and relative mRNA levels are displayed relative to GAPDH, UBC and HPRT1 
and normalised to cells cultured for 3 days with DMSO (control). Each bar in the graph represents the 
log of normalised mean± SEM of three independent experiments. *P⩽0.05, **P⩽0.01 and 
***P⩽0.001 compared with control. B Table gives a summary of the qPCR data for the 8 target genes 
for hypoxia-treated BE2C tumours following RO-3306 treatment. 
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5.4. Discussion 
Our previous findings indicated that Palbociclib and RO-3306 reduced cell proliferation and induced 
cell death in vitro under normoxic conditions. It was demonstrated in previous studies that hypoxic 
cells are more aggressive and invasive with better ability to metastasize (Azab et al., 2012; Herrmann 
et al., 2015). Here we aimed to test the effect of Palbociclib and RO-3306, alongside the well-
characterised treatment RA, on reducing metastatic behaviour of hypoxic tumours. We found that 
treating tumours grown from hypoxic cells with Palbociclib and RO-3306 reduced meatstasis and 
reversed the change of gene expression caused by hypoxia. Thus Palbociclib and RO-3306 showed a 
significant suppression activity on tumour growth and metastasis.  
5.4.1. Response of DMOG-treated SKNAS and BE2C cells in response to 
Palbociclib and RO-3306 treatment  
Our results indicated that culturing SKNAS and BE2C in the hypoxia mimetic, DMOG, for 24hr 
increased cell proliferation compared to untreated cells similar to that seen by Herrmann (Herrmann 
et al., 2015). In contrast to this, cell growth analysis using MTT assay on DMOG-treated human 
tendon stem cells (hTSCs) revealed that 1mM of DMOG for 24hr decreased proliferation by almost 
51% compared to control cells (Menon et al., 2018). This suggests that DMOG may have a different 
activity on normal cells, compared to cancer cells.  
We demonstrated that three days with 5µM Palbociclib significantly reduces cell viability of both 
DMOG-treated SKNAS and BE2C cells. Others also showed that inhibition of CDK4/6 with 5µM 
LEE011 resulted in cell cycle accumulation of BE2C in G0/G1 phase and significantly decreases the 
percentage of cells in S and G2/M. In the same study, however, the authors reported that SKNAS cell 
line was resistant to CDK4/6 inhibition and arrested in G1 only at significantly higher doses (10µM) 
of LEE011 (Rader et al., 2013).  
Palbociclib was found to reduce cell viability and promotes apoptosis in a panel of 5 human colon 
cancer cell lines regardless of the presence of hypoxia, after treatment for 48hr at 10µM (Zhang et 
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al., 2017). Fry et al demonstrated that Palbociclib could arrest the transition of the G1-S phase of the 
cell cycle in MDA-MB-453 breast carcinoma cells under hypoxia (Fry et al., 2004). The authors in this 
study found also that Palbociclib destabilizes HIF-1α and reduces Glycogen Synthase Kinase 3β (GSK-
3β) expression under hypoxic conditions. GSK-3β is an essential serine/threonine kinase in cell 
survival and NF-ĸB pathway activation; inhibition of GSK-3β also induced cell death of glioma cells 
(Kotliarova et al., 2008). Considering the therapeutic effect of Palbociclib against aggressive and 
metastatic tumours, Palbociclib effect is the same but the mechanism by which inducing this effect is 
more complex as it acts and interacts with many other pathways.  
Our results showed that inhibiting CDK1 with R0-3306 resulted in reduction of cell viability and 
apoptosis in DMOG-treated SKNAS and BE2C cells. Interestingly, it is reported that CDK1 regulates 
the expression of HIF-1α via direct phosphorylation on Serine 668. Phosphorylation of HIF1-α by 
CDK1 stabilizes HIF1α levels, even during normoxia (Warfel et al., 2013). This is likely to be due to a 
reduction in lysosomal degradation of HIF-1α and therefore increases HIF-1α protein stability (Hubbi 
et al., 2014). Increased stabilization of HIF-1α associated with an increase in transcription activity of 
HIF-dependent target genes, which functionally resulted in enhanced levels of angiogenesis, cell 
proliferation and invasion (Warfel et al., 2013; Ortmann, Druker and Rocha, 2014). Knockdown of 
CDK1 decreases HIF-1 protein levels and eventually its transcriptional activity in HeLa cells (Hubbi et 
al., 2014). Taken together, inhibiting CDK1 is shown to negatively regulate the cell cycle as well as 
HIF-1α activity leading to decreased proliferation and increased apoptosis and eventually inhibition 
of tumour progression. 
5.4.2. Hypoxia versus Normoxia tumours 
Reduced oxygen availability, hypoxia, stimulates metabolic adaptation in cancer cells and promotes 
tumour growth. Hypoxic conditions increase overexpression of HIF1-α in tumours leading to 
metastases which is associated with the aggressiveness of a majority of human cancers and 
correlates with poor overall survival  (Semenza, 2010; Muz et al., 2015; Påhlman and Mohlin, 2018). 
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HIF-α accumulation and activation alters blood vessel formation, metastasis, and metabolism via a 
number of genes including VEGF, MMPs, EMT, E-cadherin, CXCR4, GLUT1 and GSK (Muz and Azab, 
2015).   
Our results indicated that culturing SKNAS or BE2C cell lines under normoxic condition prior to 
implantation on the CAM did not prompt metastasis from the SKNAS or BE2C CAM tumours and 
invasion could not be found in any organ or tissue of the chick embryo. In contrast, both DMOG-
treated SKNAS and hypoxia-preconditioned BE2C cells were successful in forming tumour 
metastases. This finding supports that found by Herrmann et al (Herrmann et al., 2015). These 
findings, together with similar observations in multiple myeloma (MM) cancer (Azab et al., 2012), 
suggest that cells cultured in hypoxic conditions were more able to metastasise than others cultured 
under normoxia.   
Similar observations were recorded in mice bearing sarcoma tumours, where exposure to acute 
hypoxia augmented the number of lung metastases (Cairns, Kalliomaki and Hill, 2001). This indicates 
that hypoxia influences invasive and migratory behaviour of cancer cells allowing tumour 
progression and dissemination.  
5.4.3. Effect of Hypoxia on gene expression  
Hypoxia regulates tumour metabolism, neovascularization, and cell death and cell survival. In 
addition, hypoxia contributes to EMT-like cancer cell migration and cancer stem-cell-like properties 
allowing propagation of the tumour and resistance to treatment (Muz and Azab, 2015). Our results 
showed that there was significant increase in the expression of HIF-1α target genes such as VEGF, 
MMP9 and GLUT1 in hypoxic tumours compared to normoxic tumours  
Under hypoxic conditions, angiogenesis occurs due to sprouting of the pre-existing vessels caused by 
increased production of VEGF and MMPs and integrins (Muz and Azab, 2015). Here we showed that 
beside the increased levels of VEGF and MMP9 there was a significant increase in the expression of 
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integrins (ITGβ5 and ItαV), adhesion molecules known to facilitate cell metastasis (Bendas and 
Borsig, 2012). In hypoxic tumours, we showed that expression of the cell adhesion molecule VCAM 
was upregulated while anti-adhesive molecule, VCAN, was downregulated compared to normoxic 
tumours. The importance of this can be explained due to the necessity for cancer cells increase their 
attachment to the endothelial vessel wall to facilitate transmigration.   
Furthermore, under hypoxia, in addition to HIF pathway activation, other hypoxiaassociated 
pathways are activated including NF-ĸB, PI3K/AKT/mTOR and MAPK/ERK pathways, which are 
involved in cell proliferation, survival, apoptosis, metabolism, migration, and inflammation. 
In conclusion, hypoxia contributes to cancer metastasis by triggering HIF-1α pathway and altering 
many different pathways that together facilitate aggressiveness and resistance to treatment. 
Therefore targeting hypoxia with an inhibitor such as RO-3306 which reverses some pathways 
activated by hypoxia was of interest.   
5.4.4. Effect of RO-3306 on gene expression of hypoxic tumours  
As shown previously, hypoxia altered the expression of many genes involved in metastasis. Here we 
aimed to test the effect of RO-3306 on gene expression of hypoxic tumours. As discussed previously, 
CDK1 targets HIF-1α by direct phosphorylation at serine 668, leading to expression of HIF-1 targets, 
promoting tumour angiogenesis, proliferation, and tumour growth (Warfel et al., 2013). We showed 
that inhibiting CDK1 with RO-3306 significantly reduced the expression of most of the tested genes. 
In support, siRNA-mediated knockdown or RO-3306-mediated inhibition of CDK1 studies reduced 
HIF-1α half-life whereas overexpression of CDK1 enhanced HIF-1α levels (Warfel et al., 2013). Of 
note, in addition to HIF-1α activation, others demonstrated that overexpression of CDK1 enhanced 
induction of GLUT1 and VEGF mRNA expression in HeLa cells under hypoxic conditions (Hubbi et al., 
2014). 
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Together, these findings underline the importance of CDK1 inhibition in mediating HIF-1α and 
reverse the transcriptional activity caused by hypoxia. 
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Chapter Six: Discussion 
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6.1. Introduction 
Neuroblastoma is the most common extracranial solid tumour affects the children under 5 years of 
age, accounting 15% of all paediatric oncology deaths. Overall, survival for patients with high risk 
neuroblastoma tumours is poor (<50%), thus crucially indicating a need to develop additional 
therapies  (Matthay et al., 2009; Modak and Cheung, 2010). Whilst many agents tested in vitro look 
promising, remarkably few are as successful in preclinical models or eventually patients. Thus, this 
project aimed to screen new and potential therapeutic agents using an in vivo model, the chick 
embryo model. The project objectives were as listed below: 
1- Validate the CAM model a well characterised drug, RA.                                                     
2- Investigate the effect of some potential therapeutic agents specifically Palbociclib and RO-
3306 on the behaviour of the neuroblastoma tumours grown on the CAM. 
3- Investigate the effect of these therapeutic agents on hypoxia-induced metastasis.  
The project involved the use chick embryo model and four different neuroblastoma cell lines BE2C, 
IMR32, Kelly and SKNAS cells were introduced to the CAM of embryos. Morphology, cellular 
proliferation, differentation and apoptosis was observed and the metastatic behaviour of hypoxic 
neuroblastoma tumours was quantifed before and after the application of drugs. 
6.1.1. CAM Model validation   
The chick embryo as a model system has been used extensively in multiple scientific research fields, 
but mainly in development (Stern, 2005). CAM model has been used in cancer studies, including the 
use of the CAM on which to grow cells from a variety of tumours such as colon carcinoma (Cecilia 
Subauste et al., 2009), multiple myeloma (Ribatti et al., 2003), uveal melanoma (Kalirai et al., 2015) 
and neuroblastoma (Herrmann et al., 2015), and analyse the extent of angiogenesis and metastasis. 
However its value for testing the efficacy of drugs has been more limited to date (Kim et al., 2016; 
Sathe et al., 2016).  
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The chick embryo complies with widely accepted guidelines designed to reduce animal numbers, 
refine and replace animal models (the 3Rs) (Alexander, 1998). In our experiments we xenograft the 
cells on CAM at E7, the earliest time point at which the CAM is sufficiently developed, and complete 
experiments at E14. Therefore these experiments, although in vivo, are not considered animal 
experiments under UK legislation and therby replace the use of animals. Many cell lines form 
tumours on the CAM however some do not  (Balke et al., 2010; Kalirai et al., 2015; Swadi et al., 
2018) a feature we have also observed with neuroblastoma cell lines. Tumour cells need to invade 
through the epithelial layer of the CAM and this may require functioning MMPs to be secreted by 
the tumour cells. Whilst many neuroblastoma secrete MMPs only SKNAS cells, of those tested, was 
expressing the biological activator of MMP (Sugiura et al., 1998; Bjørnland et al., 2001). This provides 
an explanation for the greater efficiency of tumour formation by SKNAS cells (Herrmann et al., 2015) 
and the rationale for the use of trypsin to enhance tumour formation for IMR32, Kelly and especially 
BE2C cells. Use of trypsin may enhance the use of the CAM tumour model by expanding the range of 
cell lines that will form tumours efficiently.  
A blinded assessment, by a pathologist,  on CAM-derived and primary sarcoma tumours established 
that the CAM-derived tumours were histologically similar to the primary sarcoma tumours (Sys et al., 
2013). We used similar approach to evaluate the neuroblastoma CAM tumours looking to the 
histology of tumours. 
Drugs can be introduced to the embryo and extra embryonic tumours by topical addition, 
intravenous (IV) injection or injection into the allantois (Vargas et al., 2007). We used allantois 
injection as a drug delivery for our experiments. Yet we were interested in determining the dose 
required to detect a statistically significant effects of RA and while a daily dose of 10μM RA showed 
the appropriate trend it required two doses of 40μM RA at E11 and E13 to give statistically 
significant changes in proliferation and a change in cell morphology. This fourfold increase over the 
concentration used in culture may be due to sequestration of the RA by the receptors present in 
191 
 
cells in the embryo (Kampmann and Mey, 2007) thus potentially reducing the effective 
concentration. In addition, the cells within the tumour maybe less responsive than those in culture; 
perhaps reflecting the differing microenvironment (Chen et al., 2015). 
Here we have established a method of enhancing tumour development on the CAM, delivering 
water-insoluble drugs to the tumours and three outcomes that confirm differentiation of cells 
(reduction in proliferation, change in cell morphology and qPCR of differentiation markers). 
Ultimately, chick embryos develop rapidly with a window of only 7 days between a sufficiently 
developed CAM (E7) and the age embryos come under UK Home Office regulation (E14). 
Nevertheless tumours can form on the CAM and respond to drug treatments in this time window 
making the model highly time efficient. It is especially useful for analysing the cellular response to 
drug treatment as changes in gene expression, leading to different cell behaviours typically occur on 
a time scale of hours to days. These changes rather than, for example, changes in tumour size suit 
the short term nature of the model. Here we wanted to extend our results in order to rapidly and 
cost effectively test other potential agents to tackle resistant neuroblastoma tumours. 
6.1.2. Testing potential therapeutic agents on the CAM model 
Following the validation of the CAM model with RA, discussed previously, we next demonstrated its 
value as a model for testing the effect of therapeutic agents on tumour cell proliferation, 
differentiation, apoptosis and gene expression.  We have shown that Palbociclib proved to reduce 
cell proliferation both in vitro and in tumours for BE2C cells and whilst for SKNAS cells it initiated 
apoptosis in vitro and a reduction in cell proliferation in vivo. RO-3306 promoted apoptosis in both 
cell lines in vitro and yet surprisingly there was little or no increase in apoptosis in vivo.  This may be 
due to differing concentration of inhibitor experienced by the cells however at lower concentrations 
in culture (1µm) there was no change in either proliferation or decrease in cell viability.  Thus the 
cellular response to agents in the complex 3D environment of a tumour can be different to that seen 
in 2D cultures as has been observed by others (Gandellini et al. 2015, Anastasiou 2017).  
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Taken together, the outcomes from testing Palbociclib and RO-3306 on CAM tumours were 
promising. Whilst SKNAS cells are resistant to differentiation therapy by retinoic acid, both 
Palbociclib and RO-3306 were able to reduce cell proliferation in SKNAS tumours. Thus testing the 
response mechanisms to Palbociclib and RO-3306 on hypoxia –induced metastasis using CAM model 
was of interest.  
6.1.3. Hypoxia- induced metastasis   
Recently, it has been shown that  preconditioning neuroblastoma cell lines with either 1% oxygen or 
DMOG promotes metastasis of cells into the embryo, a phenomenon never see in these cell lines 
from tumours formed from cells grown in atmospheric oxygen (Herrmann et al. 2015). SKNAS cells 
form CAM tumours very efficiently and they continue to do so when treated with either 1% oxygen 
or DMOG. BE2C cells form tumours less efficiently and addition of trypsin to the CAM along with the 
cells enhances this. Surprisingly, treating BE2C cells with DMOG prior to CAM implantation reduced 
the efficiency so cells were grown in 1% oxygen for 3 days prior to implantation as this did not affect 
the efficiency of tumour formation. Metastasis was judged to have occurred if fluorescent cell(s) 
were found in the embryo by dissection under a fluorescent stereomicroscope. Single cells within in 
the embryo could be identified making this more efficient than previous methods of detecting 
metastatic cells (Zhao et al., 2015). Rigorous dissection of many embryos here and previously (Rice, 
2013) revealed the typical locations for the metastatic cells. Highly favoured locations for tumour 
cell invasion were the intestines, adjoining tissues in the trunk and crucially, the liver with one or 
more small clumps of cells were observed groups of individual cells. These locations are very 
common site for tumour metastasis in patients with neuroblastoma. No metastatic cells were seen 
prior to the formation of a primary tumour on the CAM and they were only seen in embryos that 
formed a primary tumour.  This confirms that the cells within the embryo were derived from the 
primary tumour rather than from the initial implantation of cells on the CAM at E7.   
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6.1.4. The effect of Palbociclib and RO-3306 on hypoxic tumours  
In proliferation quantification, Palbociclib and Ro-3306 did not show the same effect that seen on 
normoxic CAM tumours, both drugs were less effective on hypoxic cells of CAM tumours. Two 
possible explanations can be suggested here. Firstly it is possibly that the tumours derived from 
hypoxic cells are more resistant to drug treatment and secondly it is perhaps due to the change in 
timing of treatments. For the tumours derived from hypoxic cells, drugs were introduced on E10 and 
E12 whilst for the normoxic tumours they were introduced on E11 and E13.  
6.1.5. The effect of RO-3306 on gene expression of hypoxic 
tumours 
We selected the RO-3306 to analyse the mechanism by which those drugs were reducing the 
metastatic behaviour in both cell lines. Similar to experiments published earlier (Herrmann et al., 
2015), we showed that the expression of a number of genes thought to be involved in metastasis 
was changed in response to pre-treatment with 1% oxygen or DMOG.  Interestingly, most genes 
showed a reduction in their expression in response to RO-3306. For example HIF- 1α target genes 
such as GLUT1 and VEGF (Herrmann et al., 2015) and genes that more closely associated with 
metastasis like MMP9 (Hiratsuka et al., 2002; Xiao et al., 2016), ADAMTS1 (Ricciardelli et al., 2011), 
VCAM (Chen and Massagué, 2012), ITGαV and ITGβ5 (Gladson et al., 1997) showed a statistically 
significant down regulation compared to hypoxia in both cell lines. These results were obtained four 
days after a single injection of the RO-3306 suggesting that, like the initial changes resulting from 
hypoxia, these changes might be long-lasting.   
6.1.6. Limitation of the CAM model 
All in vivo models have inherent strengths and limitations. An appreciation of these limitations is 
essential in interpreting results obtained through their use and aids decisions about which model is 
suitable in which context. As a xenograft model, the chick embryo involves the addition of human 
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neuroblastoma cells into the chick embryo environment. This non-human environment may have an 
effect on aspects of cell behaviour and interactions between tumour cells and the local 
microenvironment may not be faithfully recreated. The natural immunodeficiency of the chick 
embryo, though aiding xenografting, prevents the investigation of compounds acting in an immune 
mediated fashion and does not recreate the interaction between host immune system and the 
tumour. Similar to chick embryo, mouse xenograft models have same drawbacks but do have longer 
time window. Whilst, GEMM do not have this drawback but the neuroblastoma cells are not human.  
The second limiting factor of using the CAM model is the short time period available for the 
application of treatments. Whilst the time frame in this model is appropriate for the more rapid 
screening of compounds, three or four days of treatment makes this model less than ideal to study 
the therapeutic effect of a particular drug. This could be potentially amended by transplanting 
tumours which have had three days of treatment back into an E11 or E7 embryo for further 
treatment or continuing drug delivery up until E18 under a Home Office licence.  
In preclinical models, the use of a single cell line does not accurately represent the extreme 
heterogeneity seen within neuroblastoma tumours in patients. It is known from previous work that 
certain cell lines are resistant to the effects of RA, and so the results found using a single cell line 
may not be applicable to all cell lines found in tumours (Reynolds et al., 2000). Experimentation 
creating tumours using mixture of more than one cell line for drug testing may be advantageous in 
the understanding of tumour resistance. 
The use of cell lines in this model, which although well characterised, are subject to genetic drift and 
may not represent primary disease accurately. They may also fail to reproduce the heterogeneity of 
genetic changes characteristic of primary tumours and therefore exaggerate or fail to respond to the 
therapeutic effect of targeted therapies 
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As the pharmacokinetics of the drugs in chick embryos is as yet unknown, the rapidly changing 
nature of the embryonic environment may affect factors such as the rate of drug metabolism, 
diffusion and distribution within the model.  
In accordance to the UK home office legislations, chicks were not permitted to survive beyond the 
age of embryonic day 14. As such, the metastasis experiments had to be completed within a seven 
day period from implantation at E7 to dissection at E14.  
Moreover, similar to other preclinical testing models, it is expected cells would behave in a similar 
manner to neuroblastoma growing in humans, however by its very nature, this study does not relate 
exactly to the human condition due to the fact that it has been carried out in a different species. 
6.1.7. Future directions 
The work carried out in these experiments used four neuroblastoma cell lines and four drugs. The 
success of these experiments makes it possible to extend this approach to other neuroblastoma cell 
lines, additional drugs and drug combinations and indeed other cancers 
Presently, the pharmacokinetics of Palbociclib and RO-3306 in chick embryos has not yet been 
investigated so it remains to be seen whether the drugs are still present and at what concentration 
48hr post injection.  Therefore analysing the half-life and metabolites of the drugs would be useful 
and will assist in the determination of the timing, number and concentration of these drugs used in 
this model. 
Studies with Palbociclib and RO-3306 have begun in order to test for differentiation in RA-resistant 
neuroblastoma cells, SKNAS cells, and hence both drugs reduced cell proliferation in SKNAS tumours 
it would be interesting to investigate whether the cells did begin to move down the differentiation 
pathway by qPCR using the previously characterised markers. 
This work has shown that Palbociclib and RO-3306 reduce overall metastasis.  Next we could identify 
which steps in the multistep metastatic process are targeted by these drugs. For example, in vitro 
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experiments such as trans-well migration assay, scratching assay and matrigel invasion assay can be 
carried out with and without the treatment to determine the effect of drugs on cells.  In addition, 
the intravasation and extravasation steps can be separated out and extravasation alone can be 
investigated by injected the cells into the blood stream. This would provide a better understanding 
of the mechanism of action of these drugs and potentially enable the development of combinatorial 
therapies. 
 Here the cells were manipulated by preconditioning in hypoxia or DMOG. This approach could be 
extended by manipulating the cells with siRNA or CRISPR technology to identify the role so specific 
proteins in the behaviour of tumour cells in the CAM model.   
  
6.1.8. Conclusions 
Neuroblastoma is a malignancy of childhood that demonstrates significant clinical and biological 
heterogeneity. For high risk patients mortality remains tragically, and unacceptably, very high. Thus 
new treatments able to target the distinct biological and molecular features of these patients’ 
disease are urgently required. In the field of paediatric therapeutic research, preclinical models are 
vital. With an increasing number of potential therapeutic targets being identified, the need for 
economically viable, high through put in vivo models is escalating. The chick embryo is low cost, 
highly practical and well characterised by centuries of research, and may provide a suitable 
xenograft model for work in this field. 
We have demonstrated that chick embryo is valuable model for analysing tumour formation and 
metastatic behaviour of tumour cells. We have seen that allantois injections provide an effective 
way to deliver compounds in this model. Using elements of standard therapy we have identified RA 
dose (40μM) which reduced proliferation, induced change in cell morphology and changed the 
expression of differentiation genes in CAM tumours. We also demonstrated that 20μM Palbociclib or 
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R-3306 reduced tumour growth and metastasis significantly. Palbociclib and RO-3306 reduced cell 
proliferation of neuroblastoma cell in normoxic CAM tumours; however this effect is muted on 
tumours grown from hypoxic cells. We presumed that the change of dose timing alongside the 
resistance of hypoxic tumours made the results differ from that seen in normoxic tumours. Hypoxia 
triggered the expression of genes putative in the metastasis process but this is reversed following 
the application of single dose of RO-3306.  
Our findings add to existing works which highlight the suitability of the chick embryo as a model 
system for cancer research. In addition, we identified two potential therapeutic agents that may act 
alone or in combination to tackle neuroblastoma resistance.  We hope this research may serve as 
blueprint for future works allowing the full spectrum of drug effects to be investigated. We hope 
that further drug screening programs carrying out on this model may eventually lead to compounds 
offering the novel treatment for neuroblastoma patients.  
In conclusion, this project has shown the potential the chick CAM has at being the model of choice 
during initial preclinical testing of drugs for treating cancer patients, potentially leading to an 
increase in the event free survival of individuals with neuroblastoma.   
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